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Introduction: Congenital heart disease (CHD) affects approximately 1% of liveborns and 
accounts for the largest proportion of infant mortality in developed countries. Coarctation of 
the aorta (CoA), the 6th most common CHD, consists of a narrowing of the proximal descending 
aorta. If left untreated, it has an unfavorable natural history. Surgery, balloon dilation (BD) or 
stent implantation are all current treatments that can achieve a successful long-term removal 
of the stenosis, and the choice is based on age, CoA anatomy, and personal or institutional 
preference. Coarctation is not a mere mechanical disease that is treated by removing the 
increased afterload. In fact, a good anatomic result does not avoid long-term cardiovascular 
(CV) morbidity and mortality, with late systemic hypertension (HTN) in approximately half of 
the patients, and reduced life expectancy, mostly due to CV complications and stroke. The 
abnormal blood pressure (BP) phenotype suggests that the suboptimal results are likely due 
to abnormal vascular function, which has been well documented in patients with repaired 
CoA. There are inherent changes in the arterial structure and function, impaired neuronal 
sensitivity or endocrinal auto-regulation, and acquired  features, such as age at treatment, 
that contribute to vascular dysfunction in CoA. The poor long-term vascular outcome 
may also be impacted by the different types of repair, which likely have differing effects 
on the stiffness of the repaired segment and potentially compromise both the conduit and 
cushioning functions of the aorta. The effects of treatment modality on long-term vascular 
function remain uncharacterized.  
Aims and Hypothesis: The goal of this study is to assess vascular function in this patient 
population for comparison among the treatment modalities. The central hypothesis of 
this study was that patients who have undergone successful BD will have better vascular 
function than patients who have undergone successful surgical repair or stenting since 
this modality is least likely to damage the integrity and biomechanical properties of the 
aortic wall.
Methods: Prospective assessment of vascular function using multiple non-invasive modalities, 
and compare the results among the three groups of CoA patients previously treated using 
surgery, BD or stent implantation after frequency matching for confounding variables. In 
successfully repaired CoA patients, we prospectively compared aortic stiffness by applanation 
tonometry and cardiac magnetic resonance (CMR); endothelial function by endothelial pulse 
amplitude testing; pulse waveform analysis by applanation tonometry and endothelial pulse 
amplitude testing; BP phenotype by office BP, ambulatory BP monitoring, and BP response 
to exercise; left ventricular (LV) mass and aortic morphometrics by CMR; blood biomarkers 
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of endothelial function, inflammation, vascular wall function, and extracellular matrix; and 
ideal cardiovascular health. In the statistical analysis, we adjusted for potential confounders. 
Results: This study was done in seven, large volume centers from Portugal and the United 
States of America. Participants included 75 patients treated with surgery (n=28), BD (n=23), 
or stent (n=24). Groups had similar age at enrollment, CoA severity, residual gradient, and 
metabolic profile but differed by age at treatment. Systemic HTN, aortic stiffness, endothelial 
function, and LV mass were similar among groups. However, BD had more distensible 
ascending aortas, lower peak systolic BP during exercise, less impairment in diurnal BP 
variation, and lower inflammatory biomarkers. The results were unchanged after adjustment 
for potential confounders, including age at treatment.
Conclusions: Treatment modality was not associated with major vascular outcomes such 
as systemic HTN, global aortic stiffness, and endothelial function. However, BD patients had 
a better vascular phenotype profile characterized by higher ascending aorta distensibility, 
lower night-time BP, lower peak exercise BP and lower levels of inflammatory markers. 
Further studies are required to confirm if our results may contribute to refining the CoA 
treatment paradigm by adding to the goals of therapy the preservation of vascular function 
when two or more treatment techniques are applicable.
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Introdução: As cardiopatias congénitas (CC) afetam aproximadamente 1% dos recém-
nascidos e são responsáveis pela maior proporção de mortalidade infantil nos países 
desenvolvidos. A coarctação da aorta (CoA), a 6ª CC mais frequente, consiste numa estenose 
da aorta descendente proximal. Se não for tratada, tem uma história natural desfavorável. 
A cirurgia, dilatação com balão e a implantação de stent são atualmente técnicas que 
podem atingir o objetivo de uma remoção eficaz e duradoura da estenose ístmica, sendo 
a decisão baseada na idade doente, anatomia da CoA e preferência do operador ou da 
instituição.  Contudo, um bom resultado anatómico não evita morbilidade e mortalidade 
de longo prazo, apresentando cerca de metade dos doentes hipertensão arterial 
(HTA), e registando-se mortalidade precoce, maioritariamente devido a complicações 
cardiovasculares e acidentes vasculares cerebrais. O perfil tensional anómalo sugere que 
os resultados subótimos possam ser secundários a disfunção vascular, cuja existência 
foi bem documentada em doentes com CoA tratada. Existem anomalias intrínsecas da 
estrutura arterial e função, alterações da sensibilidade neuro-hormonal ou da regulação 
endócrina, e fatores adquiridos, como a idade do tratamento, que contribuem para esta 
disfunção vascular. Os maus resultados a longo prazo podem resultar igualmente do tipo 
de tratamento efetuado, que provavelmente impactam de modo diverso a rigidez do istmo 
aórtico e potencialmente comprometem as funções da aorta. Este efeito da modalidade 
terapêutica não foi até ao momento estudado. A CoA não é uma simples doença mecânica 
que fica resolvida quando é removido o obstáculo. 
Objetivos e Hipóteses: O objetivo deste estudo é comparar a função vascular entre diferentes 
modalidades terapêuticas de CoA. A hipótese principal é a de que os doentes submetidos 
a dilatação com balão têm melhor função vascular que os doentes submetidos a cirurgia 
ou implantação de stent, pois aquela modalidade terapêutica tem menor potencial para 
danificar a integridade e propriedades biomecânicas da parede da aorta do que estas. 
Métodos: Avaliação prospetiva da função vascular usando múltiplas modalidades não 
invasivas, de modo a comparar os resultados de três grupos de doentes com CoA, tratados 
com dilatação com cirurgia, balão ou implantação de stent, após controle das variáveis de 
confusão. Em doentes com CoA tratada com sucesso, comparámos prospectivamente a 
rigidez da aorta com tonometria de aplanação e ressonância magnética cardíaca; função 
endotelial com tonometria arterial periférica endotelial; analise da onda de pulso com 
tonometria de aplanação e tonometria arterial periférica endotelial; massa ventricular 
esquerda e anatomia do arco aórtico com ressonância magnética cardíaca; marcadores 
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séricos de função endotelial, inflamação, função da parede arterial e matriz extracelular; e 
saúde cardiovascular ideal. A análises estatística incluiu ajuste para as variáveis de confusão. 
Resultados: O estudo foi realizado em sete grandes centros, de Portugal e Estados Unidos da 
América. Foram incluídos 75 doentes, tratado por cirurgia (n=28), dilatação com balão (n=23) 
e implantação de stent (n=24). Os grupos tiveram idade semelhante à data de inclusão, 
gravidade da CoA, gradiente residual e perfil metabólico, mas eram diferentes quanto à 
idade à data do tratamento. A HTA, rigidez da aorta, função endotelial e massa ventricular 
eram semelhantes entre os grupos. Contudo, o grupo da dilatação com balão tinha mais 
distensibilidade regional da aorta ascendente, menor tensão arterial (TA) sistólica durante 
o exercício, menos alteração da variação noturna da TA, e dose menor de biomarcadores 
inflamatórios. Os resultados permaneceram inalterados após ajuste das potenciais variáveis 
de confusão, incluindo idade à data do tratamento. 
Conclusões: A modalidade terapêutica não estava associada à presença de HTA, rigidez 
arterial global e função endotelial. Contudo, os doentes com dilatação com balão tinham um 
perfil de função vascular mais favorável, caracterizado por maior distensibilidade da aorta 
ascendente, TA noturna mais baixa, menor resposta hipertensiva no esforço e menores 
marcadores séricos de inflamação. São necessários mais estudos para confirmar se os nossos 
resultados poderão contribuir para o refinamento do paradigma de tratamento da CoA, ao 
adicionar ao objetivo de remoção da estenose, a preservação da função vascular, quando 
dois ou mais tratamentos são aplicáveis. 
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The most common, severe congenital anomalies are heart defects. In Portugal, the 
specialty of Pediatric Cardiology was established in 1969. These five decades have seen 
remarkable progress in the prevention, diagnosis, treatment, and rehabilitation of patients 
with congenital heart disease (CHD). The overall mortality has dropped from about 35% to 
about 3% per year and survival into adulthood is now common, even for the most complex 
CHD. This increasing population of adults with CHD, which already outnumber children, have 
given rise to new challenges. Some are specific to CHD (such as the management of the long-
term complications after single-ventricle palliation or neurodevelopmental outcomes after 
neonatal cardiopulmonary bypass), but others are merely the effect of age on a maturing 
population that happens to have had been treated for CHD in infancy, including pregnancy, 
atherosclerosis, and acquired heart disease. The quality of a treatment is not merely 
obtaining survival but achieving a good long-term outcome. The focus in CHD has shifted 
from mortality to morbidity. 
Improvements in CHD outcomes were based on few robust scientific data. Congenital 
cardiology has suffered from a lack of indisputable evidence. There have been less than 30 
prospective randomized trials worldwide, and some did not reveal a clear benefit of one 
approach over the other. Many decisions result from individual or institutional preference, 
anecdotal cases or specific institutional protocols. Clinical practice guidelines for CHD are 
mostly class II recommendations (treatments are reasonable or may be considered) based 
on type C evidence (experts’ consensus, case studies or standard of care). In sum, evidence-
based medicine is lacking in CHD. These shortcomings result from the CHD being a group 
of rare diseases with diverse presentations, mostly treated in small and autonomous 
practices and lack of suitable research end-points. In recent years, this problem has been 
well recognized, and the development of evidence-based practice based on multicenter 
consortia is considered one of the most important future trends for CHD in the next decade.2 
Clinical research is critical for evidence-based medicine.
Coarctation of the aorta (CoA) is one of the most common CHD. It consists of a narrowing 
of the proximal descending aorta. If left untreated, most symptomatic neonates die shortly 
after, and even if the presentation is later and more benign, patients rarely survive beyond 
age 50. The repair of CoA was one of the first successful surgeries performed in CHD. Several 
current surgical and percutaneous treatments can achieve a successful long-term removal 
of the stenosis, and the choice is based on age, CoA anatomy, and personal or institutional 
preference. Importantly, a good anatomical result does not avoid long-term cardiovascular 
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morbidity and mortality remain high with late systemic hypertension (HTN) in approximately 
half of the patients and reduced life expectancy, mostly due to cardiovascular complications 
and stroke. CoA can be “fixed but not cured”.3
The mechanisms responsible for the suboptimal outcomes in CoA are unclear. Patients 
who have been successfully treated have evidence of pre-treatment genetic modulation and 
neurohormonal disturbances, mild residual stenosis or arch hypoplasia that may be of more 
significance than it is usually accepted, and especially the persistence of vascular dysfunction 
in treated patients. Vascular structure and function are now recognized as a central 
pathological feature of cardiovascular disease (CVD). Vascular function can be described 
by many different functional indices, some of which are now available for use outside of a 
research setting and include arterial stiffness, endothelial function, pulse waveform analysis 
and circulating biomarkers of vascular function. One factor that compromises vascular 
function is the existence of stiff arteries. Preliminary evidence and biological plausibility 
suggest that different CoA treatment modalities may have a distinct impact on the stiffness 
of the isthmus. Treatment may affect vascular function and long-term outcome. 
This thesis was designed to assess the impact of treatment modality on vascular function. 
To answer our study question and overcome the research challenges, we designed the Long-
term Outcomes and Vascular Evaluation After Successful Coarctation of the Aorta Treatment: 
the LOVE-COARCT Study prospectivelly used multiple non-invasive modalities to perform a 
comprehensive assessment of vascular function and cardiovascular health. We assembled 
a multi-disciplinary group of investigators with established expertise in epidemiology, the 
conduct of clinical trials, study design, CHD, vascular function assessment, preventive 
cardiology and statistical analysis. A collaborative team allowed us to recruit patients at 
multiple centers to ensure sufficient statistical power in evaluating our hypothesis. This 
study may help to refine the treatment paradigm by adding to the goals of therapy the 
preservation of vascular function.
The following chapters of this PhD dissertation thesis, “Vascular Dysfunction after Repair 
of Coarctation of the Aorta”, develop the concepts briefly aluded in this Introduction and 
present in detail the LOVE-COARCT Study.
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1. COARCTATION OF THE AORTA
1.1. Introduction
CoA is a congenital malformation characterized by narrowing of the aorta, most commonly 
involving the isthmus. The term “CoA” comes from the Latin word coarctatio, which means 
narrowing.
It’s first known description is in a letter written by the famous Prussian anatomist Johann 
Friedrich Meckel to his mentor Albrecht von Haler in 1750, reporting a case of an 18 year 
old patient who had an aorta in the post-mortem examination that was “so narrow that 
its diameter seems to be hardly one third that of the pulmonary artery”.4 Another early 
description of CoA can be seen in Morgagni’s renowned treaty of autopsies “The Records and 
Causes of Death Investigated by Anatomy”, written in 1760.5 For a long time, CoA remained 
a mere anatomical rare curiosity discovered at autopsy. In 1928, all 200 cases known at the 
time were published in Abbott’s classic article.6 After surgical correction was experimentally 
demonstrated to be feasible,7, 8 CoA became of clinical importance when Crafoord successfully 
surgically corrected the lesion with an end-to-end anastomosis, in 1944.9 Patch aortoplasty 
was introduced in 1961,10 and Waldhausen introduced the subclavian flap technique to 
address the then high rate of reCoA.11 The first report of a transcatheter procedure to treat 
CoA was balloon dilation (BD) in a neonate with a post-surgical reCoA, in 1982.12 In the 
following year, BD was used to treat native CoA.13 The first investigations with intravascular 
stents were done in 1986, in the aorta of animal models,14 and preceded the widespread 
use of stents in coronary arteries. In 1993, animal experimental CoA was treated by stent 
implantation,15 and the first human cases were published in 1995.16 
After seven decades of treatment, Lindesmith’s quote in “Review of CoA of the Thoracic 
Aorta”, written in 1971, is still true in many aspects:17 “Although operation for CoA has long 
been an accepted practice, many questions regarding this defect remain at best incompletely 
answered. These include indications for operation, the type of operation which should be 
performed, the age at which operation should be carried out, the problems of recurrence and 
persisting HTN, the occurrence and management of paradoxical HTN following correction, 
and the incidence and management of complications of operative treatment.”
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1.2. Epidemiology
CHD is the most common type of severe congenital malformations. It occurs in approximately 
1% of liveborns and in 10% of aborted fetuses.18  It also accounts for the largest proportion 
of deaths due to birth defects, which is the leading cause of infant mortality in the Western 
World.19, 20 CoA is the sixth most common CHD, representing 6-8% of all cases.21-23 In 1980, 
the New England Regional Infant Cardiac Program (1975-1977), a consortium of regional 
hospitals that pooled their data concerning ill infants admitted with heart disease, reported 
an incidence of 1.7 per 100,000 live births.21 However, this study underestimated the true 
incidence of this disease, because it preceded the widespread use of echocardiography 
and did not account for patients who were not diagnosed until later in life. According to a 
recent review that pooled the data from 39 studies, CoA has an incidence of 4.0 per 100.000 
live births and is the 6th most common congenital cardiac defect.24 This same figure was 
confirmed in an on-going registry, the Metropolitan Atlanta Congenital Defects Program.25 As 
with other left-sided obstructive diseases, CoA is more common (1.3 to 1.7:1) in males.21, 26  
1.3. Etiology
1.3.1. Genetics
Most cases are sporadic, but there is substantial that left-sided obstructive lesions have a 
strong genetic component, especially when they occur in association.27-29 Data supports 
a complex but most likely oligogenic pattern of inheritance,28 but the underlying genetic 
etiologies are mostly unknown.29 Recently, a few candidate genes have been described, 
including TBL1Y,30 MCTP2,31 MATR3,32 and variants of the NOTCH1 gene,33 thus supporting 
the theory that genes play an important role in CoA.34 
There are several syndromes that have been associated with CoA. It is well-known that CoA 
has a high prevalence (10–20%) in Turner syndrome.35 Other syndromes include Williams–
Beuren, PHACES, congenital rubella syndromes, neurofibromatosis, and Takayasu arteritis.  
1.3.2. Embryology
The aorta and its branches develop between the sixth to eighth week of gestation. They arise 
from the aortic arches, which are six paired and symmetrical embryological arteries. During 
development, these aortic arches lose their original symmetry, and while some enlarge 
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and become a part of the final aortic arch and branches, others regress and disappear: the 
ascending aorta arises from the ventral aorta, the aortic arch between the left common 
carotid artery and the left subclavian artery is formed from the left 4th aortic arch and the 
3rd through the 7th segments of the left dorsal aortic root, and the thoracic descending aorta 
from that point onwards arises from the 6th aortic arch.36 The precise mechanism by which 
CoA is produced is not clearly understood and there are two main proposed theories, which 
may be complementary.
1.3.2.1. Ductal Theory
The ductus arteriosus has long been recognized to play a critical role in CoA. Craigie proposed 
a theory in 1841,37 later popularized by and known as Skoda Theory in 1855,38 in which 
an abnormal extension of ductal tissue into the aorta created a stenosis after postnatal 
ductal closure. This explanation was commonly disregarded in the mid 20th century, since 
“such an extension of peculiar issue has never been demonstrated microscopically”.39 
However, this theory has since then been abundantly demonstrated. In the 70s, histological 
studies confirmed that there is migration of the ductal tissue to the aortic isthmus.40, 41 The 
prostaglandin E receptor EP4, a receptor in the ductus arteriosus, is abundantly expressed 
in human CoA segments.42 Three-dimensional extent of ductal tissue was shown in resected 
human CoA segments using synchrotron radiation-based X-ray phase contrast tomography.43 
And finally, the in-vivo demonstration of this theory occurred in 1998,44 by successfully infusing 
prostaglandin E1, a drug that dilates the ductus, with echocardiographic demonstration of 
the CoA relief in what has become a mainstay of pre-surgical neonatal medical management. 
It is now widely accepted the concept that CoA is associated with excessive distribution of 
tissue of the ductus arteriosus.
1.3.2.2. Hemodynamic Theory
However, the ductal theory does not explain all cases of CoA, especially when there is 
accompanying hypoplasia of the aortic arch. Early reports suggested that a reorientation 
of the angle at which the ductus arteriosus meets the aorta, abnormal fetal ductal flow 
patterns, or hemodynamic compromise of fetal aortic outflow, could be responsible for 
CoA.45 In fact, the high incidence of CoA in patients with congenital heart defects that have 
in utero diminished antegrade aortic flow is a well-recognized association. Conversely, the 
paucity of CoA in patients with right-sided heart obstructions suggests that prenatal altered 
hemodynamics also plays a significant role in the development of CoA. The hemodynamic 
theory has been demonstrated in chick embryos, where alterations in intracardiac blood 
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flow that compromised left ventricle (LV) flow, disrupted both early cardiac morphogenesis 
and aortic arch development.46 In summary, the hemodynamic theory has also become an 
accepted explanation of the most severe forms of CoA and arch hypoplasia. It is likely that 
ductal tissue migration and hemodynamic changes co-occur to produce the varied spectrum 
of CoA.
1.4. Natural History
Most of the patients that present in the neonatal period or infancy do not survive beyond 
the critical period if left untreated. The remaining patients, who present after the first year of 
life, have a more benign course and mostly reach adult life. However, the mean age of death 
for this subset of patients is 35 years old.47 A necropsy study of patients that died beyond 
infancy showed that untreated patients rarely survive beyond age 50: 25% die before they 
reach 20yo, 50% by 32yo, 75% by 46yo, and 90% by age 58  (Fig. 1):
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Fig. 1. The distribution of deaths by age, excluding deaths in the first year of life. In CoA on the left and in 
normal subjects on the right, there is relatively little overlapping. (Reprinted from Campbell,48 with permission 
from BMJ Publishing Group Ltd)
In that same study, the most frequently reported causes of death were congestive heart failure 
(26%), aortic dissection (21%), bacterial endocarditis (18%), and intracranial hemorrhage 
(12%).
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1.5. Anatomy
1.5.1. Morphology
CoA is an aortic narrowing nearly always localized in the isthmus, the aortic segment 
comprised between the origin of the left subclavian artery and the emergence of the ductus 
arteriosus. Rarely, it may be located after the emergence of the brachiocephalic trunk, in the 
descending thoracic or abdominal aorta, the latter commonly designated as abdominal CoA, 
and which may represent a different disease entity. The CoA itself may be a discrete and focal 
stenosis or shaped as a long segment isthmic hypoplasia. Additionally, there may be a wide 
spectrum of accompanying aortic arch hypoplasia, that can be manifested up to the extreme 
of aortic arch interruption. Currently, Pediatric Cardiology centers use the measurements of 
the arch indexed to the body surface area (BSA) and describe them in terms of z scores, where 
one z score which represents one standard deviation for the appropriate sex, height, and 
weight. Z scores less than -2 are considered to represent arch hypoplasia. Other approaches 
are considering that the segment between innominate and left carotid should be greater 
than 60% of ascending aorta, the segment between left carotid and subclavian artery 50% of 
ascending aorta, and the isthmus not inferior to 40% of the ascending aorta. Another rule is 
to consider hypoplastic arch which size is smaller than baby’s weight plus one.49
CoA occurs in concomitance with other congenital heart defects, including ventricular septal 
defects and other left-sided obstructions, especially bicuspid aortic valve (BAV), which may 
be present in up to 60% of CoA cases (Table 1):50
Table 1. Incidence of congenital cardiac anomalies associated with CoA
Associated anomalies Incidence
Patent ductus arteriosus 77%
Bicuspid aortic valve 46%
Ventricular septal defect 26%
Subaortic stenosis 25%
Atrial septal defect 13%
Mitral valve stenosis 10%
Transposition of great arteries 8%
Shone complex 3%
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One common association is Shone syndrome, that includes supravalvar mitral ring, parachute 
mitral valve, discrete subaortic stenosis and CoA or other complex congenital heart diseases, 
such as the Taussig-Bing anomaly, univentricular heart, often with systemic outflow obstruction, 
and hypoplastic left heart syndromes.51 The most important noncardiac associated anomaly is 
intracerebral aneurysm (berry aneurysm), present in up to 10% of all cases.52
1.5.2. Histopathology
In the site of the CoA, there is usually an infolding of aortic wall tissue. Although the aorta 
and ductus arteriosus are in continuity and exposed to the same hemodynamics, the ductus 
arteriosus has structural properties similar to those of muscular arteries rather than those 
of elastic arteries. A similar intimal thickening is one of the prominent histopathological 
changes of CoA.53, 54 In the medial layer, light and electron microscopy of necropsy and 
surgical specimens showed histopathological changes including increased collagen and 
reduced smooth muscle content in the ascending but not the descending aorta.55-57 The 
expression of the smooth muscle cell phenotype in CoA is similar to that is found in the 
ductus arteriosus.58 It is interesting to note that similar changes histopathological changes 
are found in the ascending aorta of patients with BAV without CoA.59 These observations 
suggest that CoA is not a localized disease but a diffuse arteriopathy.
1.6. Pathophysiology
In the last years, it has become apparent that CoA is not a mere focal stenosis but an inborn 
systemic vascular disease. The isthmic stenosis is associated not only with altered hemodynamics 
but also with gene modulation of the vascular phenotype, impaired neuronal sensitivity, and 
endocrinal auto-regulation. All these contribute to HTN and vascular dysfunction that are 
currently well recognized to characterize the long-term follow up of CoA. 
1.6.1. Hemodynamics
CoA creates an obstacle that increases LV afterload and leads to a rise in BP proximal, 
and hypoperfusion distal to the isthmus. The hemodynamic consequences depend on 
the rapidity of the ductus arteriosus closure, the severity of the obstruction, the level of 
pulmonary vascular resistance, and associated cardiac lesions. In the neonatal and infantile 
presentation, post-natal ductus closure leads to an acute narrowing of the aortic lumen that 
results in systolic dysfunction and cardiogenic shock. In the more insidious childhood or 
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adolescent presentation, the closure of the ductus is better tolerated and elicits an adaptive 
pathophysiological adaptation that results in upper body HTN, compensatory LV hypertrophy, 
systolic dysfunction, and development of collateral blood flow.
The presence of collateral vessels allows for BP below the CoA to be only slightly decreased 
or even within normal limits.60 However, the pulse pressure (PP) is markedly reduced below 
the CoA, as a result of the attenuation of the pulse in travel through the long, tortuous and 
narrow collateral vessels. When present in native CoA, the collateral vessels provide almost 
complete replacement for the abnormal aortic conduit function, but little or none for altered 
cushioning reservoir function and only one-third of the whole arterial system is able to act 
as cushion to LV ejection.61
Exercise further accentuates the differences described above. Previous studies have shown 
that physical exertion is associated with a more accentuated increase in BP above the CoA 
than in patients that have severe essential HTN.62
1.6.2. Gene modulation
Changes in gene expression due to the mechanical stimuli of the CoA may explain these 
histopathological changes. The stenosis caused by experimental CoA results in the 
development of differentially expressed genes that are associated with altered vascular 
structure or function.63-65 In a rabbit model of CoA, immunohistochemical results showed a 
shift from smooth muscle to non-muscle myosin heavy chain isoform expression in the medial 
smooth muscle cells that reflects a long-standing change in the vascular phenotype since 
these changes persisted after removal of the induced CoA.66 Human studies also revealed 
genetic polymorphisms in CoA patients that are associated with HTN.67-69 Interestingly, these 
polymorphisms are different from those seen in patients with essential HTN67 or abnormal BP 
regulation during exercise.68 This finding reinforces the different ethiopathogenic mechanism 
for HTN in CoA.
1.6.3. Neuro-endocrine system
The renin-angiotensin-aldosterone (RAA) system may be involved in the ethiopathogenesis 
of CoA, especially in the systemic HTN. However, its role is unclear: while some studies 
provided evidence of increased RAA activity in patients with CoA,70-72 others did not confirm 
these findings.73-75 It may be that the RAA is important in the early development of, but not 
in the maintenance of HTN in CoA.76
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1.6.4. Autonomic nervous system
The autonomic system and baroreceptor function may be altered, including enhanced 
sympathetic tone set to a higher value, reduced spontaneous baroreceptor reflex sensitivity 
and heart rate (HR) variability, and diminished sensitivity to changes in arterial pressure.77-79 
Some authors suggest that these abnormalities in neuronal mediation may be involved only 
in the pre-treatment HTN, which is then reset after repair.80, 81
1.7. Diagnosis
1.7.1. Clinical Presentation
1.7.1.1. Neonates and Infants
Most of the CoA cases present in neonates and infants.82 The acute closure of the ductus 
arteriosus will lead to left heart failure or, in the most dramatic cases, cardiogenic shock with 
metabolic acidosis. Patients present with tachycardia, tachypnea, pale skin, and diaphoresis. 
They have radio-femoral pulse delay with diminished or absent femoral pulses and poor 
peripheral perfusion. The cardiac auscultation is sometimes unremarkable, but there may be 
a harsh systolic ejection murmur, best heard in the suprasternal notch or the interscapular 
area, in the back. The arm-leg BP gradient is pathognomonic of CoA but may be difficult to 
obtain in a moving infant or when cardiac output is diminished. The hypoperfusion of the lower 
body may lead to end-organ damage, including renal failure and necrotizing enterocolitis. This 
clinical presentation may be difficult to distinguish from neonatal sepsis without cardiovascular 
imaging. Rarely, there will be some infants that present with dilated cardiomyopathy.
1.7.1.2. Children, Adolescents and Adults
10-25% of patients will present later in life.82 CoA is then suspected due to complaints related 
to HTN (such as headache or epistaxis), reduced exercise capacity, claudication or cold feet. 
Often, the diagnosis is incidental and made during routine office visits such as a physical 
examination that shows cuff HTN or absent femoral pulses, or pre-exercise sports assessment 
such as changes in the electrocardiogram (ECG) that will prompt a cardiac evaluation. 
Cardiac auscultation is most often normal, but an uncharacteristic systolic ejection murmur 
best heard in the suprasternal notch or continuous murmurs in the interscapular area or 
thorax (due to collateral vessels) may occur. Atypical clinical presentations that may lead to 
the diagnosis of CoA include retinopathy in eye assessments, infective endocarditis, aortic 
dissection or rupture, and intracranial hemorrhage. 
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This relatively uncharacteristic, mostly benign clinical picture, and the absence of a clearly 
abnormal cardiac auscultation are often responsible for late diagnosis. It is well documented 
in pediatric studies that the diagnosis is often missed by the referring doctor and this has had 
little improvement over the past 20 years.83-85 Consequently, it remains critical to stress the 
importance of femoral pulse palpation and brachial cuff measurement of BP in routine child 
visits to the pediatrician or family doctor. 
1.7.2. Electrocardiogram
In the neonatal period, the ECG of CoA patients may be indistinguishable from the findings 
in the normal newborn, with right ventricular dominance with positive R, and T waves in the 
right precordial leads and QRS angle in the right lower quadrant.86 After ductal closure, the 
ECG in the neonate and infant with CoA persists with right axis deviation of the QRS axis in 
the frontal-plane, right ventricular hypertrophy and upright T waves in the right precordial 
leads, contrary to the normal newborn in whom the T wave becomes negative.87 These ECG 
changes associated with CoA persist throughout infancy and, if present beyond, may suggest 
pulmonary HTN associated with other congenital heart diseases. 
In older children, there may not be any ECG changes if there is a mild CoA. As age and 
severity progress, the ECG findings will reflect the HTN and LV hypertrophy, such as increased 
R wave amplitude in the left-sided ECG leads (I, aVL and V4-6) and increased S wave depth 
in the right-sided leads (III, aVR, V1-3) and ST and T-wave abnormalities in the lateral leads.88 
1.7.3. Chest X-Ray 
In the neonate, the chest X-ray in CoA is non-specific. If there is heart failure, there will be 
cardiomegaly and congested pulmonary vasculature, due to passive congestion and active 
fluid overload due to left-to-right shunt.
In older children and adolescents, the CoA patients have a normal or slightly enlarged heart and 
two characteristic findings: (a) figure-3 sign, that results from the combination of a localized 
indentation in the site of the isthmic stenosis with dilated proximal subclavian artery and distal 
descending aorta; and (b) rib notching, that results from the erosion of the inferior surface 
of the ribs by the prominent collateral circulation of the enlarged of intercostal arteries. Rib 
notching involvement is bilateral with distal coarctation, right- sided with proximal coarctation, 
and left-sided with distal coarctation with anomalous right subclavian artery.89
LOVE-COARCT Study
16
II. BACKGROUND
1.7.4. Echocardiography 
1.7.4.1. Prenatal
Despite all the advances in fetal echocardiography, prenatal diagnosis of CoA remains a 
challenging diagnosis even in tertiary centers, with high false positive and false negative 
rates.90-93 A recent, a large cohort study showed that CoA is one of the most commonly 
missed prenatal congenital heart diseases92 and another study showed that this detection 
can occur in less than one third of patients.93  
Early studies noted that most patients have indirect 2D echocardiographic signs, such as 
a disproportionally larger right ventricle and pulmonary artery, but only half had a direct 
visualization of the stenotic aortic arch.94 Several parameters have been proposed to assist in 
the 2D fetal diagnosis of CoA including a ratio of the left common carotid artery to transverse 
aorta > 0.73 compared with < 0.62 for the normal fetuses,95 the isthmic diameter z-scores 
< -2 and the ratio of isthmus to duct diameters < 0.74,96 and the visualization of CoA shelf. 
Finally, the presence of other commonly associated left heart obstructive lesions may help 
to raise the suspicion for the presence of CoA. The Doppler assessment helps in the prenatal 
diagnosis of CoA, including the presence of continuous isthmic flow, detected in 50% of the 
patients,91 and the inversion of flow in the ascending aorta is a pathognomonic sign.
Despite the difficulties, the prenatal diagnosis is critically important since it allows the birth 
to occur in an adequate institution. The timely early administration of proper neonatal care 
and has been shown to be associated with lower mortality and morbidity.97
1.7.4.2. Postnatal
Transthoracic echocardiography is the primary imaging modality for CoA. The crucial 
diagnostic steps are the establishment of the presence, degree, and shape of the isthmic 
stenosis; the size of the aortic arch; the anatomy of the aortic arch branches, namely the 
involvement of the left subclavian artery in the CoA and the presence of an aberrant right 
subclavian artery; and the patency of the arterial duct and associated cardiac lesions. 
In the newborn, the presence of the ductus may mask the presence of the CoA. However, the 
bidirectional ductal flow with right-to-left shunt associated with hypoplasia of the isthmus is 
indicative of the presence of a CoA. Once the ductus closes, the echocardiographic features 
will be more apparent. The best echocardiographic view is the suprasternal notch view and, 
occasionally in newborns, the subcostal view.98 In 2D, there will become evident a stenosis of 
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the aortic isthmus, and often a posterior shelf will be seen in the proximal descending aorta, 
opposite to the aortic end of the ductus (Fig. 2). In isolated CoA, the measurements of the 
arch show variable degrees of hypoplasia of the aortic arch.  
Fig. 2. Suprasternal notch view showing a CoA. The CoA (marked with an arrow) is seen as a narrowing in 2D 
imaging (left panel), where there is color Doppler flow aliasing (right panel). 
Doppler assessment is an important adjunct for the diagnosis and severity assessment of 
CoA.99 The best correlation between the Doppler-estimated gradients and the invasive peak-
to-peak hemodynamic gradient is to use the Bernoulli equation with the post-CoA velocity 
minus the pre-CoA velocity.99 The persistence of antegrade flow in diastole or diastolic run-off 
assessed by continuous wave Doppler is the most specific (100%) and sensitive (79%) in the 
diagnosis of CoA.100 The continuous and low velocity pulsed Doppler flow in the abdominal 
aorta also indicates the presence of CoA  (Fig. 3).
Fig. 3. Subcostal view with pulsed-wave interrogation of the abdominal aorta. Note the typical low velocity 
and continuous flow of CoA.
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The color-coded Doppler study is helpful in localizing a CoA when the 2D images is suboptimal, 
and shows a persistence of color flow signal throughout the whole cardiac cycle. A complete 
echocardiographic study is also important to detail possible associated congenital heart 
defects.  
1.7.5. Magnetic resonance imaging  
Cardiac magnetic resonance imaging (CMR) is the preferred advanced non-invasive diagnostic 
tool for assessment of CoA since it allows both good anatomic and functional data of the 
aortic arch, which is clinically useful for both preoperative planning and post-interventional 
monitoring.101, 102 
Regarding anatomy, CMR can provide excellent and detailed visualization of the entire aortic 
arch, the site, degree, and extent of the aortic narrowing, as well as aneurysms. Anatomic 
imaging allows for imaging the arch in multiple custom-made planes that assist in the accurate 
quantification of the vessel size along its path and quantify the LV hypertrophy, function, 
and fibrosis (with T1 mapping). The utilization of gadolinium-enhanced CMR permits three-
dimensional reconstruction of the aortic arch as well as depicting the presence and extent of 
collateral vessel formation  (Fig. 4). 
Fig. 4. 3D reconstruction of gadolinium-enhanced CMR angiography of the aorta.
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CMR can also provide valuable information regarding pathophysiology.60, 103 The severity of 
CoA can be inferred by quantification of hemodynamic parameters such as flow velocity and 
volume and estimation of pressure gradients across the CoA. The quantification of the amount 
of collateral flow has been shown to be associated with the degree of CoA. Recent technological 
developments in CMR that involve a comprehensive analysis of flow direction and its interaction 
with the aortic wall has been used as 4D CMR to the study the wall shear stress that is exerted 
in the aorta,104 and to accurately predict the invasive hemodynamic gradient.105
Compared to the other techniques, CMR is limited by (a) its relatively longer time for image 
acquisition and need for patient cooperation, which may require sedation for patients under 6 
to 8 years old; (b) its higher cost; and (c) the artifacts associated with metal stents used to treat 
CoA, which impede isthmus visualization. Therefore, CMR is not routinely used in infants but is 
recommended in in the diagnosis initial diagnosis and follow up of children, infants, and adults.
1.7.6. Computed tomography
Computed tomography (CT) scan provides the best non-invasive anatomic imaging, by 2D 
and 3D reconstructions of the aortic arch. The most important limitations of CT scan are the 
requirement of iodinated contrast that may worsen renal failure and the associated ionizing 
radiation, especially deleterious in children who may require several consecutive exams. 
However, the radiation risk is minimized with the recent availability of third-generation dual-
source scanners, which provide high-quality imaging in a single heartbeat, thus avoiding the 
need for breath holding and minimizing artifact.106, 107
1.7.7. Diagnostic catheterization 
It is currently very rare the need to perform an invasive cardiac catheterization with the 
sole purpose of a diagnostic catheterization. First, the hemodynamic significance of a CoA 
is well established by clinical and non-invasive methods. Second, the angiographies provide 
excellent imaging of the aortic arch but don’t have a favorable risk/ benefit ratio compared 
to the non-invasive imaging modalities described above.  
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1.8. Treatment
1.8.1. Indications
All hemodynamically significant CoA should be treated once the diagnosis is made. The 
American Heart Association and the American College of Cardiology, the European Society 
of Cardiology, and the Canadian Cardiovascular Society have all issued guidelines for adults 
and agree that what defines a significant CoA is a gradient greater than 20 mm Hg (Class 
I; Level of Evidence: C).108-110 There are, however, some important nuances between these 
recommendations: while the United States of America guidelines specify that the 20 mm 
Hg value corresponds to the invasive, peak-to-peak CoA gradient, the European guidelines 
consider that a non-invasive BP between upper and lower limbs greater than 20 mm Hg is 
an indication for intervention if there is associated HTN, pathological BP response during 
exercise, or significant LV hypertrophy.  
Treatment may also be indicated in hemodynamically non-significant CoA (with a gradient 
less than 20 mm Hg) if there is an imaging evidence of significant CoA (defined as a greater 
than 50% narrowing relative to the aortic diameter at the diaphragm level) and significant 
collateral flow, which may mask the severity of the CoA (Class I; Level of Evidence: C),109 
or if the patients are hypertensive (Class IIa; Level of Evidence: C).108 The guidelines above 
recommend that these treatment indications be the same for native CoA and reCoA.  
There are no specific guidelines for asymptomatic older children, but the indications noted 
above are widely accepted in clinical practice and, as for adults, the timing of treatment 
should be after the diagnosis of significant CoA is made.111 
In neonates and infants, even if only mildly symptomatic or asymptomatic, there is an urgent 
indication for treatment since they are at risk of developing heart failure. This is particularly 
true in the neonate with a patent ductus, that may not have a significant gradient due to 
the patent ductus supplying the descending aorta or ventricular dysfunction resulting in low 
cardiac output. 
1.8.2. Medical Management
The mainstay of medical treatment in the neonate with CoA is prostaglandin E1 (PGE1). Since 
the in vitro description of its role in the regulation of the intrinsic muscular tone of the 
ductus arteriosus,112 pharmacologic manipulation of the ductus has become an important 
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first line palliation in ductus-dependent CHD such as the critical CoA of the newborn. If there 
is a prenatal diagnosis or postnatal early diagnosis, prompt institution of a PGE1 infusion will 
avoid the overt heart failure that may develop in neonates with CoA. Even when a newborn 
presents critically ill, this drug can still effectively re-opens the ductus and improves flow 
into the descending aorta, which may reduce the risk of metabolic acidosis and end-organ 
ischemia such as necrotizing enterocolitis and renal failure.113 Medical management of the 
decompensated newborn may also require other measures such as mechanical ventilation, 
inotropic support, and other general supportive intensive care measures. Once clinical 
stability is achieved, the patient should proceed to repair the CoA, as soon as possible.
1.8.3. Surgical Management
1.8.3.1.Introduction
The majority of patients are managed by a left posterior thoracotomy through either the 
3rd or 4th intercostal space, sparing both trapezius and serratus muscles whenever possible. 
However, for cases with severe aortic arch hypoplasia or concomitant correction of other 
associated anomalies, median sternotomy is preferred. Collaterals in neonate and infants are 
usually not profuse, but some patients, particularly beyond infancy, and in adolescents and 
adults, dealing with profuse collaterals, during thoracotomy and aorta mobilization might be 
challenging. 
At surgery, care is taken to identify nearby nerves, thoracic lymph duct area, and collaterals. 
Mediastinal pleura is incised longitudinally over the aorta, from thoracic operculum to 
mid thoracic descending aorta and structures are identified and mobilized. Typically, left 
subclavian, aortic arch and supra aortic trunks, aortic isthmus, ductus and descending aorta 
are dissected circumferentially, mobilized and encircled with silicone loops. Particular care is 
taken with collaterals, posteriorly and laterally placed, and some medial esophageal arterial 
branches. Collaterals should be gently controlled with loops, rarely being sacrificed. This 
mobilization process is standard, but must be individualized to each surgical technique, 
as simple aortoplasty and patch corrections will need far less extensive mobilization of 
structures, than the extended end-to-end type of procedures. Once the structures are 
properly dissected and fully mobilized, the surgeon will need to make technical choices 
based on both anatomical coarctation patterns and his surgical preference. Arch hypoplasia 
is probably best dealt with extended end-to-end technique, and extreme cases will best 
be treated under cardiopulmonary bypass, through a sternotomy. For cases with a long 
hypoplastic isthmus, the subclavian flap aortoplasty may still be an alternative.
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1.8.3.2. End-to-End (and Extended End-to-End) Anastomosis 
Resection and end-to-end anastomosis (Fig. 5) is the technique most commonly used.82 
Fig. 5. End-to-end coarctectomy. (The description of the surgery is in the text)
It implies significant mobilization of the aortic arch and descending aorta, without sacrificing 
any collaterals, and ductus resection, to achieve a tension free anastomosis. An oblique 
anastomotic line with fine continuous or interrupted nylon sutures is typically used, to minimize 
circumferential stenosis at the anastomotic site, when children will grow into adolescence.
The extended end-to-end technique is the preferred method in cases when the arch is 
considered hypoplastic and needing augmentation (Fig. 6). 
Fig. 6. Extended end-to-end coarctectomy. (The description of the surgery is in the text)
It consists in bringing the thoracic descending aorta to the undersurface of the aortic arch, 
reaching a proximal level just distal to the innominate artery. This technique requires extensive 
aorta and aortic arch mobilization and a critical placement of aortic arch clamp, letting 
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innominate artery perfusing the brain, while the arch is being excluded. The anastomosis is 
beveled down to increase its circumference, suturing being similar to the technique used for 
classical end-to-end anastomosis.114, 115
1.8.3.3. Subclavian Flap and Reverse Flap 
This is a classical technique (Fig. 7), now rarely used.82 
Fig. 7. Subclavian flap coarctectomy. (The description of the surgery is in the text)
It can be particularly suitable for neonatal coarctation with isthmus hypoplasia, as it patch 
enlarges the narrowed segment with a vital subclavian flap, but it implies the sacrifice of 
arterial supply to the arm (with few relevant consequences). Despite potentially leaving 
active ductus tissue in the inner wall, the propensity to reCoA is low.
This is an easy operation, also easy to learn. Structures need to be mobilized in the usual way, 
extending subclavian dissection to the thoracic outlet, where the vertebral artery must be 
ligated to prevent steal syndromes to the cerebral circulation. Using two clamps, sometimes 
only one curve clamp, a vertical aortotomy is performed, and a long subclavian flap is slit 
open, reversed and sewn over the aortotomy, taking care to bring it down, well below the 
coarctation shelf by at least one centimeter. Concerns regarding the growth and potential 
ischemic syndromes (rarely described), whenever subclavian artery was sacrificed, would 
lead to the introduction of some clever sliding techniques, as the one introduced by Meier,116 
that preserves the left arm blood flow, as it detached the proximal subclavian artery from 
the arch and slide it down to use as the aortoplasty flap.116 Subclavian flaps have also been 
used, in combination with end-to-end repair, to augment the distal arch, with the advantage 
of using strictly autologous vital patch material, that grows with age.117
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1.8.3.4. Patch Reconstruction 
Patch reconstruction for coarctation repair was introduced earlier, to overcome two problems 
(Fig. 8). Firstly, the concerns that circumferential sutures used with end-to-end techniques 
would prevent growth, particularly when used in children. Secondly, to overcome issues of 
inadequate or non-existent conduits for interposition.118  
Fig. 8. Patch reconstruction technique for CoA. (The description of the surgery is in the text)
Patch repair for coarctation of the aorta is a technically simple procedure, typically used in older 
children and adults, consisting on enlarging the coarctation area with a patch of Dacron®, Gore-Tex® 
or heterograft pericardium. The ideal patch material has not been found, as aneurysms develop 
contra-laterally, particularly with classical Dacron® patches, due to the uneven rigidity of the aortic 
wall or direct surgical injury.119, 120 Therefore, the use of this technique has faded down.82 Some 
have used heterograft pericardium with the expectation that there is less aneurysm formation, 
but the patch reconstruction technique has faded in favor of other surgical approaches.118
1.8.3.5. Conduit Interposition 
When coarctation of aorta repair was introduced, the ideal technique was end-to-end 
anastomosis. However, for some patients, predominantly adults, the extension of coarctation 
and the incapacity to mobilize adjacent aorta, warranted the use of an interposed conduit. 
Initially, homograft material was used, but soon synthetic material would be introduced, 
Dacron® or Gore-Tex®, with excellent results.121 The use of conduits is limited by patient size, 
as growth is naturally limited. The use of conduits less than half of the normal adult aorta 
should not be used, for the risk of becoming stenotic.
Technically, the operation is simple. However, in patients with extensive collateral networks, 
the interposition of a graft may impose their dissection and sacrifice, with the risks of 
hemorrhage and eventually paraplegia, and it is rarely used today.82
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 1.8.3.6. Extra-Anatomical Conduits 
Coarctation repair should, whenever possible, privilege both the physiology and the anatomy, 
however, the objective of a nice anatomical repair should not preclude safety, and the 
primary aim of getting a good hemodynamic result. Therefore, whenever local anatomical 
challenges, namely collaterals, a long narrow segment, or in case of any complex re-do, the 
option for an extra-anatomical conduit should be considered (Fig. 9).
Fig. 9. Extra-anatomical conduit technique for CoA. (The description of the surgery is in the text)
Para-anatomical conduits are an alternative to anatomical reconstructions, whenever the 
direct correction is not possible or is considered too risky. Ipsilateral jump grafts, from the 
aortic arch or left subclavian artery to the descending aorta beyond coarctation, are easy to 
perform and pose few problems. However, truly extra-anatomical conduits will offer a more 
effective alternative to bypassing the coarctation. Typically, they are performed through 
a median sternotomy, the heart is luxated to the left shoulder (not rarely, extracorporeal 
support is recommended), exposing the aorta in a midline position before it will cross the 
diaphragm.122 Mediastinal pleura is incised, the aorta is encircled and a by using a side-biting 
clamp, a large Dacron tube (16 or 18 mm) is anastomosed terminal-laterally to the descending 
aorta. The graft is brought, typically, in between the IVC and the inferior right pulmonary 
vein, to lie laterally in the pericardial sac, in a position that will facilitate a terminal-lateral 
anastomosis to the right aspect of the ascending aorta.      
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1.8.3.7. Postoperative Management
Post-operative strategies should be oriented taking into account the preoperative course and 
patient age. A newborn who presents with low-cardiac output, metabolic acidosis and renal 
failure should undergo a different medical approach than an older child with preoperative HTN. 
As a rule, patients are usually monitored with an arterial line and an indwelling catheter to 
quantify urinary output. Noninvasive BP measurements in the upper and lower limbs are 
vital to identifying residual CoA, and somatic near-infrared spectroscopy is used to assess 
the systemic perfusion. Fluid management in older children is not restricted, but newborns 
and infants should have two-thirds restrictive fluid administration. Neonates with severe CoA 
and poor systolic function frequently need inotropic support. Milrinone and dopamine are 
the most commonly used. 
Post-operative paradoxical HTN is a common feature, can present with abdominal pain, 
mesenteric arteritis and even bowel ischemia and requires strict BP control to prevent 
anastomosis leaks and bleeding. Possible explanations are neuro-hormonal elevated 
sympathetic nervous system activity (early HTN) and the activation of the RAA system (second 
phase or later HTN). There isn’t a consensus about the best medical strategies to achieve 
that goal and variability in patient care is seen, and different pharmacological agents can be 
used.123-125 Betablockers (β-blockers) act by sympathetic blockade and should be the agents of 
choice. Esmolol is a selective short-acting β-blocker with predominant β1-receptor selectivity, 
safe and effective in CoA, and the most frequent choice in the postoperative HTN.125 It should 
be started with a 100 to 500µg/Kg bolus followed by a continuous infusion starting at 50 µg/
Kg/m titrated as needed. Labetalol has α1 and non-selective β-blocker effect and can also be 
safely used. Sodium nitroprusside acts as a direct and potent vasodilator (continuous infusion 
0,5-1 µg/Kg/m),  and in spite of the risk of thiocyanate toxicity, it is still currently used.123, 125 
In cases of severe HTN, as seen in older children, sodium nitroprusside and β-blockers can 
be considered in association. Other agents can be considered as adjunctive therapy, like 
dexmedetomidine in a continuous infusion (0,2-0,7 µg/Kg/h). This agent is a selective α2 
receptor agonist acting directly through it symphaticolytic effect, reducing HR and BP and 
indirectly by achieving pain control and sedation and therefore preventing HR and BP to 
rise.124, 126
Older children do not generally need ventilator support and are quickly extubated after 
CoA repair. Newborns that presented preoperatively with cardiogenic shock and dilated left 
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ventricle with poor systolic function may require mechanical ventilation for longer periods 
of time, at least for 24-48 hours. Ventilation weaning and extubation should be done after 
the cardiac output is reestablished (normal lactate levels, urinary output greater than 1 mL/
Kg/h) and echocardiographic signs of LV function recovery are evident.
1.8.3.8. Acute Results
Coarctation surgical repair is a standardized procedure, known for achieving excellent 
outcomes.82, 127, 128 Results for neonatal correction have been extensively reported: Two 
decades ago, two-year survivals were of 84%.127 A review of the Society of Thoracic Surgeons 
Congenital Heart Surgery Database reported contemporary results for 2705 patients, with 
a mortality of 1% and complications in 25%.82 Another recent review (343 patients; 42% 
neonates, 36% infants, and 23% older children) showed that mortality was only neonatal 
(3%), independent from surgical technique and acute outcomes were superior when 
coarctation was repaired earlier.128
The most feared but rare complication (0-0.4%) is paraplegia.82 Risk factors are CoA 
with minimal collaterals, prolonged cross-clamp times, long excluded aorta segments, 
division of collaterals, hypotension, and hyperthermia. Protective measures such as 
shunt bypass or extracorporeal circulation, local hypothermia, systemic pressures in the 
high range, and short aortic cross-clamp periods will minimize the risk for this much-
feared complication.
Recurrent laryngeal nerve injury (1.6%) with unilateral vocal cord paralysis, stridor and airway 
obstruction or phrenic nerve injury (0.4%) with hemidiaphragmatic paralysis, can occur and 
may lead to extubation failure.82 The clinical presentation depends on the severity of the 
nerve damage (transient or permanently damaged) and on patient age (newborns tend 
to do worst). Nasal continuous positive airway pressure (CPAP) can be tried in less severe 
cases. Hemidiaphragmatic paralysis can spontaneously resolve but occasionally requires 
diaphragmatic plication, especially in cases of failure of a second extubation attempt. 
Chylothorax (2.1%),82 is usually management conservatively with dietary lipid manipulation 
(restriction of long-chain fatty acids and supplementation with medium-chain fatty acids) 
or total parenteral nutrition and octreotide infusion. Surgical approach with thoracic duct 
ligation may be considered if the chylothorax recurs or if the previous measures do not 
achieve resolution. 
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Post-coartectomy syndrome generally occurs two or three days after surgery, rarely in 
neonates, and is characterized by HTN, severe abdominal pain with abdominal tenderness, 
vomiting, ileus and even melena. It is most likely caused by necrotizing arteritis of the small 
mesenteric arteries probably related to the sudden increase of BP in the mesenteric territory. 
It can be prevented by BP control and avoiding early enteral feeding, which should be started 
very slowly and after bowel sounds are present and abdominal exam normal.
1.8.3.9. Long-term Outcomes
The incidence of reCoA is 4-25% and occurs in all surgical techniques.129, 130 Neonates have 
higher reintervention rates, which is not associated with the type of repair, surgical era, 
or arch hypoplasia.107 In a recent study, freedom for reCoA was 93% when end-to-end 
anastomosis in a neonatal population (median f/u 6 years).128
Another concern is local aortic wall complications. Aneurysms have a high incidence after 
patch repair, even with more distensible patches.119 The incidence of aneurysms after surgical 
repair is reported between 2-24%.131-138 The 2017 update from the Congenital Cardiovascular 
Interventional Study Consortium (CCISC) prospective registry showed an aneurysm incidence 
of 4% with end-to-end, 17% with patch, and 9% with tube graft (results for subclavian flap 
not reported).137 The incidence of aneurysms is associated with BAV and longer follow up.138 
Late complications will affect survival, including systemic HTN and cardiovascular morbidity.
1.8.4. Balloon Dilation
1.8.4.1. Introduction
BD has been used to treat CoA for more than three decades. Conceptually, it is a simple 
procedure that consists in inflating a balloon located at the tip of a catheter, advanced over 
a guide-wire, in the CoA  (Fig. 10). 
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Fig. 10. Balloon dilation of a native CoA. Balloon dilation of CoA. In panels A and B (above), biplane aortography 
(right anterior oblique 30°, and left anterio oblique 70°) shows a native CoA. In panels C and D (below), after 
balloon dilation of the CoA, there is no residual stenosis. A small endothelial tear is seen (arrow, in panel C). 
(image from a LOVE-COARCT patient cardiac catheterization).
The inflation of the balloon produces a controlled tear of the aorta’s intima and part of the 
media, meant to achieve a relief of the stenosis when the vessel heals in the newly created 
diameter.139, 140 In experimental lamb coarctation, it was found that there was complete 
intimal healing two months after the dilation.141 
1.8.4.2. Technique
BD is done most frequently in a retrograde fashion, via femoral artery access. It can also 
be performed via an antegrade approach, through a venous access, a technique useful in 
infants with single ventricle-type malformations that allow the aorta to be accessed in such a 
fashion. There are many options for balloons, including some that were purposefully designed 
for CHD. The balloon diameter should be two to three times the minimum diameter of the 
lesion without exceeding 1.2 times the diameter of the surrounding aorta. The balloon length 
should be long enough to completely cover the area of the coarctation and provide stability 
during inflation and, at the same time, short enough not to extend too far in either direction 
away from the coarctation in which the natural curvature of the aortic arch impedes full 
inflation. If the diameter of the balloon is adequately chosen, it should be inflated until full 
resolution of the waist or the maximum inflation pressure is achieved. The contrast should 
be relatively diluted to ensure fast deflation.
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1.8.4.3. Results for native CoA
Several papers report that BD for native CoA is an acutely successful procedure in 80-94% 
of the cases.131-134, 136, 142-145 The Valvuloplasty and Angioplasty of Congenital Anomalies 
(VACA) registry published several important multicenter studies on procedural outcomes 
of BD of coarctation of the aorta, including one that reported the short-term results of BD 
in 140 patients with native CoA that showed the procedure to be safe (0.7% mortality, 17% 
morbidity) and effective (86% immediate procedural success) in relieving CoA.132
In the mid- and long-term follow up, the incidence of reCoA is variable (8-32%) and depends 
on the patients age.131, 133, 134, 136, 142-144 A mid-term follow-up (median f/u 36.2 months; range 
12-117 months) study of 102 patients with native CoA had an immediate success of 91% 
but 23% required re-intervention due to reCoA. In that study, 88% of infants > 7 months old 
and older children required no additional intervention but, in contrast, 71% of the neonates 
required reintervention, suggesting that balloon angioplasty of native CoA is effective in 
infants and older children but provides only effective palliation in neonates.133 Another 
mid-term (mean f/u 31 ± 18 months; 67 patients) confirmed a higher incidence of reCoA 
in neonates (83%), compared to infants (39%) and older children (8%).134 On the opposite 
end, a long-term study (median f/u 13,4 years; range 1-22 years) of older patients (58 
patients; mean age 24+/-9 years) reported an immediate success of 92%, no early mortality 
and only 8% of the patients with initial immediate success developed reCoA and required 
reintervention.131
The risk of aneurysm formation is a significant concern after BD but its true incidence is 
unknown, and reported between 2 and 24%.131-136, 142, 143 This is likely due to different definitions 
of an aneurysm, distinct methodologies of looking for this diagnosis, and the historical impact 
of the evolution of technique in retrospective series (low-pressure, progressive or stepwise 
BD and smaller balloon sizes). When there is late integrated imaging, the aneurysms appear 
to remain stable or regress and rarely require intervention.135, 143, 146 One recent paper looked 
at the long-term (mean f/u 8.5 years, range 2.2-13 years) aneurysm formation in 29 adult 
patients who had BD of a native CoA. An angiographic intimal tear was detected in 8 (28%), 
without signs of dissection, and remained unchanged or diminished in a three-month follow-
up angiography. MR or CT excluded late aneurysm formation, and in the latest follow-up, only 
3/8 still showed a persistent irregular aortic contour without progression or an aneurysm 
formation.146
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1.8.4.4. Results for reCoA
BD has an immediate success in 88-93% and 0-1% major complications in reCoA (including 
mortality or need for urgent surgery due to aortic rupture).147-152 The VACA registry reported 
the multicenter prospective results on 200 patients (mean age 7.0 years, range 1 month to 
26 years) and reported an immediate success in 79%, with a 2.5% procedure-related deaths 
and 8.5% vascular morbidity.152 In the long-term follow up, different studies (with median f/u 
between 3.5 to 8.1 years) showed that reCoA occurred between 10 and 27% of patients, and 
aneurysm formation between 0 and 4%.148-151 The surgical technique did not have an impact 
on acute or long-term outcomes and older age at the angioplasty was associated with a 
higher incidence of reinterventions.150
Despite the promising initial results that showed BD of native and recurrent CoA as safe 
and effective techniques, especially after the neonatal period, the concern about aneurysm 
formation inhibited BD of achieving wide popularity as a first-choice treatment for the native 
CoA, while it was accepted as the first choice for relief of reCoA. To address this discrepancy, 
a review of the VACA registry compared acute BD results of native CoA vs. reCoA from 970 
procedures (422 native and 548 recurrent lesions) performed between 1982 and 1995 in 
907 patients from 25 centers. The procedural success was significantly higher in native (81%) 
vs. reCoA (75%), and complications overall were similar for both groups, except for more 
reported intimal tears or flaps in the native coarctation group (native CoA 5.2% vs. reCoA 
1.6%). The authors concluded that acute results and complications of balloon angioplasty of 
native coarctation appeared to be equivalent or slightly superior to those of recurrent aortic 
obstructions.153 In that same study, there was an overall significant trend for failure with 
increasing age and a slightly increased risk in neonates.  
1.8.5. Stent implantation
1.8.5.1. Introduction 
After its introduction in the mid-90s, stenting of CoA (Fig. 11) has rapidly gained popularity,154 
because, contrary to the BD, the rigid endovascular prosthesis avoids vessel recoil, provides 
a sustained gradient relief and allows a more controlled dilation of the aortic wall that avoids 
over dilation and the potential risk of aortic rupture. 
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Fig. 11. Stent implantation in native CoA. In panel A (left), the aortography in a left anterior oblique projection 
shows the anatomy of the CoA. In panel B (right), the aortography is performed after the stent has been 
implanted, showing adequate stent position and no residual stenosis. In both pictures, a venous catheter is 
seen, in the pulmonary artery.  (image from a LOVE-COARCT patient cardiac catheterization).
Patient weight is a major limitation for stent placement in CoA due to the risk of femoral artery 
injury and the aorta needs to be large enough to accommodate a stent that can be dilated up 
to an adult sized aorta, even if it is done in subsequent staged interventions. Although it can be 
feasible,155, 156 most authors agree that it is generally not recommended to implant stent for CoA 
treatment in patients weighting less than 25kg.101, 111, 154, 157 
1.8.5.2. Technique
The vast majority of CoA stenting is done retrogradely since there is a fairly direct route 
from the femoral artery. Stent implantation is a little more cumbersome than balloon 
angioplasty of the CoA but currently done as a routine procedure in most Pediatric 
Cardiology catheterization laboratories. The stent is mounted over a balloon-tipped catheter 
and advanced over a guiding-wire through a long delivery sheath. When the stent is in the 
optimal position, the sheath is retracted, and the balloon inflated up to the diameter of the 
width of the surrounding aorta. Angiographic and hemodynamic assessment are done to 
decide whether there is a need for further stent inflation to achieve an optimal result. If the 
initial CoA is very tight, staged dilation may be preferable instead of expanding the stent to 
the full diameter.  
There are many technical tips and tricks that include the type and location were the guide-
wire tip is placed, the strategy to mount the balloon and loading into the sheath (front vs. 
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back-loading), the use or not of balloon predilation, the use of maneuvers to diminish the 
blood flow and assure a proper positioning (adenosine or rapid ventricular pacing) and the 
way to make control angiographies during the procedure (through the sheath vs. additional 
venous or arterial access). The current Cath Lab armamentarium is wide in terms of stents and 
balloons, and operators have to choose the type stent (different brands that have different 
sizes, metal alloys, pre- vs. unmounted, and open vs. closed cell, balloon and also sheath and 
guidewire. These choices are mostly based on personal and institutional experience, and 
many are not guided on evidence-based medicine. 
1.8.5.3. Acute Results
Numerous publications reported that stent implantation for CoA is acutely safe and effective, 
for both in native and reCoA.157-169 The success of the procedure is achieved in 95-99% and 
most patients have a very good angiographic and hemodynamic result, with a final gradient ≤ 
5 mm Hg. The mortality rate is 0-1.4% and the adverse event rate of 0-7.3%. The largest study 
to date reported the acute results of coarctation stenting (52% native) in 555 consecutive 
patients from 17 institutions.168 The median balloon to coarctation ratio was 2 (1.1–18). 
A successful procedure (defined as a final gradient < 20 mm Hg or increase in post stent 
coarctation to descending aorta ratio (CoA:DAo) of > 0.8 was achieved in 97.9%. There were 
two procedure-related deaths, and 14.3% of the procedures had complications, including 
3.9% aortic wall lesions (intimal tears in eight, aortic wall dissection/rupture in nine, and aortic 
aneurysm in six), 2.3% injury to access vessels and 8.1% technical-related complications (stent 
migration, balloon rupture). The risk of aortic dissection increased significantly in patients 
over the age of 40 years. More recently, the Coarctation of the Aorta Stent Trial (COAST), a 
prospective, multi-center, single-arm clinical study involving 19 pediatric cardiology centers 
in the United States reported their acute results of CoA bare-metal stenting (57% native 
CoA).169 All procedures started with simple BD and if the balloon waist was less than 80% 
of the maximum balloon diameter, the aorta was labeled noncompliant and the patients 
ineligible for inclusion in the trial. Stent implantation diameter did not exceed 1.4 times the 
diameter of the balloon waist during compliance testing and was not greater than 1.1 times 
the lesser diameter of the distal transverse arch or the descending aorta at the level of the 
diaphragm. All patients achieved successful stent implantation (final gradient < 20 mm Hg 
and CoA:DAo 0.84 ± 0.18). There were no deaths and 7% adverse events (aortic aneurysms 
in 4, localized dissection in 1, stent migration in 1, injury to access vessels in 2). Covered 
stents were first described to treat aortic wall complications,170, 171 but have since been used 
prophylactically in selected cases, to prevent the occurrence of such complications.172-175
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1.8.5.4. Mid-term Results
There are a few mid-term results,158, 161, 164-167, 176 and the long-term implications of stent 
placement in the aorta are mostly unknown.177 CCISC reported the mid- (3-18 months, 124 
patients) and long-term (> 18-60 months, 46 patients) results of their 34-center cohort.177 
Procedural success (defined as arm-to-leg systolic gradient < 20 mm Hg, lack of significant 
recurrent obstruction, and freedom from unplanned repeat intervention) evolved from 96% 
after the procedure, to 86% in the intermediate follow-up and 77% in the long-term follow-
up. Advanced integrated imaging including CT scan, CMR, or catheterization, showed that 
20% had reCoA and 1% had aortic wall complications, which were associated with balloon: 
coarctation ratio of > 4 and performance of pre-stent BD. Other adverse events occurred 
mainly acutely and included technical complications such as stent malposition. A significant 
number of the interventions (64%) were elective staged procedures. However, unplanned 
repeat interventions were required in 4%, due to intimal hyperplasia, stent re-stenosis, 
fracture, and arterial wall complications. The prospective COAST study also reported their 
mid-term (12- and 24-month) results: 11% had reCoA in the context of planned staged 
dilation or somatic growth and required stent re-dilation; some degree of stent fracture 
was observed in 22% but with no embolization, loss of stent integrity or necessity for re-
intervention; and 4% had de novo aneurysm, rarely requiring re-intervention. The overall 
re-intervention rate in this cohort was 14%.  
1.8.6. Decision Making
There are no randomized, prospective trials comparing the results of balloon angioplasty, 
surgery, and stent placement for the treatment of CoA. A Cochrane Collaboration® review 
was deemed impossible due to a lack of randomized controlled trials comparing CoA 
treatments and highlighted the need for prospective randomized controlled clinical trial 
with an emphasis on primary outcomes such as quality of life and long-term survival. The 
current treatment decisions are based on mostly retrospective single-treatment and a few 
retrospective comparison studies and metanalysis, that have selection bias concerning 
anatomy, age at repair, personal, and institutional preference.178, 179 Therefore, there remains 
controversy and uncertainty about the best treatment modality in coarctation of the aorta.
1.8.6.1. Native CoA in the Neonate and Young Infant
In these patients, with weight usually < 10 Kg, stent treatment is not technically feasible in 
most, due to the size of the aorta and access vessels and is only considered as a palliative 
approach in exceptional circumstances. Most studies that reported a comparison between BD 
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and surgery in this age group showed that the acute outcomes are not significantly different, 
but surgery is associated with fewer re-interventions and aortic aneurysm formation than 
BD.178, 180-184 Only a recent, retrospective comparison (92 patients) of BD vs. surgical repair 
for short-segment coarctation, found no difference in the acute and mid-term outcome.185 
Surgical repair is considered by most to be the best approach for these age groups, and BD 
should be reserved as a palliative strategy in high-risk patients to stabilize their condition 
prior to definitive correction.178, 180, 183 Many cohort studies over 35 years comparing surgical 
techniques favor the choice of aortic resection and end-to-end anastomosis,186-191 when 
possible, but few large cohorts still advocate the use of subclavian flap as a reliable and 
straightforward approach, particularly in cases with a long hypoplastic isthmus.192, 193 Arch 
hypoplasia is probably best dealt by extended end-to-end technique, and extreme cases will 
best be treated under cardiopulmonary bypass, through a sternotomy. 
1.8.6.2. Native CoA in the Older infant and Young Children
In these patients, with weight comprised between 10 and 25 Kg, the aorta’s small size 
still constitutes a technical limitation for stent implantation, and the two viable treatment 
options remain BD and surgery. There are few direct comparison studies of surgery vs. BD 
in these ages. One interesting prospective, randomized, small single-center trial compared 
BD and surgery for native CoA. The acute,194 and long-term195 results showed no difference 
in gradient reduction and reCoA, but the incidence of aortic wall injury (35% vs. 0%) and 
need for re-intervention (50% vs. 13%) were significantly higher with BD vs. surgery. Two 
small, single center retrospective studies showed similar results between BD and surgery, 
but the former had a higher incidence of re-CoA and need for re-intervention.183, 184 The 
available comparative studies favor the surgical approach vs. BD, but a review of studies, 
taking into consideration the favorable BD individual series results,196 consider this technique 
as a primary option in this age group, which is regarded as a reasonable option in patients 
beyond 4 to 6 months of age (Class, Level of Evidence: C).197
1.8.6.3. Native CoA in Older Children, Adolescents and Young Adults. 
In patients with weight > 25 Kg, all three treatment modalities are technically feasible. There 
are a few studies that compare treatment modalities, but all135, 183, 186, 198-200 except one compare 
only two of the three techniques. A clinical, randomized, 5-center trial with 58 pediatric 
patients comparing surgery and BD  showed no acute differences but a higher reCoA rate in 
the BD group in the short-term follow-up.186 One multicenter retrospective study (80 patients, 
four centers)183 compared the three treatments acute and mid-term results and found similar 
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effectiveness in acute gradient relief and again that BD was associated with a higher rate of 
re-intervention and aneurysm formation.135 Smaller single center studies comparing the three 
modalities (9 patients),183 surgery vs. stent (28 patients),198 and surgery vs. BD (46 patients),199 
found no difference in acute outcome, re-intervention, and incidence of aneurysm.
The largest and most significant study is based on the Congenital Cardiovascular Interventional 
Study Consortium (CCISC) prospective registry, started in 2005 as an attempt to answer the 
lack comparative data for the three treatment modalities, for patients ≥ 10Kg. Their results 
comparing the treatment outcomes for native CoA were initially published in 2011130 and 
recently updated (BD 85 patients, stent 422 patients, surgery 102 patients; mean f/u 36 
months; 18-92).137 The three techniques did not differ in the acute and intermediate success 
in achieving an adequate resolution of the stenosis. However, the stent group has significantly 
fewer complications in the acute and intermediate follow-up, and the complications differed in 
nature: the stent group has more vascular and technical-related complications, the BD group 
has more aortic wall injuries and the surgical group has more severe post-operative HTN, 
atrial fibrillation, pleural effusion, neurological/spinal cord injury and vocal cord paralysis. In 
the intermediate follow-up, a sub-group that had advanced aortic imaging (CT scan, CMR or 
catheterization) demonstrated that BD (39%) had more aortic wall injury (dissection/ intimal 
tear or aneurysm) than surgery (10%) or stent (5%). In contrast to surgical patients, late 
aneurysm formation in BD and stent patients is rare and typically occurs within the first year 
after the transcatheter procedure,145, 168 and rarely requires treatment. 
Despite the favorable acute BD results, only a minority of authors advocate its use as a 
first choice.145 Its association with a higher rate of recurrent obstruction and aortic wall 
injury made the treatment choice in most centers for CoA to be between surgery or stent 
therapy.111, 154, 200-202 Regarding surgical technique, the requirement for tube graft interposition 
or patch augmentation of the coarctation segment increased significantly, particularly in long 
segment CoA and only 42% of the patients > 8 years of age, 25% of patients > 12 years of age, 
and none > 16 years of age were able to undergo end-to-end repair of their CoA segment.130 
The European guidelines make no specific treatment recommendations but assert that in 
many centers, stenting has become the treatment of first choice in adults of native CoA with 
appropriate anatomy108 while the North American guidelines state that the choice between 
the treatment techniques should be a team decision based on a case-by-case, institutional, 
practitioner, and patient preference. (Class I; Level of Evidence B110 or C109). Some authors 
advocate specific treatment techniques but, given the lack of strong data, the decision is 
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ultimately based on age and weight, anatomic details, practitioners and institutional results 
and patient’s preference.
1.8.6.4. ReCoA
Despite the lack of prospective, randomized studies, the results and complications of 
percutaneous treatment for reCoA compare favorably with surgical therapy, and this is 
accepted as the preferred treatment for all reCoA. The only Class I (level of evidence C) 
indications in clinical practice guidelines regarding CoA treatment are to indicate that it is 
reasonable to use percutaneous therapy for reCoA in children197 and adults.108-110 There are 
no studies comparing surgical vs. transcatheter approaches, and these recommendations 
are based in evidence that shows that mortality for surgical reoperation is higher than for 
primary repair (1 to 3 % versus 1%) and can be as high as 5–10% if there are significant 
comorbidities or LV dysfunction.111 The choice between BD and stent is based on the same 
considerations made for native CoA.  
1.9. Follow Up
1.9.1. Morbidity and Mortality
Currently available surgical and percutaneous techniques are equally effective at eliminating 
the gradient across the aortic isthmus in CoA patients.130, 137, 154 However, even after a good 
anatomical result, patients remain to have late morbidity with high rates of late systemic 
HTN detected during routine office visits (12-65%),130, 154, 166, 177, 203-215 at peak exercise (10-
47%),211-213, 216, 217 or during ABPM (30-59%).72, 75, 213, 216-225 A recent study highlighted that 
mild aortic arch hypoplasia, a common finding in treated CoA patients usually considered 
benign in the absence of reCoA, is associated with office and exercise-induced HTN.226 
Elevated BP has long been recognized as an indicator of disease and contributes to the 
suboptimal long-term prognosis. There is a worldwide consensus on the need to identify 
and treat people with HTN before vascular or cardiac damage occurs. The abnormal BP 
profile may contribute to the suboptimal long-term prognosis successfully observed in 
repaired CoA patients.  
The increased pressure afterload after repair has been shown to increase LV mass, both by 
echocardiogram217, 221, 227-232 and CMR,75, 231, 233-236 which may explain the normal or increased 
LV systolic function based on M-Mode or 2 Dimensional echocardiography,221, 237-241 but not 
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accurately reflect myocardial performance. Recent studies, including tissue Doppler, speckle 
tracking and strain imaging show abnormal regional fiber shortening,225, 229, 230, 232, 234, 235, 238, 242-
246 and diastolic dysfunction.230, 232, 238, 244, 247, 248 According to a recent study, a combination of 
clinical assessment and CMR is the most cost-effective approach to long-term surveillance of 
patients with repaired CoA.249
Treated patients with no clinically significant gradient have reduced life expectancy, mostly 
due to cardiovascular complications (such as coronary heart disease, sudden cardiac death, 
end-stage heart failure, and rupture of aortic aneurysms),207, 250-253 and stroke (reported to be 
seen up to 13 times more frequently in patients with coarctation).254, 255 
1.9.2. Pregnancy
Pregnancy is usually well tolerated in treated patients with no residual stenosis, aortic 
wall aneurysms and none or well controlled HTN.256-258  The presence of HTN before 
pregnancy should prompt close monitoring of the BP, avoiding medication that is known 
to be teratogenic such as angiotensin-converting enzyme inhibitors or angiotensin receptor 
blockers.259 A recent review of pregnancy outcomes in women with CoA (50 patients; 38% 
with hemodynamically significant coarctation; 118 pregnancies) reported one maternal 
death (due to aortic dissection in a Turner syndrome patient), 9% of miscarriages and 3% 
premature deliveries; the neonates had CHD in 4%, and there was one neonatal death; 30% 
had HTN during their pregnancy, and related to the presence of significant isthmic stenosis.257 
Therefore, timely treatment of reCoA and aneurysms is vital to ensure a safe pregnancy.
2. VASCULAR FUNCTION
2.1. Introduction
CVD represents the visible ending of a pathophysiological process called the cardiovascular 
continuum.260, 261 This starts with many risk factors and progresses through numerous physiological 
pathways and processes to the development of end-stage heart disease. Several large studies from 
previous decades have identified what are now known as the traditional risk factors for CVD: age, 
gender, dyslipidemia, HTN, diabetes, smoking, obesity and family history  (Fig. 12):
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Fig. 12. The cardiovascular disease continuum. (Reprinted from Dzau et al,262 with permission from Elsevier). 
It is interesting that the first studies on high BP were based on recordings of the shape of 
the arterial pulse wave obtained with a sphygmograph, a mechanical device invented in the 
mid-XIX century by the German physiologist Karl von Vierordt.263 It was only in the early 
XX century that the sphygmomanometer, a device that measures the BP, gained popularity 
as the most common approach to measure BP. In recent years, the analysis of the arterial 
pulse waveform regained popularity and, together with many other measurements that 
reflect the function of the arteries, have been grouped and are now known as indices of 
vascular function. These biomarkers reflect the biomechanical properties of the vascular 
wall and circulating biomarkers (vasoactive mediators, inflammatory responses, and vascular 
remodeling modulators that affect the biomolecular arterial response) and act together in 
a cascade of events that culminates in end-organ pathology. Man studies showed a clear 
association between increased arterial stiffness and risk of major cardiovascular events.264
The interest of vascular function to researchers and clinicians is depicted in Fig. 13, that shows the 
significant increase in publications that occurred in the XXI century that report arterial stiffness:
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Fig. 13. The frequency of ‘arterial stiffness’ in the title PubMed publications. (reprinted from Townsend1 with 
permission from Karger Publications) 
2.2. The function of Arteries
The function of the systemic arterial system is to deliver blood at high pressure and in a 
continuous stream to peripheral vascular beds, and can be simplistically divided into three 
regions:265 large arteries serve predominantly as a cushioning reservoir that stores blood 
during systole and expels it during diastole; muscular arteries act predominantly as conduits 
that distribute blood to the organs and actively modify wave propagation by changing its 
smooth muscle tone and diameter; and arterioles change their caliber and control peripheral 
resistance and affect mean arterial pressure. 
Changes in the properties of large elastic arteries make them stiffer and is called arteriosclerosis 
(derived from the Greek word sclerosis which means hardening) and modifications in the 
small muscular arteries properties lead to abnormal vascular reactivity. All these biomarkers 
can be objectively measured and evaluated as indicators of this pathological process.
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2.3. Indices of Vascular Function 
The publication of the 2006 European consensus document on arterial stiffness266 and the 
2015 American Heart Association scientific statement on arterial stiffness measurements267 
have guided researchers and clinicians in the choice of methods, standardization of 
measurement and appraisal of results of vascular function. Most of the indices of vascular 
function are standardized for adults, however, measuring them in children is feasible but 
presents some age-related challenges and limitations, such as heart rate and body habitus.268
2.3.1. Arterial Stiffness 
Arterial stiffness refers to the biomechanical properties of the arterial wall, which, in turn, 
affect the way pressure, blood flow, and arterial diameter change with each heartbeat. 
Arterial stiffness reflects the vessel resistance to deformation. A complete list of arterial 
indices of arterial stiffness can be found in Table 2.
2.3.1.1. Pulse Wave Velocity
Arterial stiffness is most often determined by measuring the velocity of pulse-wave travel in 
a segment of the vessel, where a higher pulse wave velocity (PWV) signifies increased aortic 
stiffness.269 The arterial wall fiber elements are stretched and recoil with each ventricular 
contraction, and an arterial stiffening will increase the velocity of blood.
PWV can be measured in many segments of the arterial tree.266, 267 However, carotid-femoral 
PWV (cfPWV) is the one that has been extensively validated in large studies as an independent 
predictor of cardiovascular morbidity and mortality.266, 267, 270-275 cfPWV is considered the gold 
standard of arterial stiffness but PWV measured in other arterial segments also possesses 
research and clinical interest.266, 267 
There are several methods to undertake PWV measurements, namely: (a) devices that use a probe 
or tonometer to record the pulse wave with a transducer;276 devices using cuffs placed around 
the limbs or the neck that record arrival of the pulse wave oscillometrically;277 ultrasonography 
approaches;278 and CMR-based approaches.279 Any of these allow the measurement of the time 
delay or transit time (T) between the feet of the carotid artery and femoral artery waveforms. 
The distance (D) between the two sites is then measured. This measurement should be done 
precisely and in a standardized fashion, since it may introduce a human error that affects the 
results. Several ways have been used to estimate the distance between the two sites, but both 
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the European consensus document266 and the American Heart Association scientific statement267 
recommend measuring the suprasternal notch to the carotid pulsation site, and the suprasternal 
notch to the femoral pulsation site, and then subtracting the carotid from the femoral distance. 
PWV is calculated as PWV = D (meters) / T (seconds). (Fig. 14)
Cammon 
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Fig. 14. Measurement of carotid-femoral PWV with the foot to foot method. (Reprinted from Laurent et al,266 
with permission from Oxford University Press). 
PWV is influenced by the mean arterial pressure and therefore its measurement requires the 
patient to lie supine in a quiet and stable environment for at least 10 -15 minutes to ensure 
hemodynamic stability and eviction of alcohol, smoking, caffeine-containing food and drinks 
or bouts of vigorous exercise, ideally for 12 hours. HR exerts a minimal influence on PWV 
in the lower range of mean pressure values and only a small but significant effect in higher 
values.280 There are reference values published for cfPWV in both children281 and adults.282-284 
Because of distinct measurement approaches, it should be emphasized that these values are 
applicable predominantly to measurements performed with the same methodologies.
2.3.1.2. Local Elastic Properties of the Arterial Wall
There are a host of indices that have been introduced to assess the elasticity of the aortic 
wall, by measuring changes in vessel diameter as a response to changes in pressure and 
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include aortic strain (relative change in diameter), compliance (absolute change in 
diameter in response to a change in pressure), distensibility (relative change in diameter 
in response to a change in pressure), and the aortic stiffness β index (distensibility using 
the logarithmic conversion of the relative pressure). These indices are measurements 
of local elastic properties of the arterial wall, and not measurements of regional stiffness 
such as PWV (Table 2):
Table 2. Indices of arterial stiffness
Term Definition
Methods of 
measurement
Elastic modulus** The pressure change required for theoretical 100% stretch from 
resting diameter
(ΔPXD)/ΔD (mmHg)
Ultrasound*
MIRI
Young’s modulus** Elastic modulus per unit area
(ΔPXD)/(ΔDXh) (mmHg/cm)
Ultrasound*
MRI
Arterial 
distensibility**
Relative change in diameter (or area) for a given pressure change; 
inverse of elastic modulus
(ΔD)/(ΔPXD) (mmHg-1)
Ultrasound*
MRI
Arterial compliance** Absolute diameter (or area) change for a given pressure step 
ΔD/ΔP (cm/mmHg) (or cm2/mmHg)
Ultrasound*
MRI
Pulse wave velocity Velocity of travel of the pulse along a length of artery 
Distance/ Δt (cm/s)
Pressure waveform* 
Volume waveform
Ultrasound
MRI
Augmentation index The difference between the second and first systolic peaks as a 
percentage of pulse pressure
Pressure waveform*
Stiffness index (β)** Ratio of In (systolic/diastolic pressures) to (relative change in 
diameter)
β=  In (PS/Pd) 
    (Ds – Dd)/Dd
Ultrasound*
Capacitative 
compliance
Relationship between pressure change and volume change in the 
arteries during the exponential component of diastolic pressure decay
ΔV/ΔP (cm3/mmHg)
Pressure waveform*
Oscillatory 
compliance
Relationship between oscillating pressure change and oscillating 
volume change around the exponential pressure decay during 
diastole
ΔV/ΔP (cm3/mmHg)
Pressure waveform*
D = diameter; d = diastolic; P = pressure; t = time; s = systolic; v = velocity; V = volume. * Most common method of 
measurement; ** Also requires pressure measurements (Reproduced from Mackensie et al.285 with permission from Oxford 
University Press)
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An advantage of these indices is that the local arterial stiffness is directly determined, from 
the change in pressure driving the change in volume. However, because it requires a high 
degree of technical expertise and takes longer than measuring PWV, they are mostly used for 
research purposes instead of epidemiological studies or daily clinical work. In a recent review 
of published studies, it was noted that several of these indices are biomarkers of CVD, but 
in 8 out of 11 studies at least one of the arterial parameters listed had no relationship with 
outcome.267
The imaging of the artery dimensions can be done with ultrasound and more recently with 
magnetic resonance imaging. Ideally, the distending pressures should be measured invasively 
in the same point as the dimensions were obtained, but this is often not possible, and the 
pressures are usually obtained non-invasively by cuff measurement.
2.3.2. Central Pulse Wave Analysis
The afterload imposed on the LV is determined by the arterial stiffness, arteriolar caliber and 
wave reflection morphology of the arterial tree.286 No single index represents ventricular 
afterload. Central aortic pressure (CAP) and PP are two variables that express elements of this 
arterial afterload.267 Reflected pressure waves arriving in the ascending aorta are quantified 
by the augmentation index (AIx), which is the ratio of the amplitude of the reflected wave 
and the PP (Fig. 15): 
Systolic pressure (P1)
Pulse 
pressure
Diastolic pressure
(P3)
(P2)
Time
Augmentation pressure
Fig. 15. Carotid pressure waveform. (Reprinted from Laurent et al.266 with permission from Oxford University Press)
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Normal peripheral pulse amplification means that brachial pressure should not be confused 
with central SBP and PP.266 CAP is physiologically more relevant and better related to future 
cardiovascular events than brachial pressure.287 Despite being more operator-dependent 
than PWV, the analysis of the central BP and waveform are well documented as important 
clinical tools for monitoring of vascular function and has an independent predictive value 
for CV events.267 A recent meta-analysis of 11 longitudinal studies showed a significant 
increase of total CV events with a 10 mm Hg rise in CAP (1.1 relative risk), PP (1.2 relative 
risk) and AIx (1.3 relative risk).264 Despite this, AIx should not be considered an absolute 
surrogate marker of arterial stiffness.267 It is true that a stiffer vasculature has a higher PWV 
and results in reflected waves arriving earlier in systole that produces a higher AIx. However, 
the degree of augmentation is also related to the intensity of peripheral wave reflection, 
which depends on associated hemodynamic confounders and it is highly sensitive to HR.288 
For this reason, AIx is also commonly normalized for a HR of 75 beats per minute, to allow 
comparison between patients (AIx@75). This is particularly important in children, who 
have a higher HR, which varies significantly between different age groups
CAP is obtained invasively with cardiac catheterization. However, several non-invasive 
methods have been developed to estimate CAP and waveform. These include pulse 
waveform recordings from sites distal to the aorta, such as the carotid, radial or brachial 
arteries. There is a lack of consensus regarding the optimal method to estimate the CAP 
curve using tonometry and each has its strengths and weaknesses. The brachial and radial 
artery derive the CAP using a general transfer function, which has not been validated in 
children. Carotid pressure is most often used as the surrogate for CAP because of the 
close proximity of these two arterial sites.289 Carotid pressure waveforms are recorded by 
applanation tonometry and then calibrated to the brachial mean and diastolic pressures 
obtained by sphygmomanometry, based on the principle that - unlike systolic pressure - 
mean and diastolic pressure do not vary markedly throughout the arterial tree.267
2.3.3. Endothelial Function
Vascular endothelium is the largest organ in the body and plays a major role in the 
homeostasis of the vascular tone, inflammation, and thrombosis. Endothelial function 
results from the balance between vasodilators and vasoconstrictors produced by (or acting 
on) endothelial cells. Nitric oxide (NO) is produced in the endothelium from L-arginine by 
the enzyme endothelial nitric oxide synthase (eNOS). NO has a very short half-life, and it 
is continually produced as a signaling mechanism to the arterial wall, serving to inhibit the 
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adhesion of platelets and leukocytes to the vessel wall and to relax the smooth muscle cells 
to maintain vascular patency and distensibility.290, 291 The production of NO is stimulated 
by flow shear stress exerted directly on the vessel endothelium292-294 and receptor-
dependent agonists such as bradykinin, acetylcholine and adenosine triphosphate.291 In 
the smooth cells, NO activates the enzyme guanyl cyclase, which produces cyclic guanosine 
monophosphate (cGMP) that results in smooth muscle cells relaxation and vasodilation.290 
Endothelial dysfunction occurs when there is impairment of the endothelium-dependent 
vasorelaxation caused by a decline of NO bioavailability. Several human studies have shown 
that traditional risk factors for atherosclerosis such as HTN, diabetes, cigarette smoking, 
and heart failure predispose to endothelial dysfunction.295 
Endothelial dysfunction can result from decreased NO production but is largely due to 
increased production of reactive oxygen species (ROS) such as superoxide that occur 
in the context of oxidant stress, which will accelerate NO degradation and decrease its 
bioavailability.295, 296 A growing body of evidence suggests that endothelial dysfunction is 
associated with cardiovascular events and that it has prognostic implications in patients 
with established stable coronary artery disease, essential HTN, and in patients with acute 
coronary syndromes and peripheral artery disease.297
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There are several methods to quantify endothelial function (Table 3):
Table 3. Methods to measure endothelial function. 
Technique (Outcome measure) Noinvasive Repeatable Reproducible*
Reflects 
Biology
Reversible
Predicts 
Outcome†
Cardiac catheterization 
(change in diameter, change in 
coronary blood flow)
– – +/– + + +
Venous occlusion 
plethysmography (change in 
forearm blood flow)
– +/– +/– + + +
Ultrasound FMD (change in 
brachial artery diameter)
+ + +/– + + +‡
PWA (change in augmentation 
index)
+ + +/– + – –
PCA (change in refletive index) + + +/– + – –
PAT (change in pulse 
amplitude)
+ + +/– + – –
+ indicates supportive evidence in literature; – insufficient evidence; FMD - flow-mediated dilatation; PWA - pulse wave analysis; PCA- pulse 
contour analysis; and PAt - pulse amplitude tonometry.
*Reproducibility or PWA, PCA, and PAT has been less extensively investigated than FMD.
†Studies that link PWA, PCA, and PAT to outcome have not yet been reported.
‡FMD is currently the standart for noninvasive assessment of conduit artery endothelial function because there is considerable clinical trial 
experience, validation, a firm link to biology, and association with cardiovascular events.
Reprinted from Deanfield et al,298 with permission from Wolters Kluwer Health
Endothelial dysfunction can be assessed invasively by intracoronary injection of agonists of 
endothelium-dependent vasodilator acetylcholine299 and brachial artery catheterization with 
venous occlusion plethysmography. In 1992, Celermajer was the first to report the use of 
a non-invasive ultrasound test, flow-mediated dilation (FMD), to assess vascular function 
in the brachial artery.300 Since then, several additional non-invasive modalities have been 
described to assess vascular endothelial function, such as pulse wave analysis, pulse contour 
analysis, digital thermal monitoring, and peripheral artery tonometry.301 Finger pulse 
amplitude tonometry (Endo-PAT)302 has emerged as a promising technique because it is a 
simple method, in contrast to the more cumbersome FMD  (Fig. 16):
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Fig. 16. Reactive hyperemia peripheral arterial tonometry recordings. Above, is the normal reactive hyperemic 
response, characterized by a distinct increase in the signal amplitude after cuff release compared with baseline. 
Below, is the abnormal response, characterized by a blunted increase in the signal amplitude after cuff release 
compared with baseline (reprinted from Bonetti et al,303 with permission from Elsevier)
It requires insertion of one finger of each hand in peripheral tonometers and inflation of 
a cuff in the arm to achieve a 5-minute occlusion on one arm while the contralateral arm 
serves as control. The probe measures the reactive hyperemia index (RHI) that ensues 
after cuff deflation by measuring the increase in pulse amplitude and comparing it with the 
contralateral finger. Endothelial function measured by Endo-PAT can be easily performed 
with high reproducibility in the ambulatory clinical setting,304, 305 has been validated as a 
surrogate for coronary endothelial function,303 and is a risk factor for CVD.303, 306, 307
2.3.4. Circulating Biomarkers
There are many biochemical and molecular processes involved in vascular dysfunction. There 
is a growing research interest in these circulating biomarkers pathways, which constitute 
possible ‘active’ mechanisms that lead to increased arterial stiffness. Our understanding is 
growing but still limited.
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2.3.4.1. Endothelial Function
NO is a key modulator of endothelium-dependent vasodilation, but it’s rapid metabolism, 
and short half-life poses a considerable obstacle for the analytical assessment. However, 
several biochemical mediators of the NO pathway can be measured. These include L-arginine 
(NO’s precursor), endothelial NO synthase (eNOS; NO’s enzyme), asymmetric dimetilarginine 
(ADMA; NO’s inhibitor),308 and nitrite and nitrate (NOx, stable by-product of NO). Endothelial 
dysfunction leads to decreased l-arginine and increases in all other metabolites of the NO 
pathway.
2.3.4.2. Inflammation
Systemic and local inflammation is an important key in the process of atherosclerosis and 
vascular dysfunction.309 
Pro-inflammatory cytokines such as interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor 
necrosis factor alpha (TNF-α) trigger the production systemic inflammatory markers such as 
C-reactive protein.310 A large body of literature shows that high sensitivity C-reactive protein 
(hs-CRP) may help to estimate risk for initial cardiovascular events and may be used most 
effectively in people at intermediate risk for vascular events, offering moderate improvement 
in reclassification of cardiovascular risk.311-313 hs-CRP is associated with other biomarkers of 
vascular dysfunction such as PWV.314 Studies also show that the inflammatory cytokines may 
also be also markers and predictors of CVD.315 
The pro-inflammatory cytokines also act on vascular endothelium to up-regulate the 
expression of several adhesion molecules such as selectins, vascular cell adhesion molecule 
(VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and other adhesion molecules such 
of the selectin family, that play a crucial role in atherogenesis, since these are the receptors 
who mediate the cell adhesion and migration that triggers atherogenesis.309
2.3.4.3. Vascular Remodeling
Another critical area of understanding is the molecular mechanisms of aortic wall 
remodeling to hemodynamic changes. These include the role of transforming growth factor 
beta-1 (TGF-β1), a smooth cell growth-modulating factor, that is involved in the arterial 
wall response to HTN,316 and has been suggested as having a prognostic value regarding 
the degree of dilation of the aorta in Marfan syndrome317 and other dilatative pathology of 
ascending aorta.318 Another aspect is the role of the matrix metalloproteases such as MMP-2 
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and MMP-9, a family of proteolytic enzymes responsible for protein degradation and vascular 
remodeling,319 and are well documented biomarkers for the presence and risk of rupture of 
aortic aneurysm.320
2.3.5. Ventriculo-Arterial Coupling
The cardiovascular physiology concept of the ventricle and the arteries functioning as a 
coupled system is not  recent,321 is called ventriculo-arterial coupling,322 and has been the 
focus of recent attention.323An optimal ventriculo-arterial coupling occurs when the highest 
energy is transferred from the LV to the aorta with a minimum amount of energy wasted to 
overcome resistance to ejection and blood flow. Long standing arterial stiffness leads to LV 
hypertrophy and stiffness, and an altered ventriculo-arterial coupling. In such circumstances, 
heart and arteries interact in a complex interplay to limit the cardiovascular performance 
and generate symptoms.324, 325 Earlier analysis were based on detailed invasive instantaneous 
measurements that were used to plot pressure-flow curves. Recently, the ventriculo-
arterial stiffness assessment can be done with echocardiography or CMR, by measuring 
the LV contractility (representing the slope of the end-systolic pressure-volume relation, 
the end-systolic elastance, Ees), the arterial vascular load as the ratio of ventricular end-
systolic pressure to stroke volume (elastance of the arterial system, Ea), and the relationship 
between Ea/ Ees.326 
3. VASCULAR DYSFUNCTION IN COA
3.1. Treatment Does Not Equal Cure
Currently available surgical and percutaneous techniques are equally effective at eliminating 
the gradient across the aortic isthmus in CoA patients,130, 154 (except in infants and young 
children, in whom surgery is preferred). However, even after a good anatomical result, 
patients remain to have late morbidity with high rates of late systemic HTN detected during 
routine office visits (12-65%),130, 154, 166, 177, 203-215 at peak exercise (10-47%),210-217, 220, 327-332 or 
during ABPM (30-59%).72, 75, 213, 216-225 Patients show signs of premature atherosclerotic lesions 
in the retina,333 internal mammary or coronary arteries.334
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Furthermore, treated patients have reduced life expectancy (Fig. 17), mostly due to 
cardiovascular complications187, 250-253, 335-341 and stroke,255 reported to be seen up to 13 times 
more frequently  in patients with coarctation, compared to the general population.254
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Fig. 17. Single-center follow-up of 819 patients for over 60 years. (reprinted from Brown et al,207 with 
permission from Elsevier)
A metanalysis showed that CoA had the highest incidence of all CHD of long-term vascular 
complications such as 3.2% with stroke or transient ischemic attack and 5.1% with myocardial 
infarction.342 The most recent study still showed a late mortality of 5.7% at a median f/u after 
treatment of 31.4 years (range 14.1–39.9 years) corresponding to a lethality of 0.3% per 
year and estimated survival rates of 97%, 94%, 91% and 80% at 10, 20, 30 and 39 years after 
repair.343 Consequently, CoA should be regarded as a complex and systemic cardiovascular 
syndrome involving the aorta that may not be “cured” after relief of the localized mechanical 
obstruction. In light of the suboptimal long-term outcomes, an editorial has recently 
questioned if we need to redefine the current definition of successful treatment of aortic 
coarctation as a gradient < 20 mm Hg.344
3.2. Vascular Dysfunction is Common after CoA Treatment
The amply documented abnormal resting and exercise-induced BP profile suggest that 
vascular dysfunction may contribute to the suboptimal long-term prognosis successfully 
observed in repaired CoA patients. Indeed, it has long been recognized that successfully 
repaired CoA patients show abnormal vascular function.
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II. BACKGROUND
Patients show increased arterial stiffness, with higher PWV,72, 233, 244, 345-349 and altered compliance, 
distensibility, or the elastic wall modulus.228, 229, 233, 235, 242, 244, 350-356 Concerning intima media-
thickness, a measure of the presence and extent of arterial atherosclerosis, there have been 
conflicting results as to whether it is improved217, 230, 244, 350, 351, 354 or not347, 348, 357, 358 after CoA repair.
Most studies have shown compromised arterial reactivity,217, 224, 328, 345, 347, 348, 350, 359-361 while a 
minority failed to demonstrate impaired reactivity in retinal,333 peripheral362, 363 or coronary363 
arteries of repaired CoA patients when compared to controls. Repaired CoA patients show 
altered pulse waveforms with higher AIx,224, 348, 364 PP,75, 358 and CAP.348, 358, 364 
There is imbalance of numerous biomarkers of vascular function, namely of the NO-mediated 
endothelial function,347, 365, 366 systemic and local inflammation,349, 360, 364, 367 and of the vascular 
wall function349, 360, 364, 368 
Finally, the increased BP phenotype and vascular function contribute to the increase LV 
mass,75, 217, 221, 227-236 impaired LV segmental systolic225, 229, 230, 232, 234, 235, 238, 242-246 or  diastolic 
dysfunction.230, 232, 238, 244, 247, 248 Studies have also shown ambivalent results regarding the 
ventriculo-arterial coupling in CoA: some have shown that there is altered ventriculo-arterial 
coupling in patients with repaired CoA,234, 244  while others did not find that the presence of 
HTN affected the ventriculo-arterial coupling.369 The abnormal ventriculo-arterial stiffness 
may contribute to further HTN in repaired CoA.218   
3.3.  Inherent Pre-Treatment Features May Contribute to Vascular Dysfunction
The damage to the vascular wall occurs before treatment, is present at birth,353 and persists 
despite neonatal treatment.352 Inherent problems that may trigger this vascular dysfunction 
include genetic causes, changes in the arterial structure and function, impaired neuronal 
sensitivity or endocrinal auto-regulation.
The mechanical stimuli caused by an experimental CoA is responsible for the differential 
expression of genes associated with vascular function.63-65 Human studies also revealed such 
genetic polymorphisms in CoA patients.67-69 However, CoA patients do not show the most 
common genomic polymorphisms associated with essential HTN67 or BP regulation during 
exercise,68 thus suggesting a different ethiopathogenic mechanism.
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Light and electron microscopy of pre-coarctation aorta surgical specimens showed 
histopathological changes including increased collagen and reduced smooth muscle 
content.55-57 Recent findings have demonstrated molecular mechanisms that elicit phenotypic 
modulation of smooth muscle cells, accumulation of excessive collagen and inborn impaired 
arterial elasticity in patients with CoA.370 The pattern of histopathological55, 57 or functional233 
vascular changes localized in the ascending but not the descending aorta is also found in 
patients with BAV,59  themselves present in half to two thirds of CoA patients.50, 252 Finally, 
some groups found that a gothic-shaped arch is associated with a worse BP profile.208, 350, 
371-373
The role of the RAA system is unclear in the high BP in CoA. Some studies provided evidence 
of the significance of increased RAA activity in patients with CoA,70-72 while others did not.73-75 
It may be that this neuroendocrine system is important in the early development but not in 
the maintenance of coarctation HTN.76
The autonomic system and baroreceptor’s function may be altered, including an enhanced 
sympathetic tone, reset of the baroreflex to a higher value and diminished sensitivity to changes 
in arterial pressure.77-79, 374 However, some evidence suggests that the neuronal mediation may 
be involved only in the pre-treatment HTN and then normalizes after repair.80, 81
All the above suggest that CoA is not just a localized isthmic stenosis but also an inborn 
systemic vascular disease of the pre-CoA arteries.
3.4.  Acquired and Treatment-Related Factors may also Contribute to Vascular 
Dysfunction
Age of repair is the best document treatment-related factor that affects vascular function.207, 
216, 227, 229, 230, 242, 345, 349, 356, 375-378 Length of follow-up,337, 343 and mild residual narrowing may also 
contribute to vascular dysfunction217, 379-381
Medical management also impacts on vascular function, including studies that show 
the favorable impact of angiotensin-converting enzyme inhibitors,382 β-blockers,73 and 
atorvastatin383 on endothelial function or vascular function biomarkers in patients with 
repaired CoA.
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3.5. Treatment Modality may Affect Vascular Function
The hemodynamic impact of a focal vascular stiffness was shown five decades ago.384 
Different types of treatment may have varying effects on the stiffness of the repaired arterial 
segment.154 Surgical repair results in a focal scar in the site of the surgical anastomosis; 
stenting creates a short, rigid aortic segment; and BD produces a controlled tear of the 
aorta’s intima and part of the media without affecting the adventitia. It is possible that 
different treatments translate into differences in vascular dysfunction. However, the effect 
of treatment modality on vascular function has not been systematically compared, and 
management is often guided by physician or institutional preference with the primary goal 
of alleviating the anatomic narrowing.
The largest (350 patients, 36 institutions), albeit observational and non-randomized, 
comparison between the three different modalities showed a significantly lower BP in 
patients treated with BD vs. those treated with a stent or surgery.130 Similarly, another small 
retrospective study showed less frequent exercise-induced HTN in patients who underwent 
BD, compared with those who were treated with stent implantation or surgery.378 Among 
surgical techniques, those who undergo resection with end-to-end anastomosis have a lower 
prevalence of systemic HTN and arterial stiffness compared to other surgical techniques.385-387 
Another small study demonstrated a lower carotid intima-media thickness in patients who 
had undergone subclavian flap repair compared to those who had stent implantation, 
but PWV was similar between groups.230 Conclusions drawn from these prior studies are 
hampered by methodological limitations, small sample size, heterogeneous population, and 
limited focus.
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The current management paradigm of CoA is often guided by personal or institutional 
preference, with the primary goal of alleviating the stenosis by optimizing the anatomy. 
However, the suboptimal long-term outcomes in apparently successfully treated patients with 
CoA stresses the importance that further research is needed to improve the management of 
this common CHD. The evidence that (a) patients with treated CoA have long-term vascular 
dysfunction and the recognition that (b) vascular dysfunction leads to CV events in the 
general population motivated this study. 
CoA may also be a useful physiological model of HTN that occurs exclusively in the upper body 
and lessons learned in this study may also contribute to the knowledge about the impact of 
segmental stiff arteries on BP and the pathophysiology of HTN in the general population.381
There is a gap between clinical research and clinical practice has been well identified as one 
a critical challenge that requires addressing and fewer than half of all the medical treatments 
delivered today are supported by evidence.388 Furthermore, data shows that in the United 
States, only about half of the effective clinical practices are adopted.389 There are several 
challenges to clinical research, including cost, small incentives for physician participation, 
administrative and regulatory requirements, lack of clinically oriented institutions, diversity 
of clinical presentation of diseases and difficulty in recruitment and retention of patients. 
This is particularly true of CHD, that deals with rare diseases with a varied presentation, and 
especially in CoA patients, who feel mostly well and are seen in spaced clinical visits, despite 
having suboptimal long-term morbidity and mortality. LOVE-COARCT is an attempt to bridge 
this gap of knowledge, by exploring the causes of these late outcomes.  
The aim of this study is to determine whether three different treatment modalities for 
CoA (surgery, BD, and stenting) are associated with differences in arterial stiffness. The 
central hypothesis of this study was that patients who have undergone successful BD 
will have better vascular function than patients who have undergone successful surgical 
repair or stenting since this modality is least likely to damage the integrity and biomechanical 
properties of the aortic wall.
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1. PRIMARY AIM AND HYPOTHESIS
The primary aim of LOVE-COARCT’s Study was to compare arterial stiffness assessed with 
carotid-femoral PWV (cfPWV) between BD, surgery and stent. We hypothesized that BD was 
superior to surgical repair and stenting in preserving vascular function measured by carotid-
femoral PWV (cfPWV) after repair of CoA.
2. SECONDARY AIMS AND HYPOTHESIS
The secondary aims of LOVE-COARCT’s Study were to use other well-established indices of 
vascular function to compare BD, surgery, and stent, namely:
a. Carotid-femoral PWV measured with arterial tonometry and other segmental aortic 
PWV measured with CMR.
b. Indices of focal arterial stiffness measured with CMR: aortic strain, distensibility, 
compliance and aortic stiffness β index. 
c. Endothelial function determined by endothelial pulse amplitude testing (Endo-PAT) 
and circulating biomarkers (NOx, ADMA).
d. Central pulse wave analysis using arterial tonometry and Endo-PAT.
e. BP phenotype at rest, during ambulatory measurement, and at peak exercise.
f. Circulating Biomarkers of vascular function including high sensitivity C-reactive 
protein (hs-CRP) and interleukin 1 beta (IL-1β), local cytokines of vascular wall 
function (vascular adhesion molecule 1, VCAM-1) and vascular remodeling (matrix 
metalloproteases MMP-2 and MMP-9; and transforming growth factor beta-1, 
TGF-β1). NOx was determined by chemiluminescence (Sievers NOAnalyzer 280i), 
and all remaining measurements were performed with appropriate enzyme-linked 
immunosorbent assay (ELISA) kits
g. LV mass and systolic function.
h. Prevalence of ideal cardiovascular health (ICVH) in patients late after treatment of 
CoA overall and by treatment modality.
We hypothesized that BD was superior to surgical repair and stenting in preserving vascular 
function measured by other secondary indices of vascular function.
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We have considered the alternative hypothesis, namely the possibility that the results of 
this study may not support our primary and secondary hypothesis. First, it is possible that 
no significant differences are seen in vascular function between the treatment groups. A 
second possibility is that either stenting or surgery results in less stiff arteries than BD. Both 
alternative scenarios would add important considerations to the literature and guide clinical 
practice for the choice of treatment modality.
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1. STUDY OVERVIEW
LOVE-COARCT was a multicenter cross-sectional prospective observational study of patients 
with CoA previously treated using one of three treatment modalities to identify if treatment 
type is associated with differences in vascular function.    
1.1. LOVE-COARCT Participant Centers
We assembled a multi-disciplinary group of investigators with established expertise in 
epidemiology, clinical trial design, CHD, non-invasive imaging, interventional cardiology, 
vascular function assessment, preventive cardiology and statistical analysis. The rationale 
for using a multicenter design was fourfold: (a) to ensure sufficient statistical power in 
evaluating our hypothesis; (b) recruiting at several high-volume pediatric cardiac centers 
allowed us to overcome anticipated recruitment challenges; (c) it helped mitigate the impact 
of center-specific preferences for particular treatment modalities, and (d) we were able to 
leverage the broad range of expertise available at the recruiting centers to help create Core 
Laboratories for each test.
There were seven recruiting centers in the LOVE-COARCT study, two from Portugal and five 
from the United States of America. Their choice was based on center quality, large volume, 
and availability for study participation:  
•  Department of Pediatric Cardiology, Hospital de Santa Marta CHLC, Centro Hospitalar 
de Lisboa Central, EPE, Lisbon, PORTUGAL (the dissertation author’s center) (Centro de 
Referência para a área das Cardiopatias Congénitas em Portugal)
•  Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, 
Boston, USA
•  Division of Pediatric Cardiology, Texas Children’s Hospital, Baylor College of Medicine, 
Houston, USA
•  Division of Pediatric Cardiology, Department of Pediatrics, Lucile Packard Children’s 
Hospital, Stanford University, Palo Alto, USA
•  Division of Pediatric Cardiology, Children’s Hospital Colorado, Aurora, USA
•  Joint Division of Pediatric Cardiology, Children’s Hospital and Medical Center University 
of Nebraska College of Medicine Omaha, USA
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•  Pediatric Cardiology Department, Hospital Pediátrico de Coimbra, Coimbra, PORTUGAL 
(Centro de Referência para a área das Cardiopatias Congénitas em Portugal)
The LOVE-COARCT study was registered in the Clinical Trial Registration site (URL: 
https://www.clinicaltrials.gov) with the unique identifier NCT03262753
1.2. LOVE-COARCT Core Laboratories
To ensure data fidelity and minimize multicenter-derived errors, core laboratories (core labs) 
were established. This strategy allowed to leverage the broad range of expertise available 
at the recruiting centers. The core labs had the following tasks: (a) designing the formal 
Manual of Operations for the tests under its supervision, which was then strictly followed 
by all recruitment centers; (b) support data collection and provide counselling on procedural 
questions; (c) ensure quality control by reviewing all collected data; and (d) perform further 
data analysis, as per protocol. This was particularly true of the CMR core lab, where all CMR 
images were reviewed and further calculations were done. Here is the list of all core labs:
•  Cardiac Magnetic Resonance Core Lab (responsible: Ashwin Prakash): Department of 
Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, USA
•  Preventive Cardiology Core Lab (responsible: Sarah de Ferranti): Department of 
Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, USA
•  Biostatistics Core Lab (Responsible: Kimberlee Gauvreau): Department of Cardiology, 
Boston Children’s Hospital, Harvard Medical School, Boston, USA
•  Tonometry and BP Assessment Core Lab (Responsible: Justin Zachariah): Division of 
Pediatric Cardiology, Texas Children’s Hospital, Baylor College of Medicine, Houston, 
USA
•  Biomarkers Core Lab (Responsible: Maria Guarino): CEDOC Chronic Diseases, Nova 
Medical School, Lisbon, PORTUGAL
•  Endothelial Function Core Lab (Responsible: Elif Seda Selamet Tierney): Division of 
Pediatric Cardiology, Department of Pediatrics, Lucile Packard Children’s Hospital, 
Stanford University, Palo Alto, USA
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2. SELECTION CRITERIA
The medical records of potentially eligible patients were screened by a local study investigator 
using a pre-specified screening form to ensure that they satisfied our selection criteria.
2.1. Inclusion Criteria
We included patients with (a) diagnosis of isthmic CoA; (b) current age between 8 (to 
allow cooperation with study procedures, including EST test and non-sedated CMR) and 
35 years (to avoid confounding by the age-related vascular dysfunction that ensues);390 (c) 
treatment for CoA after 1994 (after which all three modalities were in clinical use); and 
(d) treatment at least 6 months after enrollment (to allow completion of the healing and 
fibrosis associated with treatment) (Table 4):
Table 4. LOVE-COARCT Inclusion Criteria
Criteria Definitions
CoA Isolated, isthmic CoA
Current age 8-35 years
Treatment for CoA after 1994
Treatment > 6 months before enrollment
CoA = coarctation of the aorta
2.2. Exclusion Criteria
We excluded patients with (a) ReCoA defined by a systolic upper-to-lower extremity BP 
gradient > 20 mm Hg (which is a confounder since it impacts vascular function); (b) Co-
morbidities that could independently affect vascular function, including associated significant 
CHD, history of known vasculopathy, genetic syndromes (such as Turner syndrome) or other 
cardiovascular risk factors; (c) History of two treatment types for CoA, or surgical techniques 
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other than the most commonly used end-to-end surgical anastomosis (to avoid confounding 
with other factors that may impact on the biomechanics of the isthmus); and (d) CoA types 
likely representing a different entity or patients amenable to one single treatment type 
(surgery), including atypical CoA site (such as mid-thoracic or abdominal), severe hypoplasia 
of the aortic arch, and an age of treatment < 1 year of age (which is a more severe disease 
subset that is essentially treated with only one of the three treatment types). The details of 
the exclusion criteria are shown in Table 5:
Table 5. LOVE-COARCT exclusion criteria
Criteria Definitions
ReCoA Systolic upper-to-lower extremity BP gradient> 20 mm Hg*
Atypical CoA Mid-thoracic or abdominal CoA.
Severe transverse aortic arch 
hypoplasia
Transverse arch diameter z-score at initial echocardiogram 
<-4 †
Treatment of CoA at age <1y
Clinically significant associated 
cardiac defects
Mitral stenosis (echocardiographic mean inflow Doppler 
gradient >6 mm Hg) aortic stenosis (echocardiographic mean 
Doppler gradient >20 mm Hg); ventricular septal defect (>3 
mm in diameter); atrial septal defect (required surgical or 
percutaneous closure other than a patent foramen ovale); 
other cardiac lesions that required medical, surgical or 
interventional treatment
Use of two treatment 
modalities for CoA
This does not include BD and subsequent stent placement at 
the same catheterization procedure
History of known vasculopathy 
with vascular dysfunction
Examples: Kawasaki disease, Takayasu’s arteritis, Raynaud’s 
disease
Genetic syndromes with diffuse 
arteriopathy
Examples: Williams syndrome, juvenile rheumatoid arthritis
Known traditional 
cardiovascular risk factors
Severe obesity (body mass index >95% for age and sex in 
children and >40 Kg/m2 for adults); diabetes (fasting plasma 
glucose ≥126mg/dl or random (non-fasting) glucose ≥200 
mg/dl); hyperlipidemia (triglycerides ≥250 mg/dl; fasting 
LDL ≥190 mg/dl; HDL≤ 30 mg/dl, currently taking statins or 
first-degree relatives with familial hypercholesterolemia); 
smoking
BP = blood pressure; BD = balloon dilation; CoA = coarctation of the aorta; reCoA = residual coarctation of the aorta
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2.3. Recruitment Challenges
Despite CoA being one of the most common congenital heart defects, we anticipated that 
recruitment for this study would be arduous due to three reasons. First, our focus on a 
comparison of treatment-associated vascular function outcome required restrictive inclusion 
and exclusion criteria and matching treatment groups for potential confounders. This meant 
establishing a lower treatment age limit of 1 year, therefore excluding a large majority of CoA 
patients, who present in infancy, and are almost always managed by surgery. We also used 
lower current age cutoff of 8 years to facilitate the completion of the study tests and a higher 
age limit of 35 years to avoid overlap with aging-related vascular dysfunction. Although 
treatment for CoA has been available for five decades, we would only include patients who 
had undergone treatment after 1994, after which all three treatment modalities became 
available. We would exclude patients who received treatment using more than one modality. 
Second, recruitment could be challenging because treatment in our patient population 
occurred many years ago making loss to follow up more likely, especially when in 
asymptomatic patients without reCoA, as our enrollment criteria specified. And third, we 
anticipated that our one to two-day visit to the enrolling center could deter some patients to 
accept participate in the study for patients who feel mostly well and have spaced clinic visits.
3. OVERVIEW OF THE STUDY WORKFLOW 
Study procedures occurred in a one- or two-day visit and were performed at each recruiting 
site, except for patients from Hospital Pediátrico de Coimbra, who were tested in Hospital de 
Santa Marta. All the CMR from both Portuguese centers were done in Caselas, Ressonância 
Magnética, S.A. Lisbon, PORTUGAL (Responsible, Nuno Jalles, MD).
Upon arrival for testing, formal consent for participation were obtained. Assessment of 
arterial stiffness, endothelial function, and blood sampling for biomarkers was done while 
fasting. Cardiopulmonary stress test was performed on the same day. CMR and ambulatory 
blood pressure monitoring (ABMP) were arranged for the same or for the following day (Fig. 
18). When the study tests could not be exceptionally completed on the first visit, they were 
completed within 3 months of the first visit.
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Fig. 18. LOVE-COARCT study workflow. ABPM = ambulatory blood pressure monitoring; BP = blood pressure; CMR = cardiac 
magnetic resonance imaging; PWA = pulse wave analysis; PWV = pulse wave velocity; RHI = reactive hyperemia index.
4. RECRUITMENT 
The study protocol was approved by the Institutional Review Board or Institutional Ethics 
Committee at each participating center, and informed consent and assent were obtained, 
depending on age, from patients and their parents/legal guardians before trial enrollment. A 
retrospective review of the patient database at each participating institution was performed 
to assemble a cohort of patients with CoA who had previously undergone treatment with 
BD, surgery or stenting. The recruitment started in June 2013 and ended in March 2017. 
Study data were collected and managed using REDCap electronic data capture tools hosted 
at Boston Children’s Hospital.391
5. MEDICAL HISTORY
A retrospective chart review was performed to collect demographic and clinical data including 
severity of CoA, type and details of CoA treatment and presence of associated conditions. 
The main study variables from medical history are depicted in Table 6:
Table 6. Medical history variables
Variables Comments or Definitions
Minimum transverse arch diameter Z-score on initial echo Using published normative values392 
Isthmus z score on initial echo Using published normative values392
Initial Doppler CoA gradient mm Hg
Bicuspid/Bicommisural Aortic Valve? Yes/No
Initial arm-leg systolic BP gradient mm Hg
BP = blood pressure; CoA = coarctation of the aorta
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6. STUDY PROCEDURES
6.1.  Arterial Stiffness 
6.1.1. Measurements
Carotid-femoral PWV (cfPWV) was measured using applanation tonometry. Segmental PWV 
was measured using CMR. Segmental measures of arterial distensibility were be measured 
using CMR. The full list of arterial stiffness variables are in Table 7 and Table 8.
Table 7. Applanation tonometry variables
Variables Units
Central systolic BP mm Hg
Central PP mm Hg
Carotid-femoral PWV meters/second
AIx (%) %
AIx@ 75 %
AIx = augmentation index; AIx@75 = augmentation indez at 75 beats per minute; BP = blood pressure; HR = heart rate, PP 
= pulse pressure; PWV = pulse wave velocity
Table 8. CMR variables
Variables Formulas and units
LV mass indexed to BSA g/m2
Ascending Ao - Descending Ao PWV (Ascending Ao to proximal, mid  meters/second
Type of arch Romanesque; Gothic; Crenel
Diameter of ascending aorta, proximal and distal transverse arch, mm; indexed to BSA
Aortic strain (Ascending, Proximal, Mid and Distal Ao)
Aortic compliance (Ascending, Proximal, Mid and Distal Ao)  cm2/mm Hg
Aortic Distensibility (Ascending, Proximal, Mid and Distal Ao)  mm Hg-1
Aortic beta stiffness index (Ascending, Proximal, Mid and Distal Ao)
Ao = aorta; BSA = body surface area; LV = left ventricle; PWV = PWV
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6.1.2. Manual of Operations for Tonometry
For applanation tonometry, some centers used the NIHem system (Cardiovascular 
Engineering, Inc., Norwood, MA USA) and others the SphygmoCor device (AtCor Medical, 
West Ryde, NSW, Australia). The technology is similar and the results comparable.267
The patient demographics and brachial BP were entered into the system. First, the tonometer 
was placed over the right carotid artery, just lateral to the thyroid cartilage. The location 
was adjusted, and pressure applied as needed to optimize waveform. After ensuring that 
the tracings are optimal, the tracing was recorded. The carotid site was marked. Then, the 
tonometer was placed over the right femoral artery, and the same process for obtaining an 
optimal curve recording was followed. The femoral site was marked. Finally, in the centers 
that used the SphygmoCor device, a third recording of the radial artery was performed, in 
the same fashion. A caliper was used to measure the distance from the suprasternal notch 
to the carotid site and from the suprasternal notch to the femoral site. Both distances were 
entered in the system. 
For PWV and AIx calculation, both systems analyzed the curves and the data was supplied 
with the proprietary software package, without any input from the examiner.
For pulse wave analysis (CAP, PP) the analysis procedure differed slightly between systems. 
The system’s software did the analysis from the NIHem system. In the centers that used 
SphygmoCor, the signal averaged carotid pulse wave was digitalized and calibrated (by the 
same operator, D.O.) according to a published approach:393, 394 The brachial diastolic and 
mean pressures was used, and the same diastolic and mean pressures were assigned to 
the averaged carotid pulse. Moreover, the radial pressure waveform was used to retrieve 
the correspondent time instants of diastolic and mean pressures. Given the two pressure 
values and the correspondent time instants, it is possible to calibrate each averaged carotid 
pressure waveform. This process allowed a quantitative analysis of the pulse waveform. 
6.1.3. Manual of Operations for CMR
CMR was performed using commercially available whole-body 1.5 T scanners (Achieva; Philips 
Healthcare, Best, the Netherlands; Signa 1.5T or GE Medical Systems, Milwaukee, WI, USA). 
ECG-gated steady state free precision (SSFP) localizers were used in sagittal, coronal and 
axial planes during free breathing. Ventricular function was assessed from short axis stack to 
cover ventricles from base to apex, acquired using the following imaging parameters: slice 
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thickness 5-8 mm, slice gap 0-1 mm, slice number 12-14, cardiac phases 30, retrospective 
gating with breath-holding. In patients unable to breath-hold 3 signal averages during free-
breathing were used. SSFP cine imaging was also performed in two orthogonal long-axis 
planes of the left ventricular outflow tract (during breath-hold), short axis of the ascending 
aorta (AAO), and in the long axis of the aortic arch (free-breathing, used as reference for PWV 
measurements), proximal descending aorta (DAO, 2-3 cm distal to the isthmus, sufficiently 
distal to dephasing jets), mid DAO (diaphragmatic level) and distal DAO (just above iliac 
bifurcation). ECG-gated through-plane phase-contrast flow measurements were performed 
at the AAO (5 mm distal to the sinotubular junction), and in proximal, mid and distal DAO 
segments (matched to location of the cine SSFP acquisitions) using the following imaging 
parameters: signal averages = 2, cardiac phases 100 (TFE factor/views per segment/ = 1 (to 
maximize temporal resolution), velocity encoding 200-250 cm/s (higher if needed to avoid 
aliasing (Fig. 19). ECG and respiratory navigator-gated 3-D SSFP MRA of the aortic arch was 
performed in the sagittal plane. 
Fig. 19. ECG-gated through-plane phase-contrast flow assessment. The global PWV is measured from the 
AAo to prox DAO, and segmental PWV is measured for the arch (AAO to prox DAO), mid aorta (prox to mid DAO), 
and distal aorta (mid to dist DAO)AAO = ascending aorta; DAO = descending aorta. 
The patient’s right arm BP while on scanner table and length of time since last meal and 
content of last meal were recorded. Images were analyzed by a single observer (A.P.) in 
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the CMR core lab using a commercial computer workstation (Extended Workstation; Philips 
Healthcare) and using commercially available analysis software (QMass and QFlow, Medis, The 
Netherlands). We used CMR, by measuring area change during the cardiac cycle, paired with 
brachial and central BP measurements to allow quantification of local arterial strain (relative 
change in diameter), compliance (absolute change in diameter in response to a change in 
pressure), distensibility (relative change in diameter in response to a change in pressure) 
and the aortic stiffness β index (distensibility using the logarithmic conversion of the relative 
pressure). Ventricular function and mass were calculated using standard techniques. Cross-
sectional areas of the AAO, and proximal, mid and distal DAO were directly planimetered at 
peak systole and mid diastolic frames to calculate parameters of segmental aortic stiffness 
as previously described.395 PWV was measured using the transit-time method.233 PWV was 
calculated for the entire aorta (AAO to distal DAO), as well as in the following segments: AAO 
to proximal DAO, proximal DAO to mid DAO, and mid DAO to distal DAO. Aortic arch shape 
was classified, and the aortic arch index calculated as previously described.371
6.1.4. Rationale
The CoA treatment affects the elasticity of the isthmus, and this may alter global aortic 
stiffness. Arterial stiffness is often assessed by PWV, which measures the speed of the arterial 
pulse propagation through the arterial system. There are several approaches to measuring 
PWV. 
In LOVE-COARCT, we used two methods to measure PWV. The first was applanation tonometry, 
the most widely accepted method for estimating PWV, which uses a probe or tonometer to 
record the pulse wave with a transducer. Both the NIHem (Cardiovascular Engineering, Inc., 
Norwood, MA USA) and the SphygmoCor (AtCor Medical, West Ryde, NSW, Australia) devices 
have been validated in large cohort trials.267 We used both devices, based on local availability.
A potential pitfall of this technique is that it assumes a homogenous stiffness across the aortic 
length and does not take into consideration vessel stenosis or distortion causing incorrect 
estimation of true carotid to femoral artery length. Therefore, in LOVE-COARCT we also 
used CMR to measure PWV. This technique enables the detection of more subtle changes in 
segmental stiffness, above vs. below the CoA site and with the use of real aortic travel paths 
to circumvent these issues. CMR has been validated against noninvasive279 and invasive396 
techniques to calculate PWV,397 including the ascending-to-descending aorta PWV.233 
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The measurement of the diameter vs. pressure relationships requires direct visualization of 
the artery, by echo-tracking or CMR. We chose the latter, since this was our chosen approach 
for PWV measurement. The choice of echography would require that our patients performed 
an additional exam in an already lengthy study protocol.
6.2. Endothelial Function
6.2.1. Measurements
Endothelium-dependent RHI and AIx were measured using the Endo-PAT 2000 system 
(Itamar Medical, Caesarea, Israel) (Table 8)
Table 9. Endo-PAT variables
Variables Formulas and units
RHI
AIx %
AI@75 %
AIx = augmentation index; AIx@75 = augmentation index at 75 beats per minute; RHI = reactive hyperemia index
6.2.2. Manual of Operations for Endothelial Function
The testing room was arranged to provide a quiet, restful environment with a comfortable 
temperature of 22 to 24°C. Before testing, subjects were asked to fast overnight for 12 
hours, except for the consumption of water. Unless the patients were taking a daily vitamin, 
they were asked to refrain from taking vitamin pills and over-the-counter medications; in 
the case that an over-the-counter medication was used, it was documented.
The Endo-PAT (Itamar Medical Ltd, Caesarea, Israel) testing protocol,304 was performed in 
the morning (starting time between 8 and 11:00 am) and fasting. Any restrictive clothing 
that could interfere with blood flow to the arms or fingers was removed, including heavy 
coats or clothes with thick sleeves, watches or rings or other jewelry on the hands and 
fingers, and long fingernails shortened with a fingernail clipper. 
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Non-invasive pneumatic probes were placed on the index fingers of both hands. The pulse 
wave amplitude was recorded continuously from both index fingers. Reactive hyperemia 
was performed by achieved by occlusion of the brachial artery of one arm with a BP cuff 
for 5 minutes (to 200-220 mm Hg). The tracing in the non-occluded arm will serve as 
a control for changes in overall physiologic state. The Endo-PAT data was analyzed with 
the proprietary software package, without any input from the examiner. The Endo-PAT 
index is defined as the ratio of the average pulse amplitude during the 1-minute period 
beginning after exactly 90 seconds of reactive hyperemia compared with the average pulse 
amplitude during the 210-second pre-occlusion baseline period.
6.2.3. Rationale
In LOVE-COARCT, we used Endo-PAT because analysis of the pulse waveform allows for an 
automated calculation of flow-dependent, endothelium-mediated vasodilation in one arm, 
while the contra-lateral serves as a control. Therefore, this is a patient standardized method, 
which is important in children, in whom normative are beginning to be established.301 It is also an 
easy to perform method, with reliable results. Nevertheless, few studies have been performed 
in congenital heart disease.395,396 A potential pitfall of this technique is that the associated 
vasodilation is not entirely NO-dependent and there is an interaction with autonomic nervous 
system. Our research protocol included measures to minimize the influence of the autonomic 
nervous system, including fasting and avoidance of food with high NO content. 
6.3. Pulse Waveform Analysis 
6.3.1. Measurements
CAP and PP were measured using applanation tonometry). AIx was measured using 
applanation tonometry and Endo-PAT  (Table 7 and Table 9).
6.3.2. Manual of Operations
Please refer to Methods, sections 6.1.2 and 6.2.2.
6.3.3. Rationale
In CoA, the stiff ascending aorta and the repaired aortic isthmus may be important reflecting 
sites and thus impact the pulse waveform. The non-invasive analysis of the pulse waveform 
by tonometry and Endo-PAT have been shown to be reliable in prior studies.267 There is a lack 
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of consensus regarding the optimal method to estimate the CAP curve using tonometry. The 
NIHem system assumes that carotid artery pulse waveform accurately reflects the central 
aortic waveform and therefore, the pulsed wave analysis is automatically calculated from 
the carotid waveform. The SphygmoCor device uses a generalized transform function to 
generate a central aortic PP curve from the radial or carotid pressure tracings. This transfer 
function has not been validated in children. To maintain consistency between data acquired 
on each device in our largely pediatric group, we didn’t use the transfer analysis and used 
the non-processed, signal-averaged carotid tracing as the central aortic tracing. This tracing 
was digitized to calculate the CAP, following a previously published approach (Fig. 20):393, 394 
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Fig. 20. Process to obtain central aortic pressure from SphygmoCor. Panel A (left) depicts a pressure curve that 
was obtained with from the transducer placed in the carotid artery and exported directly from the SphygmoCor 
software. This tracing is a non-processed (Nproc) curve (no generalized transfer function was applied to 
transform it into a mathematically generated central aortic pressure curve). This curve is digitalized, point by 
point, and calibrated with the mean and diastolic blood pressure, which is shown in Panel B (left). Note that the 
pressure scale is distinct between the two curves. (images from one of LOVE-COARCT’s patients).
6.4. BP Phenotype 
6.4.1. Measurements
The BP phenotype was measured using several techniques including auscultatory right arm 
BP measurement, measurement of BP gradient between arm and leg, BP response during 
treadmill exercise stress test (EST) and ABPM. (Table 9)
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Table 10. BP profile variables
Variables Formulas and units
Office BP
     Residual SBP gradient Supine and automated; mm Hg
     Right arm BP Seated and manual; mm Hg
ABPM
     24h average systolic and diastolic BP mm Hg
     Daytime average systolic and diastolic BP mm Hg
     Nighttime average systolic and diastolic BP mm Hg
     24h systolic and diastolic load %
     Diurnal systolic and diastolic dipping %
Exercise test
     Exercise duration minutes
     Pre-Exercise SBP gradient mm Hg
     Pre-Exercise SBP gradient mm Hg
     Peak exercise BP mm Hg
     Exercise HTN If systolic BP is ≥220 mm Hg
ABPM = ambulatory blood pressure monitor; BP = blood pressure; DBP = diastolic blood pressure; HTN = hypertension; 
SBP = systolic blood pressure
6.4.2. Manual of operations for BP Phenotype
For measurement of the right arm, auscultatory BPs, the patient was seated with the feet 
flat on the floor, with the knees at 90-degree angle and the back supported. After 5 minutes 
of resting quietly, with no conversation or television, the auscultatory BP was obtained in the 
right arm. For cuff choice, the length of the Bladder encircled no less than 80% and no more 
than 100%, of the bicep and the width of Bladder encircled no less than 40% and no more 
than 50%, of the circumference of patient’s arm circumference, measured at the widest 
area of bicep, midway between the tip of the patient’s shoulder and the tip of the patient’s 
elbow. The patient’s right arm was placed at heart level, supported at the level of the nipple 
by resting arm on a table or chair arm or propped on a pillow. The stethoscope’s bell was 
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placed over the patient’s brachial pulse. The cuff was inflated up to 140 mm Hg and deflated 
slowly while listening for the Korotkoff sounds, systole being number when the sound is 
first heard consistently and diastole when the last pulsation is heard, or when it muffles. If 
pulsations were immediately audible, the cuff was deflated entirely, and the patient allowed 
to sit quietly for one minute. Then, the cuff was again inflated to 160 mm Hg (or higher) and 
the steps above were followed. This procedure was repeated until the BP is not immediately 
audible. Three BP were obtained, allowing one minute between deflation and re-inflation 
of the cuff for each measurement. The average of the 2nd and 3rd measurements was 
considered the final right arm BP and interpreted according to the published guidelines for 
children400 and adults.401
While the patient was supine, two sets of four extremity, automated BPs, were measured 
with the automated BP monitor (Dinamap). The BP pressure gradient was registered, 
between the second systolic right arm measurement and the highest of the two legs systolic 
second measurements. 
For the ABPM measurement, the choice of the cuff followed the same guidelines described 
for manual auscultation of right arm BP. Cuff inflation was programmed for 15 to 20-minute 
intervals. During nighttime, intervals were wider, but not fewer than one per hour and 
preferably more. The patient recorded the sleep time, wake time, and any periods of vigorous 
exercise. The patient was instructed to avoid direct contact of the monitor with water and 
participation in activities that could damage it. The study was considered adequate if there 
was a record of at least one reading per hour, i.e. no more than 1 hour between consecutive 
readings for a full 24-hour study. If less than 12 hours were recorded, the ABPM data was 
considered inadequate. The diurnal pattern was determined by the patient diary. Vigorous 
exercise periods were excluded. Patients were staged as having ambulatory HTN, masked 
HTN, white coat HTN or normotensive, according to the age-based normative tables 
based on statements for children and adolescents402 and adults.403 Patients currently on 
antihypertensive medication were also classified into the hypertensive group (Table 11):
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Table 11. Classification of BP phenotype by ABPM
Classification Office BP SBP or DBP * 24h Mean ABPM SBP or DBP †
Non-hypertensive
Pediatric: <95th %tile
Adults: <140/90 mm Hg
Pediatric: <95th %tile
Adults: <135/85 mm Hg
White Coat HTN
Pediatric: ≥95th %tile
Adults: >140/90 mm Hg
Pediatric: <95th %tile
Adults: <135/85 mm Hg
Masked HTN
Pediatric: <95th %tile
Adults: <140/90 mm Hg
Pediatric: >95th %tile
Adults: >135/85 mm Hg
Ambulatory HTN
Pediatric: >95th %tile
Adults: >140/90 mm Hg
Pediatric: >95th %tile
Adults: >135/85 mm Hg
AMBP = Ambulatory blood pressure monitoring; BP = Blood Pressure; ABPM = Ambulatory Blood Pressure Monitoring; 
Pediatric patients have age < 18yo and adult patients age ≥ 18yo; %tile = percentile; BP = blood pressure; DBP = diastolic 
blood pressure; HTN = hypertension; SBP = systolic blood pressure.
* For pediatric patients, based on the National High Blood Pressure Education Program Task Force normative data400; for 
adult patients, based on the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure report.401
† For pediatric patients, based on normative pediatric ABPM values from the American Heart Association Atherosclerosis, 
Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young; 402 for adult patients, 
based on the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood 
Pressure Research report.404
Before the exercise stress test (EST), for patient safety issues, medical history, medications, 
activity level and symptoms were reviewed, and the EST protocol explained. Antihypertensive 
medications were continued the day of testing. The patient was asked to lay supine, and a right 
arm and right or left leg BP measured using a commercial oscillometric and appropriately sized 
cuff-bladders were recorded as pre-exercise BP values and gradient. The patient then stepped 
onto the treadmill and instructed to hold the handlebar throughout the test. We used the 
standard Bruce treadmill protocol and, when available, a Met Cart. As the patient exercised, 
their symptoms and ECG were continuously monitored. At 2-mins of each stage, a BP was taken 
in the right arm by having the patient take their hand off the treadmill and hold onto the arm 
of the person performing the test. The test was terminated when the patient could longer 
continue the exercise, reached a systolic BP higher than 240mm Hg, had clinically relevant 
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symptoms or ECG changes. Immediately after the exercise ended, BP in the right arm and the 
left leg was recorded in a supine position. For the recovery period, the patient set upright in a 
chair, and right arm BP was recorded at 1, 3, 5, and 7 mins of recovery, at which time the test is 
ended. When available, cardiorespiratory physiological data was documented. 
6.4.3. Rationale
It is well known that the BP phenotype is abnormal despite successful treatment of CoA. 
We were careful to implement a thorough assessment in LOVE-COARCT. Based on the 
auscultatory BP and ABPM results, we used the appropriate children and adult guidelines 
to classify our patients, according to Table 11. Patients currently on antihypertensive 
medication were also classified as hypertensive. Comparing BP values between children and 
adults is difficult, because the definition of HTN in the former is based on normative values 
that depend on somatic measurements, while the latter use pre-defined cutoff values. This 
challenge was present in the design of the LOVE-COARCT protocol, since there is a diverse 
current age in the enrolled patients. However, it was possible to create discrete categories 
for the office and ABPM HTN definitions, since the office pediatric400 and adult400 reports, 
and the ABPM pediatric402 and adult404 reports are harmonized and use the same definitions. 
However, there are no such documents for the EST in children and adults, and we could not 
create discrete categories to compare exercise-induced HTN in different age groups, and 
therefore limited our analysis to the continuous variables.
6.5. LV Mass and Aortic Morphometrics
6.5.1. Measurements
LV mass, the size of the aorta and aortic arch shape were measured by CMR.
6.5.2. Manual of Operations fo LV Mass and Aortic Morphometrics
Please refer to Methods, section 6.1.3.
6.5.3. Rationale
The altered BP phenotype that persists after CoA treatment represents an increase in 
afterload that leads to LV hypertrophy. CMR is a well-established method for calculation 
of LV mass, volumes and function. Our CMR protocol included sequences that allowed this 
quantification. The aortic size and shape can also be accurately measured with CMR.
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6.6. Biomarkers 
6.6.1. Measurements
We measured biomarkers of endothelial function (total oxides of nitrogen- NOx and ADMA), 
inflammation (hs-CRP), vascular wall function (VCAM-1 and IL-1β) and vascular remodeling 
(MMP-2; MMP-9 and TGF-β1). NOx was determined by chemiluminescence (Sievers 
NOAnalyzer 280i) and all remaining measurements were performed with appropriate 
enzyme-linked immunosorbent assay (ELISA) kits: ADMA (Sunred Biological Technology, 
Shanghai, China); hs-CRP (BoosterBio, Pleasanton, USA); VCAM-1; IL-1β; MMP-9; MMP-2 
and TGFβ-1 (RayBiotech, Inc. Norcross, USA) (Table 12):
Table 12. Biomarkers variables
Variable Units 
NOx ug/ml
ADMA ng/L
High Sensitivity CRP mg/L
VCAM-1 ng/ml
IL-1b pg/ml
TFG-b ng/mL
MMP-2/Gelatinase A ng/ml
MMP-9/Gelatinase B ng/ml
ADMA = Asymmetric Dimetilarginine; HDL = High-density lipoprotein cholesterol; hs-CRP = High sensitivity C-Reactive 
Protein; IL-1b = Interleukin 1 beta; LDL = Low-density lipoprotein cholesterol; MMP-2 = Matrix Metalloproteinase-2; 
MMP-9 = Matrix Metalloproteinase-9; NOx = Nitric Oxide; TFG-b = Transforming Growth Factor beta; VCAM-1 = 
Vascular Cell Adhesion Molecule 1
6.6.2. Manual of Operations for Biomarkers
The patients followed a low-nitrate diet for three days before the blood sample collection, 
which avoided of a list of foods with a high content in nitrites that influence nitric oxide 
determination, including bacon, beets, broccoli, canned food, cauliflower, celery, Chinese 
cabbage, corned beef, ham, hot dogs, lettuce, old cheese, radish, salami, sausages, smoked 
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fish, spinach and turnip. After an overnight fast (for 12h), samples were collected by 
venipuncture from catheters maintained with saline only, since heparin interferes with the 
accuracy of the biomarkers assessed. The first 5-10mL of blood were discarded and 2.7 ml 
of venous blood were collected into 3.2% sodium citrate (light-blue) tubes (BD Vacutainer®), 
and into plastic microtubes (Safe-Lock Eppendorf). Within 3 hours of collection, samples 
were centrifuged for 20 minutes at 3000g (4°C). Aliquots of 250µl of the supernatant were 
collected into 14 labeled microtubes of 1.5ml and immediately stored at -80ºC until shipping 
to the Biomarkers Core Laboratory.
Aliquots for NOx analysis were deproteinized using cold ethanol precipitation methodology. 
Ethanol was refrigerated to 0°C and added to the plasma sample in a 1:3 proportion. After 
letting it stand at 0°C for 30 minutes, the sample was centrifuged at 14000rpm for 10 
minutes. The supernatant was then removed for analysis. The quantification of plasma NO 
levels was carried out using a nitric oxide analyzer, the Sievers Instruments NOA 280i™, a 
high sensitivity detector of that allows determination of NO based on a chemiluminescence 
reaction between NO and ozone.
Plasma ADMA; VCAM-1; hs-CRP; IL-1β; MMP-2 and MMP-9 were quantified using the 
following double-antibody sandwich enzyme-linked immunosorbent assay ELISA kits: Human 
asymmetrical dimethylarginine, ADMA (Sunred Biological Technology, Shanghai, China); high-
sensitivity C Reactive Protein (hs-CRP, BoosterBio, Pleasanton, USA); vascular cell adhesion 
molecule 1 (VCAM-1); interleukin-1-Beta (IL-1β); MMP-9/Gelatinase A ; MMP-2/Gelatinase B 
and transforming growth factor beta (TGFβ-1)  (RayBiotech, Inc. Norcross, USA).
6.6.3. Rationale
We chose a wide variety of biomarkers, to encompass several pathways that may be involved 
in the genesis or maintenance of vascular dysfunction in patients with treated CoA, namely 
the NO-dependent endothelial function, systemic and local wall inflammation, and aortic 
wall remodelling. All of these tests were obtained from a single, fasting blood sample, that 
was collected at the beginning of the study visit, for patient convenience. 
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6.7. Cardiovascular Health Assessment 
6.7.1. Measurements
We assessed health factors (BP, total cholesterol, plasma glucose), behaviors (smoking, body 
mass index BMI, physical activity and diet) and family history of cardiovascular disease and 
risk factors. 
6.7.2. Manual of Operations for Cardiovascular Health Assessment
The following questionnaires were used as a lifestyle questionnaire (Table 12) and family 
history questionnaire (Table 13):
Table 13. Lifestyle questionnaire questions
Lifestyle Questionnaire
On an average weekday, how many hours do you watch TV?
On an average weekday, how many hours do you play video/computer games or use a computer 
for something that is not school/work related?
In the past week, how many days were you/was your child physically active for a total of at least 
30 minutes per day?
In the past week, how many days did you/your child eat breakfast? In the past week, how many 
days did you/your child eat food from a fast food restaurant?
In the past week, how many days did all or most of your family sit down and eat dinner at home?
On an average weekday, how many hours of sleep do you get a night?
Have you smoked one or more cigarettes in the past month? If yes, please quantify.
Were you previously a smoker?
Do you live in a household with a smoker?
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Table 14. Family history questionnaire
Family History Questionnaire
     Biological relatives of you/your child with Overweight/Obesity
     Biological relatives of you/your child with Type 2 Diabetes
     Biological relatives of you/your child with High Blood Pressure
     Biological relatives of you/your child with High Cholesterol
     Biological relatives of you/your child with Heart Disease/Stroke
     (all answers had the following options: No/ Parents/ Siblings/ Grandparents/ Aunts)
6.7.3. Rationale
Cardiovascular health is very important in patients with CoA, who experience early CVD 
(please refer to Background,  section 1.9.1). We implemented a simple questionnaire to assess 
family history of CV disease and ICVH according to the procedures and recommendations of 
the American Heart Association.405
7. STATISTICAL ANALYSIS
The statistical analysis was done in the Biostatistics Core Lab (Responsible: Kimberlee 
Gauvreau) from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical 
School, Boston, USA. Analyses were performed in SAS (version 9.4, Cary, NC, USA).
7.1. Adjustment for Confounders
Since several known factors other than treatment modality can influence vascular function, we 
will frequency-match our treatment groups for documented confounders. The confounding 
variables included: (a) age at treatment; (b) current age; and (c) BAV as it is associated with 
impaired aortic elasticity.406 Because of the relatively large number of matching variables and 
three treatment groups, matching individual subjects was not feasible. During recruitment, 
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we attempted to frequency match the three treatment groups. During analysis, the treatment 
groups were compared for each of these confounding variables and appropriate adjustments 
were made using multivariable modeling, as needed. Age at treatment and presence of 
a BAV were thought to be possible confounding variables and were observed to differ by 
treatment group; therefore, linear and logistic regression models were used to adjust for 
confounding when comparing selected outcome variables across treatment groups.  In these 
models, the surgical group was used as the reference category against which BD and stent 
were compared.  Each model adjusted for age at treatment as a continuous variable, and 
presence of a BAV as a binary variable.  
7.2. Analytic Plan.
Categorical patient characteristics, clinical variables, and outcomes were summarized as 
frequencies and percentages and compared across the three treatment groups using Fisher’s 
exact test.  Continuous variables that which were approximately normally distributed were 
summarized using means and standard deviations and compared using one-way analysis of 
variance; continuous variables which were not normally distributed were summarized using 
medians and ranges and compared using the Kruskal-Wallis test.
Our primary outcome variable was cfPWV assessed by tonometry. Differences in cfPVW 
across groups were explored using one-way analysis of variance. When differences in 
matching variables were detected among the groups, adjustments were made using analysis 
of covariance. Post-hoc analyses were performed as necessary.
Sample size estimates were obtained based on prior data that showed that ascending- 
descending PWV measured by CMR is 3.3±0.6 m/s in normal subjects and 4.7±1.1 m/s after 
CoA surgery.233, 407 Sample size estimates for comparison of PVW between three equal-sized 
treatment groups (assuming overall significance level=0.05 and power=0.8) are shown in 
Table 15. We planned on recruiting 24 to 30 patients in each group for a total sample size of 
72 to 90:
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Table 15. Sample size calculation
Smallest Mean 
PWV (m/s) 
Among Groups
Largest Mean 
PWV (m/s) Among 
Groups
Standard 
Deviation
Sample Size for 
Each Group
Total Sample 
Size
4.0 4.8 1.0 30 90
4.0 4.8 1.1 36 108
4.0 4.8 1.2 43 129
4.4 5.3 1.0 24 72
4.4 5.3 1.1 29 87
4.4 5.3 1.2 34 102
PWV = pulse wave velocity; m/s = meters per second
7.3. Choice of the Primary Outcome Variable
There is no single, universally accepted marker of vascular dysfunction. Therefore, we chose 
cfPWV as our primary outcome variable because: (a) it has been validated as a simple, 
accurate and reproducible measure of arterial stiffness with a proven association to hard 
cardiovascular outcomes and (b) it can be reliably measured by two different techniques, 
applanation tonometry, and CMR.  
7.4. Choice of the Secondary Outcomes Variables
No single parameter encompasses all aspects of vascular function. Therefore, including 
other parameters such as other measures of arterial stiffness, endothelial function, pulse 
waveform analysis, BP phenotype, blood biomarkers and LV mass allowed us to perform a 
comprehensive assessment of vascular function in small and large arteries.  
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Below is Fig. 21 (central illustration), that shows in one figure a comparison of the key 
vascular function parameters from the LOVE-COARCT study between the three groups:  
Fig. 21. Comparison of key vascular function parameters between groups (Central Illustration).
BD in blue; Surgery in red; and Stent in green. AAO = ascending aorta; BSA = body surface area; CMR = cardiac magnetic 
resonance; Endo-PAT = endothelial pulse amplitude testing; hs-CRP = high sensitivity C-reactive protein; IL-1β = interleukin 
1 beta; LV = left ventricle; MMP-9 = matrix metalloprotease 9; PWV = pulse wave velocity; SBP = systolic blood pressure; 
TGF- β1 = transforming growth factor beta-1
A detailed presentation of the LOVE-COARCT results is presented in the follow pages.
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1. STUDY SUBJECTS
Patient characteristics by treatment group are summarized in Table 16.
Table 16. Patient characteristics at treatment
Surgery 
(n=28)
Balloon 
Dilation 
(n=23)
Stent  
(n=24)
p 
Value
Age at treatment (years) 6 (1, 26) 5 (1, 17) 15 (7, 26) <0.001
SBP gradient (mm Hg) 43.7 ± 19.3 34.6 ± 15.0 38.4 ± 21.0 0.29
TAA diameter z-score -1.9 ± 1.0 -1.5 ± 1.4 -1.9 ± 0.8 0.38
Isthmus diameter z-score -3.59 ± 1.21 -3.92 ± 0.89 -3.31 ± 1.37 0.32
Initial Doppler gradient (mmHg) 48.0 ± 14.7 47.9 ± 14.8 52.5 ± 20.3 0.60
Male sex 79% 74% 75% 0.94
Bicuspid aortic valve 71% 45% 50% 0.13
Values are mean ± standard deviation, median (minimum, maximum), or percent. SBP = systolic blood pressure; TAA = 
transverse aortic arch
Among pre-treatment characteristics, the treatment groups were similar with respect to CoA 
severity, sex distribution, and the prevalence of BAV. However, patients treated with a stent 
were older at the time of treatment compared to those treated with surgery or BD.
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Table 17. Patient characteristics at enrollment
Surgery  
(n=28)
Balloon  
Dilation  
(n=23)
Stent  
(n=24)
p 
Value
Age at enrollment (years) 15 (8, 33) 17 (11, 26) 20 (9, 33) 0.12
BMI at enrollment 22 (15, 32) 21 (16, 33) 23 (16, 38) 0.69
SBP gradient at enrollment  
(mm Hg) -7.1 ± 14.0 -3.0 ± 12.3 -3.7 ± 14.5 0.52
NYHA class at enrollment 0.37
     Class I 89% 100% 92%
     Class II 11% 0% 8%
Metabolic profile at 
enrollment
     Total cholesterol, mg/dL 159 (112, 210) 153 (123, 229) 152 (108, 227) 0.59
     LDL, mg/dL 86 (53, 145) 81 (59, 179) 85 (44, 130) 0.66
     HDL, mg/dL 53 (34, 90) 48 (31, 90) 51 (32, 88) 0.99
     Triglycerides, mg/dL 76 (29, 224) 52 (29, 149) 74 (29, 167) 0.07
     Plasma glucose, mg/dL 82 (74, 98) 81 (59, 93) 86 (63, 108) 0.15
     Insulin, uIU/mL 6 (3, 44) 6 (3, 17) 7 (2, 20) 0.86
     Hemoglobin A1c, % 5.3 (4.1, 5.7) 5.3 (4.4, 5.7) 5.3 (4.8, 5.9) 0.60
Anti-HTN Medication 14% 26% 33% 0.14
     β-blockers 2 (7) 5 (22) 4 (17) 0.12
      ACE inhibitors  5 (18) 2 (9) 3 (13) 0.88
     ARBs 0 (0) 0 (0) 1 (4) 0.94
Values are mean ± standard deviation, median (minimum, maximum), or percent. ACE inhibitors = angiotensin-converting-
enzyme blockers; ARBs = angiotensin II receptor blockers; β-blockers  = betablockers; BSA = body surface area; BMI = body 
mass index (weight (kg)/ height (m)2); HTN = hypertension; LDL = low density lipoprotein; HDL = high density lipoprotein; 
NYHA = New York Heart Association; SBP = systolic blood pressure; TAA = transverse aortic Arch
The mean age (min, max) of our entire cohort was 18 (8, 33) and 76% were male. At study 
enrollment, the treatment groups were similar with respect to baseline characteristics 
including age and body mass index at enrollment, reCoA severity, and metabolic profile. 
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2. AORTIC STIFFNESS
Results of aortic stiffness assessment by CMR and applanation tonometry are summarized in 
Table 18, Table 19 and in the Fig. 21.
Table 18. Aortic stiffness results by CMR
Surgery  
(n=28)
Balloon  
Dilation  
(n=23)
Stent  
(n=24)
p 
Value
PWV (m/s)
     Global (AAO to Distal DAO) 4.0 ± 0.5 4.2 ± 0.9 4.2 ± 0.7 0.72
     Arch (AAO to prox DAO) 4.7 ± 1.5 4.0 ± 1.2 5.5 ± 3.8 0.12
     Prox to Mid DAO 3.8 ± 0.9 4.0 ± 1.3 3.9 ± 1.4 0.87
     Mid to Distal DAO 4.4 ± 1.6 4.8 ± 1.7 4.5 ± 1.5 0.70
Strain
     AAO 0.38 ± 0.14 0.51 ± 0.25 0.36 ± 0.19 0.02
     Proximal DAO 0.27 ± 0.09 0.31 ± 0.13 0.30 ± 0.15 0.47
     Mid DAO 0.37 ± 0.11 0.36 ± 0.10 0.36 ± 0.16 0.97
     Distal DAO 0.37 ± 0.14 0.40 ± 0.12 0.30 ± 0.12 0.04
Distensibility (10-3mm Hg-1)
     AAO 7.8 ± 3.6 9.8 ± 5.2 6.6 ± 4.3 0.05
     Proximal DAO 5.6 ± 2.1 6.1 ± 3.3 5.6 ± 2.7 0.71
     Mid DAO 7.5 ± 2.5 6.9 ± 3.3 6.8 ± 3.4 0.67
     Distal DAO 7.8 ± 4.1 7.5 ± 3.1 5.9 ± 3.2 0.15
Compliance (mm2 mm Hg-1)
     AAO 2.23 (1.21, 4.08) 2.90 (1.61, 5.93) 2.35 (1.15, 7.35) 0.02
     Proximal DAO 1.05 (0.65, 2.83) 1.24 (0.19, 2.82) 1.26 (0.64, 2.84) 0.15
     Mid DAO 1.16 (0.54, 2.54) 0.91 (0, 2.28) 1.07 (0.50, 2.02) 0.58
     Distal DAO 0.63 (0.27, 1.85) 0.74 (0, 1.66) 0.51 (0.08, 1.83) 0.09
β stiffness index
     AAO 1.76 ± 0.73 1.59 ± 1.15 2.49 ± 1.48 0.02
     Proximal DAO 2.53 ± 1.59 2.63 ± 1.89 2.50 ± 0.96 0.96
     Mid DAO 1.75 ± 0.76 1.93 ± 0.75 2.15 ± 1.11 0.26
     Distal DAO 1.84 ± 0.91 1.72 ± 0.68 2.98 ± 3.70 0.11
Values are mean ± standard deviation. AAO = ascending aorta; AI = augmentation index; aortic arch PWV = AAO to proximal 
DAO pulse wave velocity; DAO = descending aorta; Endo-PAT = endothelial pulse amplitude testing; HR = heart rate; m/s = 
meters per second; PP = Pulse pressure; SBP = Systolic blood pressure; total PWV = AAO to distal DAO pulse wave velocity.
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Combining the three treatment groups, the results for PWV (in m/s) were 4.1 ± 0.7 for global 
PWV, 4.8 ± 2.5 for arch PWV, 3.9 ± 1.2 for mid aorta, and 4.5 ± 1.6 for distal aorta. 
Table 19. Aortic stiffness results by applanation tonometry
Surgery  
(n=28)
Balloon  
Dilation  
(n=23)
Stent  
(n=24)
p 
Value
cfPWV (m/s) 5.2 ± 0.9 5.3 ± 1.1 5.0 ± 0.9 0.64
AIx at HR 75 bpm (%) -14 ± 13 -13 ± 21 -6 ± 18 0.24
Central SBP (mm Hg) 114 ± 18 109 ± 14 112 ± 21 0.60
Central PP (mm Hg) 50 ± 20 46 ± 13 45 ± 19 0.49
Values are mean ± standard deviation. AIx = augmentation index; cfPWV = carotid-femoral pulse wave velocity; DAO = 
descending aorta; HR = heart rate; PP = Pulse pressure; SBP = Systolic blood pressure
The combined cfPWV of the three treatment groups is 5.2 ± 1.0 m/s. At comparable distending 
pressures (Table 20), overall PWV was similar among the treatment groups by both CMR and 
applanation tonometry (Fig. 21). In segmental PWV measurements by CMR, aortic arch PWV 
was lowest in the BD group, but the difference did not reach statistical significance (Fig. 21). 
Among CMR segmental aortic stiffness parameters, BD patients had the most distensible 
AAO, while stent patients had the least distensible AAO, with surgical patients demonstrating 
intermediate values (Fig. 21). Compared to stent patients, BD patients showed 48% higher 
AAO distensibility and 27% lower aortic arch PWV. Segmental stiffness parameters were 
mostly similar across treatment groups at the DAO (proximal, mid, and distal), except for 
distal DAO strain, which was lowest in the stent group. 
To assess for potential confounding by age at treatment or BAV (known to be associated 
with impaired aortic elasticity)406 on the relationship between treatment modality and 
aortic stiffness, we used multivariable modeling for key stiffness parameters. The univariate 
relationships shown in Table 18 and Table 19 remained unchanged in the multivariable 
models after adjustment for the potential confounding variables (age at treatment, and BAV) 
(details in Table 30).
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3. ENDOTHELIAL FUNCTION
Endothelial function assessed using the Endo-PAT index was similar across treatment groups 
(Table 20 and Fig. 21). 
Table 20. Endo-PAT results
Surgery  
(n=28)
Balloon  
Dilation  
(n=23)
Stent  
(n=24)
p 
Value
Endo-PAT index (RHI) 2.15 ± 0.77 2.00 ± 0.78 2.25 ± 0.68 0.51
AIx @ 75 bpm -6 ± 12 -4 ± 14 2 ± 11 0.14
Values are mean ± standard deviation. BPM = beats per minute; Endo-PAT = endothelial pulse amplitude testing; RHI = 
reactive hyperemia index.
The combined RHI of the three treatment groups was 2.14 ± 0.74. The univariate relationships 
remained unchanged in the multivariable models after adjustment for the potential 
confounding variables (age at treatment, and BAV) (details in Table 30).
4. PULSE WAVEFORM ANALYSIS
The pulse waveform analysis (central SBP and PP measured with applanation tonometry, and 
AIx measured with both applanation tonometry and Endo-PAT) did not show any differences 
between the three treatment groups (Table 19 and Table 20). 
5. BP PHENOTYPE
Results of office BP measurements are summarized in Table 21, ABPM results are in Table 
22, and EST results are in Table 23. There were no significant differences across treatment 
groups concerning the prevalence of HTN by office measurements or ABPM, and average 
systolic and diastolic BP by ABPM. However, the BD group showed lower nighttime BP and 
less impairment in diurnal variation, compared to the stent and surgery groups (Fig. 21).
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Table 21. Office BP results
Surgery  
(n=28)
Balloon  
Dilation  
(n=23)
Stent  
(n=24)
p  
value
Office BP 0.20
     Normal 15 (54%) 13 (57%) 7 (29%)
     Pre-HTN 10 (36%) 8 (35%) 15 (63%)
     Stage 1 HTN 3 (11%) 2 (9%) 1 (4%)
     Stage 2 HTN  0 (0%) 0 (0%) 1 (4%)
Values are mean ± standard deviation, or number (percent). BP = blood pressure; HTN = hypertension
Combining the three treatment groups, the office BP in LOVE-COARCT shows that 44% of the 
patients had pre-HTN and 9% had either stage 1 or stage 2 office HTN, and the ABPM results 
show that 36% have either HTN/masked HTN, or anti-HTN medication.  
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Table 22. ABPM results
Surgery  
(n=28)
Balloon  
Dilation  
(n=23)
Stent  
(n=24)
p  
value
24-hr average SBP (mm Hg) 123 ± 13 118 ± 9 124 ± 10 0.19
24-hr average DBP (mm Hg) 68 ± 8 66 ± 6 68 ± 8 0.77
Day average SBP (mm Hg) 125 ± 13 122 ± 10 127 ± 10 0.34
Day average DBP (mm Hg) 69 ± 9 69 ± 7 71 ± 9 0.82
Night average SBP (mm Hg) 116 ± 12 106 ± 10 113 ± 10 0.005
Night average DBP (mm Hg) 60 ± 7 56 ± 5 59 ± 4 0.05
% SBP readings above diurnal threshold 32 ± 29 19 ± 19 30 ± 27 0.19
% DBP readings above diurnal threshold 16 ± 20 13 ± 14 14 ± 16 0.72
Diurnal systolic variation (%) 7 ± 7 13 ± 6 11 ± 6 0.01
Diurnal diastolic variation (%) 13 ± 10 19 ± 6 16 ± 7 0.06
Non-dippers (%) 17 (65%) 7 (32%) 12 (55%) 0.08
Classification by ABPM 0.76
     No HTN 16 (59%) 18 (82%) 15 (68%)
     White coat HTN 3 (11%) 1 (5%) 1 (5%)
     Masked HTN 6 (22%) 2 (9%) 5 (23%)
     HTN 2 (7%) 1 (5%) 1 (5%)
Classification including medication use
      HTN/masked HTN, or anti-HTN 
medication
8 (30%) 9 (39%) 10 (45%) 0.49
     No HTN/ white coat HTN 20 (70%) 14 (61%) 14 (55%)
Values are mean ± standard deviation, or number (percent). ABPM = ambulatory blood pressure measurement; BP = blood 
pressure; DBP = diastolic blood pressure; Dippers = night-time BP dipping ≥10%, non-dippers = night-time BP dipping <10%; 
HTN = hypertension; SBP = systolic blood pressure
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On EST, there were no significant differences between the treatment groups with respect to 
exercise duration, peak VO2, VE/VCO2 slope, or upper-lower extremity SBP gradient. (Table 
23): 
Table 23. EST results
Surgery  
(n=28)
Balloon  
Dilation  
(n=23)
Stent  
(n=24)
p  
value
Exercise duration (minutes) 12 (7,21) 11 (9, 21) 13 (5,17) 0.45
Pre-exercise SBP gradient (mm Hg) -3 ± 21 1 ± 9 6 ± 18 0.17
Peak-exercise SBP gradient (mm Hg) 32 ± 30 33 ± 22 26 ± 27 0.64
Peak right arm SBP (mm Hg) 177 ± 35 157 ± 27 177 ± 33 0.05
Peak right arm DBP (mm Hg) 71 ± 13 75 ± 9 73 ± 11 0.50
VO2 Max (ml/Kg/min) 41 ± 11 32 ± 27 41 ± 11 0.30
VE/CO2 slope 26 ± 4 26 ± 5 26 ± 6 0.98
Values are mean ± standard deviation, or median (minimum, maximum). DBP = diastolic blood pressure; SBP systolic blood 
pressure; VO2 Max = peak exercise oxygen consumption; VE/CO2 = relationship between ventilation and CO2 output
However, the peak SBP during exercise was lower in the BD group (Fig. 21) and this relationship 
persisted after adjustment for potential confounding variables (age at treatment, and BAV) 
(details in Table 30).
6. LV AND AORTIC MORPHOMETRICS
The treatment groups were similar with respect to LV size, ejection fraction, and mass (Table 
24 and Fig. 21): 
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Table 24. LV measurements by CMR
Surgery  
(n=28)
Balloon 
Dilation  
(n=23)
Stent  
(n=24)
p  
value
EDV indexed to BSA (ml/m2) 71 ± 13 76 ± 17 73 ± 18 0.64
Ejection fraction (%) 63 ± 6 61 ± 5 62 ± 5 0.52
Mass  indexed to BSA (g/m2) 56 ± 13 58 ± 9 57 ± 13 0.83
Values are mean ± standard deviation. EDV = end-diastolic volume
Aortic dimensions, including those of the transverse aortic arch, were similar between the 
treatment groups. Isthmic dimensions were slightly smaller in the BD group compared to the 
surgical group but could not be measured in stented patients due to ferromagnetic artifact 
from the stent. Arch shape distribution was also similar between the treatment groups, 
assessed both qualitatively and quantitatively (using the arch shape index)408 (Table 25):
Table 25. Aortic dimensions and shape by CMR
Surgery  
(n=28)
Balloon 
Dilation  
(n=23)
Stent  
(n=24)
p  
value
Aortic Diameters (mm indexed to BSA)
     Ascending aorta 19.1 ± 3.0 20.6 ± 3.2 20.7 ± 3.4 0.18
     Proximal transverse arch 12.6 ± 1.2 12.8 ± 1.8 12.7 ± 2.9 0.96
     Distal transverse arch 11.5 ± 1.7 11.2 ± 1.6 11.9 ± 2.1 0.45
     Isthmus 12.6 ± 3.7 10.4 ± 2.8 N/A* 0.03
     Descending aorta 12.4 ± 1.1 12.6 ± 1.8 12.5 ± 1.6 0.95
Arch Shape 0.33
     Romanesque 11 (39%) 10 (43%) 10 (42%)
     Crenel 2 (7%) 5 (22%) 2 (8%)
     Gothic 14 (50%) 6 (26%) 12 (50%)
Arch Shape Index 0.64 ± 0.14 0.65 ± 0.11 0.68 ± 0.13 0.64
Values are mean ± standard deviation, or number (percent). * N/A = not available, due to presence of stent artifact. Arch 
shape index = aortic arch height divided by width; BSA = body surface area
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7. BLOOD BIOMARKERS
Patients in the BD group had lower levels of hs-CRP, and higher levels of MMP-9 and TGF-β1 
(Table 25 and Fig. 21): 
Table 26. Blood biomarkers results
Surgery  
(n=28)
Balloon  
Dilation  
(n=23)
Stent  
(n=24)
p  
value
NOx (ug/mL) 18 (12, 31) 20 (12, 37) 20 (10, 34) 0.18
ADMA (ng/L) 6 (1, 45) 7 (1, 51) 3 (0, 31) 0.20
hs-CRP (mg/L) 1.28 (0.74, 1.49) 1.26 (0.66, 1.41) 1.30 (0.95, 1.46) 0.02
VCAM-1 (ng/mL) 133 (66, 203) 134 (61, 206) 128 (66, 168) 0.42
IL-1β (pg/mL) 0.91 (0.04, 1.26) 1.06 (0.68, 1.98) 0.95 (0.06, 1.49) 0.1
TGF- β1 (ng/mL) 0.35 (0.12, 1.24) 0.64 (0.23, 3.21) 0.31 (0.05, 2.07) 0.006
MMP-2/gelatinase A (ng/mL) 1.14 (0.10, 3.37) 1.53 (0.00, 4.93) 0.62 (0.00, 3.62) 0.26
MMP-9/gelatinase B (ng/mL) 474 (91, 3157) 738 (158, 4453) 421(487, 1739) 0.01
Values are median (minimum, maximum). ADMA = asymmetric dimethylarginine; hs-CRP = high sensitivity C-reactive 
protein; IL-1β  = interleukin 1 beta; MMP = matrix metalloprotease; NOx = nitrite/nitrate; TGF- β1 = transforming growth 
factor beta-1; VCAM-1 = vascular adhesion molecule 1
These differences persisted after adjustment for potential confounders (details in Table 30). 
Levels of other blood biomarkers were similar across the treatment groups.
8. IDEAL CV HEALTH
The only difference between the three treatment groups are in the number of days that the 
family ate dinner at home together (Table 27).
LOVE-COARCT Study V. RESULTS
100
Table 27. Ideal CV Health
Surgery  
(n=28)
Balloon 
Dilation  
(n=23)
Stent  
(n=24)
p 
value
Hours of TV on average weekday 1.5 (0.5, 6) 2 (0, 5) 1.8 (0, 5) 0.58
Hours of video/computer games on average 
weekday
1 (0, 6) 2 (0, 5) 1 (0, 5) 0.34
Days physically active for ≥30 minutes in past 
week
5 (0, 7) 2 (0, 7) 4 (0, 7) 0.13
Days ate breakfast in past week 7 (0, 7) 7 (0, 7) 7 (0, 7) 0.30
Days ate food from a fast food restaurant in 
past week
0 (0, 7) 0 (0, 7) 1 (0, 7) 0.06
Days family ate dinner at home in past week 4 (0, 7) 7 (4, 7) 5 (0, 7) 0.001
Hours of sleep per night on average week 7.5 (5.5, 10) 8 (7, 11) 7.4 (4, 10) 0.07
Smoked ≥1 cigarette in past month 2   (7) 2   (9) 1   (4) 0.86
Previously a smoker 2   (7) 3 (13) 1   (4) 0.66
Live in household with smoker 7 (25) 6 (26) 2   (8) 0.21
Biological relatives overweight/obese 0.26
     Parents/siblings 4 (14) 8 (35) 3 (13)
     Grandparents/aunts/uncles 6 (21) 4 (17) 2 (8)
     Both 5 (18) 2 (9) 4 (17)
     No 11 (39) 9 (39) 15 (63)
     Unknown 2 (7) 0 (0) 0 (0)
Biological relatives with type 2 diabetes 0.37
     Parents/siblings 2 (7) 5 (22) 4 (17)
     Grandparents/aunts/uncles 10 (36) 8 (35) 5 (21)
     Both 1 (4) 0 (0) 0   (0)
     No 13 (46) 10 (43) 15 (63)
     Unknown 2 (7) 0 (0) 0 (0)
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Biological relatives with high blood pressure 0.18
     Parents/siblings 5 (18) 3 (13) 7 (29)
     Grandparents/aunts/uncles 13 (46) 11 (48) 5 (21)
     Both 2 (7) 1 (4) 5 (21)
     No 6 (21) 8 (35) 7 (29)
     Unknown 2 (7) 0 (0) 0 (0)
Biological relatives of with high cholesterol 0.16
     Parents/siblings 7 (25) 7 (30) 8 (33)
     Grandparents/aunts/uncles 6 (21) 4 (17) 5 (21)
     Both 5 (18) 6 (26) 0 (0)
     No 8 (29) 6 (26) 11 (46)
     Unknown 2 (7) 0 (0) 0 (0)
Biological relatives with heart disease/stroke 0.85
     Parents/siblings 1   (4) 2   (9) 1   (4)
     Grandparents/aunts/uncles 12 (43) 8 (35) 9 (38)
     Both 0 (0) 1 (4) 0 (0)
     No 13 (46) 11 (48) 14 (58)
     Unknown 2 (7) 1   (4) 0 (0)
Values are median (minimum, maximum). CV = cardiovascular.
9. ADJUSTMENT FOR POTENTIAL CONFOUNDERS 
As seen in Table 16, despite efforts at frequency matching, there were differences 
between the treatment groups with respect to potential confounding variables including 
age at treatment and the presence of a BAV (known to be associated with impaired aortic 
elasticity).406 Analyses to assess the impact of these confounding variables are summarized 
in Table 28, Table 29 and Table 30. 
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As seen in Table 28, age at treatment was significantly associated with AAO strain, Endo-PAT 
index, right arm diastolic BP, and 24-hour diastolic BP but not with other key outcome variables:
Table 28. Assessment for confounding by age at treatment
 1-3 4-9 10-14 ≥15
p  
Value
MRI proximal PWV (m/s) 4.8 ± 2.1 4.2 ± 1.1 5.6 ± 4.4 4.9 ± 1.3 0.35
AAO strain (%) 0.48 ± 0.24 0.44 ± 0.16 0.45 ± 0.24 0.28 ± 0.15 0.02
cfPWV (m/s) 5.4 ± 1.1 4.8 ± 0.8 5.4 ± 1.1 5.3 ± 0.9 0.13
AI (%) -12 ± 14 -14 ± 20 -7 ±18 -3 ± 19 0.21
Endo-PAT index 1.85 ± 0.55 1.89 ± 0.72 2.50 ± 0.73 2.34 ± 0.75 0.02
Right arm SBP (mm Hg) 121 ± 14 117 ± 12 124 ± 13 123 ± 12 0.34
Right arm DBP (mm Hg)   61 ± 5   63 ± 9   69 ± 11 68 ± 11 0.05
24-hour average SBP (mm Hg) 119 ± 14 120 ± 11 124 ± 8 126 ± 10 0.20
24-hour average DBP (mm Hg)   66 ± 8 64 ± 7   69 ± 7 71 ± 8 0.04
HTN Classification 0.14
     No HTN   7 (58%) 19 (70%) 9 (53%)   6 (35%)
     White coat HTN 1 (8%) 1 (4%) 2 (12%) 1 (6%)
      HTN/Masked HTN/Anti HTN 
meds 4 (33%) 7 (26%) 6 (35%) 10 (59%)
Peak exercise right arm SBP 
(mm Hg)
161 ± 34 169 ± 35 170 ± 27 180 ± 33 0.47
hs-CRP (mg/L) 127  
(104, 146)
127  
(66, 143)
129 (86, 
149)
128 (98, 
146) 0.67
MMP-9/gelatinase B (ng/mL)
707  
(246, 4228)
411  
(91, 2004)
515  
(487, 3157)
409  
(150, 4453)
0.15
Values are mean ± standard deviation, number (percent), or median (minimum; maximum). AAO = Ascending aorta; AI = 
Augmentation index; cfPWV = carotid-femoral pulse wave velocity; DBP = Diastolic blood pressure; Endo-PAT = Endothelial 
pulse amplitude testing; hs-CRP = High sensitivity C-reactive protein; HTN = Hypertension; MMP = matrix metalloprotease; 
MRI = Magnetic resonance imaging; PWV = Pulse wave velocity; SBP = Systolic blood pressure.
As seen in Table 29, the presence of BAV was not signifcanlty associated with any outcome 
variables:
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Table 29. Assessment for confounding by presence of BAV
 BAV No BAV p Value
MRI proximal PWV (m/s) 5.2 ± 3.1 4.2 ± 1.1 0.07
AAO strain (%) 0.37 ± 0.19 0.46 ± 0.21 0.07
cfPWV (m/s) 5.2 ± 0.8 5.1 ± 1.2 0.75
AI (%) -7 ± 18 -14 ± 19 0.14
PAT index 2.13 ± 0.75 2.17 ± 0.75  0.79
Right arm SBP (mm Hg) 122 ± 12 119 ± 13 0.21
Right arm DBP (mm Hg) 66 ± 10 64 ± 9 0.47
24-hour average SBP (mm Hg) 121 ± 12 123 ± 10 0.54
24-hour average DBP (mm Hg) 68 ± 8 67 ± 7 0.68
HTN Classification 0.86
     No HTN 22 (55%) 18 (58%)
     White coat HTN 3 (7%) 1 (3%)
      HTN/Masked HTN/Anti HTN 
meds
15 (38%) 12 (39%)
     Unknown 2 1
Peak exercise right arm SBP 
(mm Hg)
174 ± 32 166 ± 34 0.29
High sensitivity CRP (mg/L) 128 (74, 149) 128 (66, 146) 0.98
MMP-9/gelatinase B (ng/mL) 488 (91, 4228) 546 (49, 4453) 0.45
Values are mean ± standard deviation, number (percent), or median (minimum; maximum). AAO = Ascending aorta; AI = 
Augmentation index; cfPWV = carotid-femoral pulse wave velocity; DBP = Diastolic blood pressure; Endo-PAT = Endothelial 
pulse amplitude testing; hs-CRP = High sensitivity C-reactive protein; HTN = Hypertension; MMP = matrix metalloprotease; 
MRI = Magnetic resonance imaging; PWV = Pulse wave velocity; SBP = Systolic blood pressure.
Table 28 summarizes the results of multivariable modeling comparing key outcome variables 
between treatment groups while adjusting for these confounding variables (age at treatment 
and presence of BAV). Adjusted and unadjusted models did not differ significantly for these 
key outcome variables, suggesting that the impact of these potential confounding variables 
on our study measurements was not significant. 
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Table 30. Adjustment for potential confounders
Unadjusted Model Adjusted Model
 Coefficient p value Coefficient p value
CMR proximal PWV (m/s)
     Balloon dilation -0.76 0.29 -0.49 0.50
     Stent 0.77 0.26 0.87 0.28
AAO strain (%)
     Balloon dilation 0.14 0.02 0.12 0.04
     Stent -0.02 0.73 0.03 0.68
cfPWV (m/s) 
     Balloon dilation 0.05 0.84 0.07 0.79
     Stent -0.20 0.46 -0.54 0.09
AIx (%)
     Balloon dilation 8.65 0.08 10.6 0.04
     Stent 18.3 0.001 18.0 0.003
Endo-PAT index
     Balloon dilation -0.15 0.48 -0.12 0.59
     Stent 0.11 0.62 -0.12 0.64
24-hour average SBP (mm Hg)
     Balloon dilation -4.99 0.12 -5.24 0.11
     Stent 0.42 0.89 -2.30 0.36
24-hour average DBP (mm Hg)
     Balloon dilation -1.15 0.60 -0.26 0.91
     Stent 0.48 0.83 -2.57 0.29
Peak exercise right arm SBP (mm Hg)
     Balloon dilation -20.1 0.03 -19.3 0.04
     Stent -0.28 0.97 -3.28 0.76
Log hs-CRP (mg/L)
     Balloon dilation -0.07 0.07 -0.07 0.10
     Stent 0.02 0.65 0.03 0.54
Log MMP-9/gelatinase B (ng/mL)
     Balloon dilation 0.53 0.02 0.64 0.01
     Stent -0.27 0.22 -0.29 0.28
Multivariable linear models adjusted for age at treatment and presence of bicuspid aortic valve. For each comparison, the 
surgical group is the reference group. AAO = ascending aorta; AI = augmentation index; CMR = cardiac magnetic resonance 
imaging; DBP = diastolic blood pressure; hs-CRP = high sensitivity C-reactive protein; MMP-9 = matrix metalloprotease 9; 
PWV = pulse wave velocity; SBP = systolic blood pressure
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In this multicenter, prospective  comparison of optimally treated patients with CoA treated 
with surgery, BD, or stenting, we found that the treatment groups were similar with respect 
to several parameters of vascular function including the prevalence of systemic HTN, global 
aortic stiffness, CAP, endothelial function, and LV mass. However, despite adjustment for 
potential confounding variables (including age at repair), the BD group showed a better 
vascular phenotype characterized by a more distensible AAO, a lower peak SBP during 
exercise, and less impairment in diurnal BP variation.  
1. STUDY SUBJECTS
Our study groups differed by age at treatment, with older stent patients than surgical and 
BD patients. This is not surprising, considering that LOVE-COARCT was designed to include 
patients with more than one year old (yo) at treatment, and that stent patients usually have 
more than 6 yo at this time (please refer to Background,  section 1.8.6.). However, this was 
also likely unavoidable: an earlier draft of the study design specified that the lower limit for 
recruitment was patients older 6 yo at time of treatment, however a preliminary review of 
the participating center’s databases showed that this would exclude a significant part of 
the BD and surgical patients and render recruitment nearly impossible. To address this, our 
approach was therefore to implement a careful adjustment for potential confounding by 
age at treatment and other variables and found to have no impact on our results (please 
refer to Methods, section 7.1). 
Many retrospective studies showed a correlation between older age of treatment and 
worse BP phenotype and vascular function.207, 216, 227, 229, 230, 242, 251, 335, 338, 345, 349, 356, 375-378 Early 
studies reporting the outcome of large cohorts of surgical patients showed that late HTN 
and CV mortality were strongly related to age at surgery.251, 335, 338 The first study designed 
to specifically assess the impact of early surgery on BP showed that patients operated in 
infancy had less HTN (4%) than those treated later (27%).377 The first report demonstrating 
that the timing of operation has a selective impact on specific measures of vascular function 
was a cohort of 64 surgical patients (median age at operation 4 months old), where it 
was shown that patients who underwent surgical repair of CoA < 4 months of life had 
normal PWV (measured by photoplethysmography) but impaired brachial artery reactivity 
(measured by NO-dependent FMD and NO-independent nitroglycerin infusion).345 Another 
cohort of older surgical patients confirmed these findings, and showed that persistent 
LOVE-COARCT Study
108
VI. DISCUSSION
impairment of arterial reactivity after repair of coarctation was more likely to be present in 
patients treated > 9 yo, than in those treated < 9 yo, when compared to controls.375 Since 
these publications, other indices of vascular dysfunction have also been associated with 
older age of repair or transcatheter treatment.207, 216, 230, 242, 409 
A few papers that studied the impact of repair in vascular function prospectively, found that 
the elastic properties remain impaired after repair.66, 224, 228, 352, 354, 355 One interesting study 
reported the results of an experimental model of CoA in rabbits, that was created with silk 
(permanent) or Vicryl (degradable) suture. 12 weeks beyond the time for the biodegradable 
suture and hence the induced CoA to disappear, these animals remained with altered 
BP and endothelial function.66 In humans, prospective assessment of vascular function 
was reported in three small studies, after stent implantation (one with 12 patients,224 and 
another with 13 patients)228 or BD (13 patients).355  The results showed that the ascending 
aortic elastic properties and other indices of vascular function remained abnormal after 
repair. Another small study (15 patients) reported similar finding in the mid-term follow 
up, after stent implantation.354 Finally, a study found that, even after neonatal repair (15 
patients), patients remain with impaired elastic properties of the aorta, at a mean age of 
3.0 ± 1.0 years.352 
All these studies concurred to demonstrate that age at operation is a strong, independent 
variable associated with impaired vascular properties of the aorta. To address this difference 
in age at treatment between the three treatment groups - which we anticipated that could 
occur, in the study design phase - our approach was two-fold: at the recruitment stage, we 
attempted to frequency match the three treatment groups for what we considered the 
main confounding variables, age at treatment, current age and BAV; at the analysis stage, 
we implemented a careful adjustment for potential confounding by age at treatment 
(please refer to Methods, section 7.1). Our statistical analysis for the possible effect of 
confounding by age (and the other variables, which did not differ) showed that this had no 
impact on our results.
Importantly, LOVE-COARCT’s three treatment groups had no difference in any other 
confounding variables. Current age did not differ between the three treatment groups. 
The mean age of our cohort is 18. Length of follow up is an important determinant of late 
vascular dysfunction and abnormal BP profile, as is demonstrated by a large study in which 
an immediate decrease of BP after treatment was followed by an increasing incidence 
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of HTN after five years of follow up.337 In our cohort, there were no differences in the 
severity of native CoA (BP gradient, echocardiographic dimensions of arch and isthmus, 
and Doppler estimated gradient). Several studies showed that the severity of the CoA, the 
presence of reCoA or even a mild residual narrowing at the site of CoA repair predisposed 
to late HTN379, 380 and impaired vascular function,217, 381 but this was not confirmed in other 
studies, who found no impact of reCoA on vascular function.214, 348 
There were no differences between the incidence of BAV between the three treatment 
groups. As previously stated in the Background (please refer to Background, section 
1.5.1), about half of the patients with CoA have this associated anomaly, which has 
been associated with impaired arterial stiffness.406 Despite observing no differences, we 
performed a statistical analysis, and found that the presence of BAV had no impact in 
LOVE-COARCT results. 
76% of our cohort were male patients, which is in accordance to what has been described 
in previous studies of patients with CoA.21, 26
2. AORTIC STIFFNESS
2.1. Global Assessment of the Aortic Wall
In LOVE-COARCT, global aortic stiffness assessed using cfPWV by applanation tonometry 
with the NIHem system (Fig. 22), or the SphygmoCor (Fig. 23), and using AAO to distal 
DAO PWV by CMR, did not show any differences between the three treatment groups. 
Segmental aortic stiffness of the aortic arch (AAO to prox DAO), mid (prox to mid DAO), 
and distal (mid to dist DAO) aorta did not also reveal any differences between treatment 
groups. 
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Fig. 22. Arterial tonometry with NIHem. Both carotid and femoral curves are superimposed in the same 
graphic, calibrated with blood pressure and time. The proprietary software analyses the pulse wave contour and 
automatically marks the critical points with a spike and measures the distances, to calculate the carotid-femoral 
pulse wave velocity (purple), pulse pressure (red) and augmentation index (green). (Image from a LOVE-COARCT 
patient)..
It is of note that, despite the non-significance of any of these results, the values of the arch 
PWV, the segmental measure that is mostly focused on the treated segment of the aorta, are 
the ones that suggest a potential difference (BD 4.0 ± 1.2 m/s, surgery 4.7 ± 1.5 m/s, and stent 
5.5 ± 3.8 m/s) but do not reach statistical significance in our sample (0.12). This difference is 
effaced when healthier segments of the aorta are involved in the PWV estimation.  
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Fig. 23. Arterial tonometry with SphygmoCor. The foot of both carotid (Site A) and femoral (Site B) tracings are 
automatically detected with the proprietary software and the time delay between them is divided by the carotid 
to femoral distance to calculary the carotid-femoral pulse wave velocity. (Image from a LOVE-COARCT patient). 
There are no previous studies that compared the three different treatments for CoA with 
regard to global or segmental PWV, and three papers reported comparisons of arterial 
stiffness outcomes between different surgical techniques. One publication compared a small 
sample of 20 patients treated with end-to-end anastomosis and subclavian flap surgical, 
and found that right arm PWV was higher in the subclavian flap compared to end-to-end 
anastomosis patients, while the latter did not differ from controls.386 Another study, with 39 
patients, found similar results.387 However, a third study, comparing these same two surgical 
techniques, found no difference in carotid to radial PWV. 
There are several publications that reported comparisons between patients with CoA and 
healthy controls, which show that PWV is increased in arterial segments above (carotid-
radial or brachial-radial)233, 345-349 but not across (carotid-femoral or brachial-ankle)72, 244, 349 
or below (femoral-dorsalis pedis)345 the coarctation site. These studies have used different 
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techniques, including photoplethysmography,345-347  applanation tonometry244, 348, 349 or, more 
recently, by CMR.233 
Regarding the healthy population, there are now a few pediatric studies, and a large number 
of large studies with adult populations that have reported data on applanation tonometry 
assessment of cfPWV.283, 410-412 Nevertheless, considering the number of covariates that 
are known to influence PWV in children, it is recommended that these ‘normal’ values be 
interpreted only for the specific device used.267 Therefore, we did not pursue any comparisons 
between the combined results of our three treatment groups as a whole, and those values. 
CMR has an excellent spatial and temporal resolution, and low interobserver error,413 but 
only a few studies have used it to characterize AAO to DAO PWV. Therefore, despite the well 
standardized protocols that were used for measuring CMR PWV, we did not have a control 
group and therefore these comparisons need be read carefully. 
2.2. Segmental Assessment of the Aortic Wall
In LOVE-COARCT, this was done with CMR. The segmental assessment of the aortic wall with 
PWV and other distensibility measures of arterial stiffness that relate arterial dimensions vs. 
pressure by CMR (strain, distensibility, compliance and β stiffness index), differences emerged 
between treatment groups. Proximal aortic (AAO and aortic arch) stiffness was lowest in BD 
patients and highest in stent patients. Surgical patients had intermediate values of stiffness. 
AAO distensibility in BD patients was similar to values reported in normal controls, while 
patients in the stent and surgery groups had lower values.414 
There are no studies that compare the treatment techniques with regard to the assessment 
of segmental arterial function, but there are a few albeit small reports that compare patients 
with CoA and healthy controls, and  this assessment was made using vascular ultrasound,228, 
244, 350-354 transthoracic,229 intracardiac,355 or transesophageal echocardiogram,242, 356 and, more 
recently, with CMR.233, 235 The older of these studies (23 patients), used transesophageal 
echocardiography, and found that patients with CoA treated with surgery have less distensible 
ascending aortas but normal descending aorta.356 More recently, two studies used CMR (one 
with 50 patients,235  another with 40 patients)233 to report that strain, distensibility, or β 
stiffness index were altered in the pre, but not the post-CoA aorta. A recent study used 
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M-mode echocardiography to described similar findings in 17 neonates, who presented with 
impaired elastic properties of the ascending aorta.353 Finally, an increased proximal aortic 
stiffness evidenced by an elevated PWV and lower distensibility was reported in the largest 
study of the lot (64 patients) that were focused on surgical treatment for CoA, in comparison 
to healthy controls.353 We were careful to use simultaneous BP measurements with the CMR, 
for the calculations of compliance and other variables. We acknowledge the limitation of 
using brachial artery BP instead of invasive aortic pressure measurements, but, for ethical 
and practical reasons, this was not feasible.
Segmental values of normal arch PWV obtained by CMR for adolescents have been 
published.414 The combined result of our three treatment groups have values that appear 
higher than those.
All of these previous data point to the presence of an altered vascular function in the 
segments above, but not below, CoA. This is even more significant when one considers that 
in normal subjects, the elastic properties of the aorta decrease as distance from the aortic 
root increases,415 which is precisely the inverse of what we and the previous studies found. 
LOVE-COARCT’s results are in line with these works.
However, our study is the first to systematically compare aortic stiffness across treatment 
modalities and, more importantly, observing a difference between them. This significant 
result supports the LOVE-COARCT’s study hypothesis. However, the mechanism leading to 
a more distensible proximal aorta in BD patients remains unclear and our study was not 
designed to answer that question. It is possible that the absence of a surgical scar or rigid 
stent at the isthmus contributes to a lower stiffness at the CoA site. We acknowledge that 
the BD group underwent treatment at a younger age, however differences in AAO stiffness 
persisted after adjustment for age at treatment.
3. ENDOTHELIAL FUNCTION
In LOVE-COARCT, we measured endothelial function with Endo-PAT, which is a novel non-
invasive and reproducible technique that assesses changes in pulsatile arterial volume with 
a fingertip probe (Fig. 24):
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Fig. 24. Endo-PAT of a LOVE-COARCT patient. The upper tracing is control finger and the lower tracing depicts 
the test finger, in the contralateral arm. After a baseline period, there is a temporary cuff occlusion, followed 
by cuff deflation. The dilation in pulse amplitude is measured automatically by the proprietary software, to 
calculate the reactive hyperemia index, shown in the lower tracing. (Image from a LOVE-COARCT patient).
Our results did not show a difference between the three treatment groups with regard Endo-
PAT’s index, RHI.  To the best of our knowledge, the effect of treatment type on endothelial 
function has not been previously studied in CoA. Our results are therefore the first to report 
Endo-PAT’s RHI index in patients with CoA, similar across treatment groups. 
There are, however, a significant number of studies that reported the arterial reactivity in 
patients with CoA and compared it to normals. The majority of these studies show that 
both vascular flow-mediated (endothelium-mediated) and glyceryltrinitrate-mediated 
(endothelium-independent) dilation are impaired in successfully repaired CoA patients.217, 
224, 328, 345, 347, 348, 350, 359-361 The oldest of these studies is a 25 yo study, that is remarkable for 
having been done only two years after the first clinical report of the FMD technique, by 
the same group, merely two years before.300 It is of note that, only a minority of studies 
failed to demonstrate impaired reactivity in retinal,333 peripheral362, 363 or coronary363 arteries 
of repaired CoA patients when compared to controls. The majority of these studies were 
done with either photoplethysmography or echo-measured changes in the brachial artery 
mediated by flow (FMD), but a minority was done with Endo-PAT.362, 374 
Our RHI results, either individually for each treatment type, or combining them as a single 
group, suggest that endothelial function is preserved after CoA treatment in our LOVE-
COARCT patients. This comparison is done with the seminal study that established normal 
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values in healthy children and adolescents, which is less than a decade-old.304 Our protocol 
was designed and implemented by the authors of this study. In CoA, the loss of central aortic 
pulsatility, which buffers systole, generates chronic shear stress downstream in smaller 
arteries, adversely affecting endothelial function. Therefore, we expected to measure an 
impaired endothelial function with Endo-PAT. There are only two publications that used 
Endo-PAT to study endothelial function in CoA.362, 374 And, interestingly, the values obtained 
in our cohort are comparable to those reported using a similar technique in a small cohort 
(20 patients), comprised of mostly end-to-end surgically repaired CoA.362 However, the other 
existent study (23 patients) described an impaired endothelial function in another group of 
surgical patients, the majority repaired by subclavian flap. The age and follow up is similar 
in these two studies and one possible, but speculative explanation, could be the different 
surgical techniques. 
4. PULSE WAVEFORM ANALYSIS
In LOVE-COARCT, there were no differences in the results of pulse waveform analysis between 
treatment groups, both with applanation tonometry and Endo-PAT results. The lack of difference 
in calculated central aortic pressure is in line with our findings of BP profile, presented in the 
following section 5. We anticipated that the presence of an undistendable metallic stent could 
translate into more reflected waves and higher AIx than in the other two treatment groups. 
However, despite a tendency for a higher AIx@75 calculated with both applanation tonometry 
and Endo-PAT in the stent group, this did not reach statistical significance in our results.
The analysis of the pressure waveform is an important clinical tool for monitoring of vascular 
function and its indices are independent markers, and predictors of cardiovascular events.287 
It is also an important instrument to assess response to treatment, as the large Conduit Artery 
Function Evaluation (CAFE) study showed that the differential impact of BP–lowering drugs 
was only detected on pulse wave analysis and not on office BP measurements.416 Peripheral 
reflected pulse waves return to the aortic root rapidly via stiffer arteries, which can augment 
systolic pressure leading to increased central pulse pressure. There are no previous studies 
that compared results of pulse wave analysis between treatment types. There are, however, 
several studies showing that repaired CoA patients have  altered functional parameters of 
the pressure waveform, such as a higher AIx,224, 348, 364 a wider PP,75, 358 or an increased central 
aortic pressure.348, 358, 364 The most significant of these studies, specifically designed to assess 
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the pulse waveform morphology, showed an increased PP but not a higher AIx in 46 surgical 
patients, as compared to healthy controls.358 There is one study that has mostly surgical but 
a few stent patients,364 one reporting only stent patients,348 and the remainder are based on 
patients with CoA that were treated with different surgical techniques. 
There are several reasons for a careful comparison between these studies and our LOVE-
COARCT results: all of these studies were done in adults, and the mean age of their patients 
(from 25 to 41 yo) is higher than in our LOVE-COARCT cohort (18 yo); all of the above were 
done with tonometry and ours included both tonometry and Endo-PAT; it is well known 
that the pulse waveform changes with age, so comparisons between our study should be 
done with care; and finally, even if central BP and AIx do not depend upon any distance 
measurements, they are somewhat operator-dependent and require a tonometric skill set 
of the operator,268 which should be underlined in comparison with our results, which were 
obtained from multiple centers and different operators. Having stated this, one example of 
a comparison that should be done with care is the finding of negative AIx, such as we had in 
LOVE-COARCT, is common in children, but not in adults.417
5. BP PHENOTYPE
To achieve a detailed characterization of the BP profile, we assessed BP with four different 
approaches. We used the manual auscultation technique to measure the right arm office 
BP while the patient is resting and sitting. This was followed by supine four extremity 
oscillometric BP measurement to assess for reCoA (section 1). Subsequently, we used ABPM 
to measure the circadian BP profile. And finally, our patients performed an EST to assess the 
BP response to exercise and exercise-induced arm to leg BP gradient, exercise tolerance, HR 
response to exercise, and functional capacity parameters.
5.1. Office BP
In LOVE-COARCT, we found no differences of office BP measurements between treatment 
groups. A pilot, retrospective study from our group, compared the BP response to EST 
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between the three CoA treatment types, BD (12 patients), stent implantation (8 patients) 
and surgery (4 end-to-end, and 8 subclavian flap), and found that BD patients had a less 
exaggerated BP response and less arm to leg gradient, in comparison with the other two 
types of treatment.378 There is only one prior study that reported a comparison between the 
three treatment types (350 surgery, BD, and stent patients; 36 institutions) of BP phenotype 
long-term outcomes.130 Here, it was described that, in the intermediate follow up, there 
may be more normotensive patients treated by BD (72% ) vs. surgery (96%) and stent (82%), 
but this falls short of reaching statistical significance (p =  0.09);  and in a subgroup analysis 
(age 6 to 12 yo), the short term results show that patients have less anti HTN medication, 
however the values of SBP do not differ between the three groups. These values need to be 
interpreted with care, since this is a retrospective study with 36 contributing institutions, 
distinct methods to acquire BP, and a different definition of office HTN than the one we used 
in LOVE-COARCT. Three retrospective studies compared the influence of surgical technique 
on BP outcomes: a small study (10 end-to-end anastomosis; 11 subclavian flap);386 a mid-
sized study (21 end-to-end anastomosis; 22 subclavian flap),385 and a large study (137 end-
to-end anastomosis; 118 polytetrafluoroethylene patch aortoplasty).119 All reported that 
end-to-end anastomosis, has less HTN than the other surgical approaches. 
Overall, 44% of our patients had pre-HTN and 9% had either Stage 1 or Stage 2 office HTN. 
The prevalence of HTN on office measurement were within the range of prior reports (12-
65%).130, 154, 166, 177, 203-215 Most studies do not publish the methodology of the measurement of 
BP (seated or lying down, method to choose the size of cuff, the number of measurements 
taken, and in how many clinic visits). Consequently, comparisons need to be done carefully. 
Additionally, these reports differ significantly in their definition of HTN, which can be in 
children from a SBP > 90 percentile (in older studies),205 SBP or DBP ≥ 95 percentile,207 or 
SBP ≥ 97.5 percentile of normal subjects (age and sex adjusted);130  in adults a value of SBP 
> 140 or DBP > 90;207 and in any age group, the use antihypertensive drug treatment, HTN 
at ABPM, or during exercise.213 This latter study is, in fact, the largest, single center study 
on HTN in CoA (Coarctation Long-term Assessment (COALA) Study), which reports that 
only 43% of 404 patients had a normal BP profile. Another factor to take into consideration 
when comparing our overall results with other studies is the length of follow up, because, 
age (in the general population) and time from treatment (in patients with CoA)89 are both 
associated with increased incidence of HTN. Our cohort has a younger age than most of the 
above mentioned studies. Despite all existent epidemiologic data on BP in repaired CoA, we 
still don’t fully understand the mechanisms underlying HTN in these patients.418 One study 
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described that HTN, and not CoA itself, was an independent risk factor for CV complications 
in these patients.419
5.2. ABPM
In LOVE-COARCT, there were no differences between treatment groups with respect to 
the prevalence of HTN on ABPM, or the average 24-hour systolic or diastolic BP. However, 
we did find that BD patients demonstrated lower night-time systolic and diastolic BP, and 
more physiologic nighttime dipping in BP, compared to the surgery and stent groups. This 
improved BP phenotype in the BD group, in comparison to the other two treatment groups, 
has not been previously reported and is in line with our study hypothesis. The only previous 
comparison of ABPM results between treatment types are a two small studies (one with 
43,385 and another with 39 patients)230 that showed end-to-end anastomosis to have better 
24-hour SBP and DBP, and daytime and nighttime SBP during ambulatory monitoring than 
patients repaired with subclavian flap technique). Our finding of blunted nighttime dipping 
and lower nighttime BP has been previously linked to the development and progression 
of end-organ disease in patients with essential HTN, diabetes mellitus, obesity, and black 
race.420 Nevertheless, the impact of this finding on long-term outcomes in CoA patients 
deserves further study. 
Overall, 36% of the LOVE-COARCT patients were either on an anti-hypertensive medication 
or had HTN/masked HTN based on ABPM results. ABPM may be superior to office BP 
measurement in its ability to distinguish patients at the highest risk for target-organ 
damage,402 and identifies patients with vascular disfunction such as increased arterial 
stiffness421 and endothelial dysfunction.422 In prior studies in patients with CoA, the diagnosis 
of HTN based on ABPM was between 30-59%.72, 75, 213, 216-225 As was said for office HTN, the 
definitions of HTN on ABMP studies vary between studies and therefore, and therefore any 
detailed comparisons between LOVE-COARCT and these studies should be done with care.
5.3. EST
In LOVE-COARCT, the EST results showed that the BD group showed a less exaggerated BP 
elevation to exercise, compared to the surgery and stent groups. There is only one study 
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that compared CoA treatments with regard to EST, already mentioned above. It reported 
exclusively on two surgical techniques, and showed that end-to-end anastomosis has less 
systolic BP at peak exercise when compared to subclavian flap.385 In the general population, 
exercise-induced HTN has been shown to be predictive of future development of resting 
HTN,423 and an independent risk factor for cardiovascular events and mortality.424 This finding 
also aligns with our study hypothesis and requires further study to assess its clinical impact, 
currently unknown in a population of treated CoA patients. 
We did not calculate overall measurements for the entire LOVE-COARCT cohort (please refer 
to Methods, section 6.4.3). However, the abnormal BP profile with exercise that persists after 
treatment for CoA has been abundantly demonstrated in the last decades, with all treatment 
techniques, with exercise-induced HTN (10-47%) 210-217, 220, 327-332 or intolerance 332, 425, 426 and 
exaggerated BP response to exercise correlated with LV mass.427 However, a few studies 
were unable to show HTN response compared to controls.214, 221, 428 As previously stated, 
comparisons need to be done carefully, due to different methodologies applied in different 
studies. For example, HTN during exercise can be defined when the peak SBP is greater than 
two standard deviations more than the age- and work load–dependent reference value,213 
when the peak SBP higher than 220 mmHg in men and higher than 190 mmHg in women,216 
or if the SBP has an increase higher than the 95th percentile for their age and sex.215
6. LV MASS AND AORTIC MORPHOMETRICS
6.1. LV Mass
In LOVE-COARCT, despite some differences in BP phenotype and other indices of vascular 
function, we found that LV end-diastolic volume, LV mass and LV ejection fraction were 
similar across treatment groups. Furthermore, these values were normal when compared to 
previously reported values in healthy subjects.429 There are no studies comparing treatment 
types with regard to LV volumes, mass, and function. However, The increased pressure 
afterload after repair has been shown to increase LV mass, both by echocardiogram217, 221, 227-
232 or CMR,75, 231, 233-236 which may justify the finding of a normal or increased global LV function 
based on echocardiography,221, 237-241 or CMR369, 430 but not accurately reflect myocardial 
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performance. Recent studies, including tissue Doppler, speckle tracking and strain imaging 
have also shown abnormal regional fiber shortening225, 229, 230, 232, 234, 235, 238, 242-246 and diastolic 
dysfunction.230, 232, 238, 244, 247, 248 The Framingham Study has shown that the incidence of left 
ventricular hypertrophy is strongly related to high BP and carries a grave prognosis for cardiac 
events.431 
Overall, our results contrast with this evidence of previously reported increased LV mass 
values in patients with repaired CoA.233 In effect, our LV mass values were lower compared 
to this prior report but are similar to the values reported in a more recent publication, which 
had a similar age at enrollment as our sample.226 One possible explanation for the absence of 
significant LV hypertrophy in LOVE-COARCT may be related to the relatively young age of our 
patients, and good blood-pressure control in our population, in comparison to most of the 
studies that were previously published, in adult populations, with more HTN. To prove this 
point, there is one previous work that studied a group of treated children with a young age 
(mean age 6.4 ± 3.0) who had compromised elastic properties of the ascending aorta after 
successful surgical coarctoplasty compared to controls, but similar LV mass compared to our 
LOVE-COARCT study.432 
6.2. Aortic Morphometrics
In LOVE-COARCT, we did not see any difference in the size or shape of the aortic arch 
between the three treatment groups. Several papers, mostly from the same research group, 
have described that the shape of the aortic arch impacts the vascular function, namely age-
related decrease in curvature433 or (conversely) a gothic arch is a predictor of both resting208, 
371 and exercise-induced HTN372 as well as increased aortic stiffness.350, 373 However, these later 
results were unconfirmed in studies from different groups.434, 435 Despite these controversial 
findings, the congenital heart community is now aware that the arch shape may impact 
blood flow hemodynamics and potentially vascular function.436 
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7. BIOMARKERS
7.1. Endothelial function
In LOVE-COARCT, there were no differences in NOx or ADMA levels between treatment 
groups, consistent with the lack of difference in endothelial function using Endo-PAT. NOx and 
ADMA are biomarkers related to endothelial function, and their levels have been correlated 
with the risk of atherosclerosis due to endothelium-dependent NO regulation of smooth 
muscle-derived vascular tone, in the general population.437 There are no studies comparing 
treatment types, but recent insights are being gained regarding these biochemical and 
molecular pathways in repaired CoA patients. However, studies are small and often present 
contradictory results. Biomarkers of the nitric oxide-mediated endothelial function were 
found to be altered in animal models365 and patients with repaired CoA, including evidence 
of enhanced NO inactivation,347, 366 and increased ADMA levels. 347A different study did not 
find altered NO in CoA patients.347 
7.2. Inflammation
In our study, BD patients had lower levels of hs-CRP, which supports our initial hypothesis. 
Inflammation is a second aspect that relates to vascular dysfunction.309 There are numerous 
markers of systemic inflammation, such as interleukins and hs-CRP, which act on the vascular 
endothelium to upregulate a number of adhesion molecules that reflect vascular wall 
function such as VCAM, with a crucial role in atherogenesis.315, 438 There are no comparisons 
of inflammation biomarkers between treatment types, and prior results of inflammatory 
biomarkers in patients with CoA are inconclusive. Inflammatory biomarkers such as TNF-α367, 
IL-1β,360 IL-6349, 367, 439 and IL-10364, 367 or e-selectin are increased in repaired CoA. However, 
other studies showed no change in TNF-α,364 IL-6,360, 364 e-selectin,367, 368 or high sensitivity C 
reactive protein (hs-CRP) in CoA patients.367, 368 
Three interesting studies, from the same group of investigators, explored the role of 
inflammation and its response to medication, in patients with repaired CoA. A randomized, 
cross-over, controlled trial study reported that, after treatment with ramipril for 4 weeks in 
20 patients, there was an improvement in endothelial function and decrease in serum levels 
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of IL-6 and sVCAM-1, which was independent of the BP lowering.382 A similar study, from 
the same group of investigators, showed that after 4 weeks of atorvastatin, CoA patients 
had reduced circulating levels of IL-1b  and sVCAM-1, but no change in IL-6 levels.383 A third, 
and very recent study, performed an innovative assessment of the aortic wall inflammation 
with positron emission tomography/computed tomography  with 18F-fluorodeoxyglucose,428 
which is the gold-standard imaging modality to noninvasively assess vascular inflammation 
in vivo. In this pilot study (15 patients), they found that patients with surgically repaired CoA 
have increased aortic wall inflammation. 
There is a strong association between hs-CRP and risk of cardiovascular disease, but, despite 
multiple larger population trials, there remains a lack of consensus regarding its clinical use, 
namely the cutoff value for increased risk, since this protein is influenced by sex, traditional 
CV risk factor such as HTN and lipids.440
7.3. Vascular remodeling
The third set of biomarkers that we assessed were the ones involved in aortic wall remodeling. 
In LOVE-COARCT, values of both TFG-β1 and MMP-9 were elevated in the patients with CoA 
treated with BD, in comparison to the two other treatment types. There are no previous 
studies comparing CoA treatments in respect to vascular wall remodeling biomarkers in CoA, 
but patients with repaired CoA have altered biomarkers of the vascular wall function such 
as increased TGF-β,349 or adhesion molecules (sICAM-1, sVCAM-1).360, 364, 368 However, these 
results were unconfirmed in a different study where it was found, in contrary, that sICAM-1 
and sVCAM-1 did not differ between CoA patients vs. controls.367 A recent study explored 
the expression of genes of aortic wall remodeling and stiffness, as well as the pathological 
examination of the aortic wall itself, in an animal model of experimental stent treatment 
for CoA.441 They found that  an increased expression of MMP-9 genes in the ascending, but 
not the descending, aorta which points to molecular mechanisms of aortic wall remodeling 
in stented CoA. TGF-β1, and the family of metalloproteinases (such as MMP-2, and MMP-
9) are biomarkers related to fibrotic remodeling such as the aortic remodeling that occurs 
in response to hemodynamic changes.442 Elevated circulating levels have been reported in 
dilated aortas in patients with inherited aortopathy,317 and are biomarkers for the presence 
and risk of rupture of an aortic aneurysm.320 Experimental studies showed that increased 
aortic wall motion is associated with a higher risk of aneurism formation.443 This may explain 
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our results in BD, who have an increased AAO strain and higher MMP-9 values The clinical 
implications of these findings are unclear and further research is needed to evaluate whether 
these biomarkers are related to the risk of aneurysm formation in the BD group, which has 
been a concern in this patient group.111, 154, 200-202
8. IDEAL CV HEALTH
In LOVE-COARCT, there were no differences in the lifestyle characteristics of our three 
treatment groups (eating habits, exercise, smoking) or in the hereditary risk factors for CV 
disease (HTN, diabetes, obesity). The baseline metabolic assessment was also not different 
between the three treatment groups. The only minor finding was that BD patients ate more 
at home with the family than the other two treatment groups. Cultural differences may 
explain this finding, but our study was not designed to answer that question. Overall, these 
results are important to exclude the contribution of well-known risk factors in our LOVE-
COARCT cohort and underline the validity of our other findings reported above. A growing 
body of literature in the general population has demonstrated that risk of cardiometabolic 
disease and accelerated atherosclerosis is mitigated by ideal cardiovascular health (ICVH),405 
defined as having optimal levels of health factors (BP, total cholesterol, plasma glucose) and 
behaviors (smoking, body mass index, physical activity, and diet). All these factors have been 
well documented as risk factors for CV events, such as BMI (strongly linked to CV events in, 
as has been shown in a metanalysis of 239 prospective studies),444or lipid metabolism.445
To the best of our knowledge, the prevalence of ICVH in patients late after repair of coarctation, 
including the composite ICVH score and individual elements of ICVH, in unknown. LOVE-
COARCT is the first study to report on ICVH in patients with CoA. This is important, since 
these patients experience increased CVD compared to the general population. Therefore, 
the control of traditional cardiovascular risk factors and knowledge of family history is 
particularly important. 
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9. STUDY LIMITATIONS
As previous authors have noted, research in CoA is challenging. 446, 447 There are several 
limitations to our study. 
The first limitation of our study is related to the patient selection criteria. CoA is a heterogeneous 
disease, ranging from a simple discrete stenosis to a long tubular narrowing accompanied by 
aortic arch hypoplasia, and can occur as an isolated anomaly or coexist with other congenital 
heart defects. The choice of treatment modality is dictated by the age of presentation, the 
morphology of the CoA, the anatomy of the arch, the initial response to treatment (valid for 
percutaneous BD vs stent), and the associated anomalies. Some of these factors may play a role in 
vascular function outcome. Our restrictive inclusion and exclusion criteria excluded a significant 
subset of patients, namely those that required treatment in infancy or have anatomies that 
were not amenable to all treatment with all techniques. Therefore, our results reflect vascular 
function in isolated, discrete CoA and may not be representative of the population of CoA as a 
group. Specifically, our results may not be generalizable to neonatal and infantile CoA, which is 
on the one hand more severe at presentation but also on the other has an earlier treatment. 
Our plan was to compare three treatment modalities, and, despite our attempted frequency-
matching to balance the treatment groups with respect to key confounding variables, our 
groups were not perfectly matched for age at treatment. However, surprisingly, multivariable 
analyses (Table 28, Table 29, and Table 30) showed that these potential confounding 
variables (including age at repair) did not significantly affect the comparison of key variables 
between treatment groups. 
Despite a multicenter design, our study is limited by a relatively low sample size. However, 
based on sample size estimates, the study had sufficient statistical power to detect 
group differences in CMR PWV. The multicenter design carries some other limitations. 
Retrospectively gathered data from medical records (e.g., surgical notes, original anatomy) 
of multiple centers makes it more likely that data may be missing for some participants. 
Variation in antihypertensive medication protocols between different institutions may also 
affect vascular parameters. Because some centers did not have a cycle ergometer, we chose 
the treadmill for the exercise test, which hinders the acquisition of metabolic data associated 
with anaerobic metabolism and makes the measurements of exercise BPs less reliable than 
those obtained with the cycle ergometer. 
VI. DISCUSSION
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We recognize that there is no single marker of vascular dysfunction and that large vessel 
and small vessel functions interact mechanistically and in terms of outcomes. Additionally, 
the study of the impact of treatment on the aortic wall in patients with CoA is challenging 
because these patients show a congenitally altered aortic wall compliance. Therefore, we 
studied both small and large arteries, BP phenotype, biomarkers and cardiovascular health 
status to comprehensively model cardiovascular event risk feature differences among the 
three treatment groups. This wide approach carried the intrinsic limitations of each specific 
test. To overcome this limitation, we standardized all methodologies, to reduce the variability 
of the study testing measures, and institute Core Laboratories where a single researcher is 
responsible for the interpretation and sometimes, as for the biomarkers, the execution of 
the technique. We prescribed a low-NO diet and non-smoking indication for participants but 
had no way of measuring the compliance with this diet other than the patient’s assertion. 
And, finally, we compared the vascular function after treatment but have no such pre-
treatment assessment of our patients. Consequently, despite our best efforts to create 
three treatment groups that do not differ with regard to the main confounders, the vascular 
function assessment of our patients does not take into consideration the baseline vascular 
dysfunction of each patient.
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CoA, a narrowing of the proximal descending aorta, is one of the most common congenital 
heart defects. There are several percutaneous and surgical techniques that may be equality 
effective ate relieving the stenosis. The persistence significant late cardiovascular morbidity 
and mortality showed that CoA is not a simple lesion that is “cured” with the relief of the 
anatomic narrowing but as a complex arterial syndrome that requires lifelong follow-up. 
As a recent editorialist wrote, “Simple CoA is an example of a disease process requiring us 
as clinicians to understand the interaction of inherent risk (genetic determinants, intrinsic 
arteriopathy) with superimposed anatomic (native and intervened aortic), physiological 
(compliance, BP, flow) and environmental (smoking, overweight, diabetes, sedentary 
lifestyle) modifiers, in a longitudinal construct”.381 
With this quote as background, it was highlighted the emphasis has been placed in recent 
years on the long-term morbidity due to systemic vascular dysfunction in successfully treated 
CoA patients. The association between vascular dysfunction and cardiovascular events is 
well established in the general population. There is ample evidence to suggest that CoA is a 
systemic arterial disease and not merely a focal stenosis of the aortic isthmus. Despite this, 
the current management paradigm is often guided not only by CoA anatomy and patient 
age but often by anecdotal, personal and institutional preference, with the primary goal of 
alleviating the anatomic stenosis. 
We aimed to clarify if the treatment modality could contribute to the well-known vascular 
dysfunction that exists late after CoA treatment. It was hypothesized that BD would be 
associated with the best vascular outcome since it is the approach that best preserves the 
arterial wall integrity. The LOVE-COARCT study was designed as a multicenter, prospective, 
observational trial to answer this question and constitutes the bulk of the present PhD 
dissertation thesis written by the candidate. This work will be the first systematic, focused 
and comprehensive comparison of vascular function between three different treatment 
modalities in CoA patients.
This PhD thesis dissertation compared the three treatments with well-established indices 
of vascular health. It was found that there was no difference between the three treatment 
groups in the most robust indices vascular function including the prevalence of systemic 
HTN, global aortic stiffness, endothelial function, and LV mass. However, we did find that the 
BD group showed a somewhat better vascular function phenotype with more physiologic 
nocturnal dipping in BP, a more distensible AAO and aortic arch, a lower peak SBP during 
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exercise, and lower blood levels of pro-inflammatory biomarkers. These results may be 
viewed as hypothesis generating basis for a randomized control trial, or a prospective, 
pre- and post-treatment vascular function assessment. The LOVE-COARCT database holds 
potential for several secondary analysis that may be performed in further studies. 
To conclude, the LOVE-COARCT results suggest that the treatment modality may impact on 
(at least some indices) of vascular function and some merit to our initial hypothesis, that the 
introduction of a non-distensible stent or surgical scar may have more deleterious effects 
on late vascular function than simple BD. A lot needs to be clarified, including if the hard 
vascular outcomes, which were unchanged in our young sample will be affected in the long-
term and what is the compromise in the conduit and cushioning aortic function in CoA. 
Further studies are required to confirm these results and to confirm that LOVE-COARCT may 
contribute to refining the CoA treatment paradigm by adding to the goals of therapy the 
preservation of vascular function when two or more treatment techniques are applicable.
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Aortic arch geometry after aortic coarctation repair: Systematic
magnetic resonance study in a consecutive series of patients
Geometria do arco aórtico em coartac¸ões da aorta corrigidas: estudo
sistemático por ressonância magnética numa série consecutiva de doentes
José Diogo Ferreira Martinsb,∗, Boban Thomasa, Nuno Jalles Tavaresa, Fatima F. Pintob
a Servic¸o de Cardiologia Pediátrica, Hospital de Santa Marta, Lisboa, Portugal
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Systemic hypertension at rest or during exercise persists in a
significant number of patients after early repair of coarcta-
tion of the aorta (CoA). Recoarctation explains only a small
percentage of these cases, and recent studies have sug-
gested intrinsic anomalies in aortic arch geometry (‘‘gothic
arch’’) as a possible cause, irrespective of whether the
repair was surgical or percutaneous.1,2
We retrospectively assessed all magnetic resonance
imaging (MRI) studies in a consecutive series of patients fol-
lowed in our institution, analyzing the prevalence of the
various types of aortic arch geometry: gothic, romanesque
and crenel. All the studies were performed using a Signa
1.5T (GE Medical Systems, Milwaukee, WI, USA). Anatomi-
cal types were classified by two physicians experienced in
MRI (>1500 exams between them), based on images acquired
using black blood, cine or angiographic techniques.
The type of aortic arch could be classified in 59 of the
77 consecutive patients with corrected CoA. Those with
recoarctation or other significant aortic arch abnormalities,
such as arch hypoplasia in the context of hypoplastic left
 Please cite this article as: Martins, JD. Geometria do arco aór-
tico em coarctac¸ões da aorta corrigidas: estudo sistemático por
ressonância magnética numa série consecutiva de doentes. Rev Port
Cardiol. 2012. doi:10.1016/j.repce.2012.03.006
∗ Corresponding author.
E-mail address: jdferreiramartins@gmail.com
(J.D. Ferreira Martins).
heart syndrome, were excluded. The results showed the fol-
lowing distribution of types: romanesque (n = 22; Figure 1),
gothic (n = 20; Figure 2) and crenel (n = 17; Figure 3), which is
similar to the distribution described for international series
reported in the literature.
Figure 1 Romanesque arch geometry.
2174-2049/$ – see front matter © 2011 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L. All rights reserved.
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Figure 2 Gothic arch geometry.
Figure 3 Crenel geometry.
A significant proportion of our series of patients with cor-
rected CoA had aortic arch geometry that predisposes to
hypertension at rest or during exercise. Besides screening for
anatomical and physiological signs of recoarctation, mag-
netic resonance study after aortic coarctation repair should
also assess aortic arch geometry, since this has a significant
impact on the management and prognosis of these patients.
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INTRODUCTION
Current treatment techniques are equally effective at 
eliminating the stenosis in CoA patients.[1] However, a 
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ABSTRACT
Background : Coarctation of the aorta (CoA) can be treated using surgery, balloon angioplasty, or 
stent implantation. Although short‑term results are excellent with all three treatment 
modalities, long‑term cardiovascular (CV) morbidity and mortality remain high, likely 
due to persistently abnormal vascular function. The effects of treatment modality on 
long‑term vascular function remain uncharacterized. The goal of this study is to assess 
vascular function in this patient population for comparison among the treatment 
modalities.
Methods : We will prospectively assess vascular Afunction in large and small arteries fusing 
multiple noninvasive modalities and compare the results among the three groups of CoA 
patients previously treated using surgery, balloon angioplasty, or stent implantation 
after frequency matching for confounding variables. A comprehensive vascular function 
assessment protocol has been created to be used in 7 centers. Our primary outcome is 
arterial stiffness measured by arterial tonometry. Inclusion and exclusion criteria have 
been carefully established after consideration of several potential confounders. Sample 
size has been calculated for the primary outcome variable.
Conclusion : Treatment modalities for CoA may have distinct impact on large and small arterial 
vascular function. The results of this study will help identify the treatment modality 
that is associated with the most optimal level of vascular function, which, in the long 
term, may reduce CV risk.
Keywords : Arterial stiffness, cardiac magnetic resonance imaging, coarctation of the aorta, 
long‑term outcomes, pulse wave velocity, vascular function
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good anatomical result does not preclude late systemic 
hypertension in office visits (12%–65%),[1‑6] at peak 
exercise (10%–47%),[3‑5,7,8] or during ambulatory blood 
pressure (BP) monitoring (30%–59%).[7‑10] Furthermore, 
treated patients have reduced life expectancy [Figure 1],[2] 
mostly due to cardiovascular (CV) complications[2,11‑14] 
and stroke.[15]
Successfully treated CoA patients have stiffer large 
arteries[16‑21] and compromised vascular reactivity in 
small arteries,[8,10,22‑26] their arterial pressure waveform 
is altered,[9,10,23,27,28] have imbalances in vascular 
function biomarkers,[24,25,27,2925,27,29,30] and increased left 
ventricular (LV) mass.[8,9,19‑21,26,31,32] Vascular dysfunction is 
associated with older age at treatment,[2,19,22,29,31,33] but early 
treatment does not guarantee normal vascular function.[16,22]
Different treatment modalities may have varying effects 
on the stiffness of the repaired arterial segment:[34] Surgical 
repair results in a focal scar in the anastomosis; stenting 
creates a short, rigid segment; and balloon dilation (BD) 
produces a controlled tear of the intima and part of the 
media. Although it is possible that these differences 
translate into differences in vascular dysfunction, this 
has not been systematically compared. The largest, albeit 
observational and nonrandomized, comparison between 
the three modalities showed a lower BP in patients 
treated with BD versus those treated with stenting or 
surgery.[1] A small retrospective study showed less frequent 
exercise‑induced hypertension in BD patients compared 
with other treatment types.[33] Conclusions drawn from 
these prior studies are hampered by methodological 
limitations and limited focus. In the general population, 
arterial stiffness is associated with major CV events.[35] 
Thus, choosing the CoA treatment option that optimizes 
vascular function is crucial for long‑term outcomes in CoA.
Aim and hypothesis
The Long‑term Outcomes and Vascular Evaluation after 
Successful Coarctation of the Aorta Treatment study 
aims to determine whether surgery, BD, and stenting 
are associated with differences in arterial stiffness in 
optimally treated patients. Our hypothesis is that patients 
who underwent successful BD will have better vascular 
function than patients who underwent successful surgical 
repair or stenting since this modality may least likely 
damage the biomechanical properties of the aortic wall.
METHODS
Study overview
This study is a cross‑sectional prospective observational 
study of patients with CoA previously treated using one 
of three treatment modalities. Patients will be recruited 
at seven large pediatric cardiac centers from Europe and 
the United States of America [Appendix 1]. The study 
procedures will occur in a 1‑ or 2‑day visit [Figure 2].
Recruitment
Selection criteria are depicted in Table 1. The study 
protocol was approved by Institutional Review Boards. 
Recruitment occurred between June 2013 and December 
2017. The study data are collected and managed 
using REDCap software, hosted at Children’s Hospital 
Boston.[36]
Study procedures
A list with the main clinical and study tests variables are 
depicted in Tables 2 and 3. The comprehensive list of 
study variables is in Appendix 7
Arterial stiffness
CoA treatments alter the biomechanics of the isthmus and 
may increase arterial stiffness. The velocity of the pulse 
wave velocity (PWV) travel in the arterial tree increases 
with arterial stiffness. Carotid–femoral PWV (cfPWV) is 
extensively validated in large studies a marker of aortic 
stiffness, and an independent predictor of CV events.
[37] We will measure cfPWV with applanation tonometry, 
using either the NIHem (CV Engineering, Inc., Norwood, 
MA USA) or the SphygmoCor (AtCor Medical, West Ryde, 
NSW, Australia) devices.[37] This technique assumes a 
homogenous stiffness across the aorta and may potentially 
not accurately estimate the true carotid‑to‑femoral 
artery length. Cardiovascular magnetic resonance (CMR) 
measurements of PWV, on the other way, enables the 
detection of more subtle changes in segmental aortic 
PWV, above versus below the CoA site, and uses real aortic 
travel paths.[38] We will also use CMR to measure aortic 
area change during the cardiac cycle, paired with BP 
measurements, to quantify local arterial strain, compliance, 
distensibility, and the β‑stiffness index [Appendix 2a and b].
Endothelial function
In CoA, the loss of central aortic pulsatility, which 
buffers systole, generates chronic shear stress 
Figure 1: Survival after treatment of coarctation of the aorta. 
Survival curves of 819 surgical patients for over 60 years (reprinted 
with permission from Elsevier, license number 4131890880395)
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downstream in smaller arteries, creating endothelial 
dysfunction, which is associated with CV events.[39] We 
will measure endothelial function with the reactive 
hyperemia index using endothelial pulse amplitude 
tonometry (endo‑PAT), a novel noninvasive and 
reproducible technique that measures changes in 
pulsatile arterial volume with a fingertip probe.[40] 
Analysis of the pulse waveform allows for automated 
calculation of endothelial function in one arm, while the 
contralateral serves as control, making this is a patient 
standardized method [Appendix 3].
Pulse waveform analysis
In CoA, the stiff aorta and repaired isthmus may be 
important reflecting sites that impact the pulse waveform. 
Its analysis is an important clinical tool for monitoring 
of vascular function and predicting CV events.[37] We will 
measure three variables that express pulse waveform: 
central aortic pressure (CAP), pulse pressure (PP), and 
augmentation index (AIx; ratio of the amplitude of the 
reflected wave in the ascending aorta and the PP).[37] 
CAP, PP, and AIx can be measured noninvasively using 
applanation tonometry (and Endo‑PAT for AIx), calibrated 
by the peripheral diastolic and mean arterial pressure.[37] 
There is a lack of consensus regarding the optimal method 
to estimate the CAP with tonometry. The NIHem system 
assumes that carotid artery pulse waveform accurately 
Figure  2:  Long‑term Outcomes  and Vascular  Evaluation  after  Successful Coarctation  of  the Aorta  Treatment  study workflow. 
ABPM: Ambulatory blood pressure monitoring, AIx: Augmentation index, BP: Blood pressure, CMR: Cardiac magnetic resonance 
imaging, PWA: Pulse wave analysis, PWV: Pulse wave velocity, RHI: Reactive hyperemia index
Table 1: Inclusion and exclusion criteria
Criteria Definitions and comments
Inclusion criteria
Coarctation of the aorta
Current age 8‑35 years Lower age to allow facilitate the completion of the study tests and higher age to avoid overlap 
with aging‑related vascular dysfunction) years 58
Treatment for CoA after 1994 Date after which all three modalities were in clinical use.
Exclusion criteria
Residual CoA Systolic upper‑to‑lower extremity BP gradient >20 mmHg.* Residual gradient is a confounder 
since it impacts vascular function. 8
Atypical CoA Mid‑thoracic or abdominal coarctation.
Severe transverse aortic arch hypoplasia Transverse arch diameter z‑score at initial echocardiogram <‑4†
Treatment of CoA at age <1y A more severe disease subset, essentially amenable to surgery
Clinically significant associated cardiac 
defects that may affect independently 
vascular function
Mitral stenosis (echocardiographic mean inflow Doppler gradient >6 mmHg) aortic stenosis 
(echocardiographic mean Doppler gradient >20 mmHg); ventricular septal defect (>3 mm in 
diameter); atrial septal defect (required surgical or percutaneous closure other than a patent 
foramen ovale); other cardiac lesions that required medical, surgical or interventional treatment
Use of two treatment modalities for CoA This does not include balloon dilation and subsequent stent placement at the same 
catheterization procedure
History of known vasculopathy with 
vascular dysfunction
Examples: Kawasaki disease, Takayasu’s arteritis, Raynaud’s disease
Genetic syndromes with diffuse 
arteriopathy
Examples: Williams syndrome, juvenile rheumatoid arthritis
Known traditional cardiovascular risk 
factors
Severe obesity (body mass index >95% for age and sex in children and >40 Kg/m2 for adults); 
diabetes (fasting plasma glucose ≥126 mg/dl or random (non‑fasting) glucose ≥200 mg/dl); 
hyperlipidemia (triglycerides≥250 mg/dl; fasting LDL ≥190 mg/dl; HDL ≤30 mg/dl, currently 
taking statins or first degree relatives with familial hypercholesterolemia); smoking
Legend: y=years; BP=blood pressure; CoA=coarctation of the aorta; LDL=low‑density lipoprotein cholesterol; HDL=high‑density lipoprotein cholesterol; 
*using highest lower extremity systolic blood pressure; †using previously published normative values[57]
Table 2: List of main clinical variables
Variables Comments or definitions
Medical history
Minimum transverse arch diameter 
Z‑score on initial echo
Using published normative 
values*
Isthmus z score on initial echo Using published normative 
values*
Initial Doppler coarctation gradient mmHg
Bicuspid/Bicommisural Aortic Valve? Yes/No
Initial arm‑leg systolic BP gradient mmHg
Visit BP
Residual systolic BP gradient Supine and automated mmHg
Right arm BP Seated and manual mmHg
Legend: BP=blood pressure; *using previously published normative 
values[57]
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reflects the central aortic waveform and the pulsed wave 
analysis is automatically calculated from the carotid 
waveform. The SphygmoCor device uses a generalized 
transform function to generate a central aortic PP curve 
from the radial or carotid pressure tracings, which has 
not been validated in children. Considering our largely 
pediatric group and need to maintain consistency 
between data acquired on each device, we use the 
nonprocessed, signal‑averaged SphygmoCor carotid 
tracing as the central aortic tracing which will be then 
digitized to calculate the CAP, following previously 
published approach [Appendixes 2a and 3].[41]
Blood pressure phenotype
BP phenotype is abnormal despite successful treatment 
of CoA. Office hypertension is a known risk factor for CV 
disease and the BP response during the ET is predictive 
of future development of resting hypertension in the 
general population.[42] Ambulatory blood pressure 
monitoring (ABPM) is superior to the office measurement 
in its ability to distinguish patients at the highest risk 
for target‑organ damage.[43] We will assess BP phenotype 
with the manual auscultation technique to measure the 
right arm office BP; supine four extremity oscillometric BP 
measurement to assess for residual coarctation; ABPM to 
measure the circadian BP profile; and ET to assess the BP 
response to exercise and exercise‑induced arm to leg BP 
gradient. Based on the office BP and ABPM results, we will 
classify our patients according to Table 4 [Appendix 4].
Biomarkers
We will measure asymmetric dimetilarginine (ADMA; 
NO’s inhibitor),[44] and nitrite and nitrate (NOx, 
stable by‑product of NO), biomarkers of endothelial 
function. Arterial stiffness is associated with increased 
systemic inflammation markers, which we will quantify 
with high‑sensitivity C‑reactive protein (hs‑CRP) 
and local inflammatory cytokines of vascular wall 
function vascular adhesion molecule 1 (VCAM‑1) and 
interleukin‑1 beta (IL‑1β).[25,45] We will finally assess 
the molecular mechanisms of aortic wall response to 
vascular dysfunction, with matrix metalloproteases 
(MMP‑2 and MMP‑9),[46] and transforming growth factor 
beta‑1 (TGF‑β1, a smooth cell growth‑modulating factor 
involved in the arterial wall response to hypertension).[30] 
NOx will be determined by chemiluminescence (Sievers 
NOAnalyzer 280i) and all remaining measurements will 
be performed with enzyme‑linked immunosorbent assay 
kits: ADMA (Sunred Biological Technology, Shanghai, 
China); hs‑CRP (BoosterBio, Pleasanton, USA); VCAM‑1; 
IL‑1β; matrix metalloproteases (MMP)‑9; MMP‑2; and 
TGFβ‑1 (RayBiotech, Inc. Norcross, USA) [Appendix 5].
Left ventricular mass
The altered BP phenotype that persists after CoA 
treatment represents an increase in afterload that leads 
to LV hypertrophy, strongly related to high BP and 
carrying a grave prognosis for cardiac events.[47] We will 
quantify LV mass by CMR, a well‑established method for 
its calculation [Appendix 2b].
Cardiovascular health assessment
Patients with CoA experience increased CV disease 
compared to the general population. Literature in 
the general population has demonstrated that risk of 
cardiometabolic disease and accelerated atherosclerosis is 
mitigated by ideal CV health (ICVH),[48] defined as having 
optimal levels of health factors (BP, total cholesterol, and 
plasma glucose) and behaviors (smoking, body mass 
index, physical activity, and diet). We will implement a 
questionnaire to assess family history of CV disease and 
ICVH according to the guidelines of the American Heart 
Association [Appendix 6].[48]
Table 3. List of main study test variables
Variables Comments or 
definitions
Applanation tonometry
Central systolic blood pressure mmHg
Central pulse pressure mmHg
Carotid‑femoral PWV meters/second
Augmentation index at HR75 %
CMR
Left ventricular mass indexed to BSA g/m2
Ascending Ao ‑ Descending Ao 
PWV (Ascending Ao to proximal, mid 
and distal descending Ao)
Meters/second
Type of arch Romanesque; 
Gothic; Crenel
Aortic strain
(Ascending, Proximal, Mid and Distal Ao)
Aortic Distensibility
(Ascending, Proximal, Mid and Distal Ao)
 mmHg‑1
Endo‑PAT
Reactive hyperemia index (RHI)
Augmentation index at 75 bpm %
ABPM
24 h Average systolic and diastolic BP mmHg
24 h systolic and diastolic load %
Exercise test
Pre‑Exercise SBP gradient mmHg
Peak exercise BP mmHg
Biomarkers
NOx ug/ml
ADMA ng/L
High Sensitivity CRP mg/L
VCAM‑1 ng/ml
IL‑1β pg/ml
TFG‑β
MMP‑2/Gelatinase A ng/ml
MMP‑9/Gelatinase B ng/ml
Legend: ADMA=Asymmetric Dimetilarginine; Ao=Aorta; BP=blood 
pressure; BP=Blood Pressure; BSA=Body Surface Area; CMR=Cardiac 
magnetic resonance; DBP=Diastolic Blood Pressure; HDL=High‑density 
lipoprotein cholesterol; Hs‑CRP=High sensitivity C‑Reactive Protein; 
IL‑1β = Interleukin 1 beta; LDL=Low‑density lipoprotein cholesterol; 
MMP‑2=Matrix Metalloproteinase‑2; MMP‑9=Matrix Metalloproteinase‑9; 
NOx=Nitric Oxide; PWV=Pulse Wave Velocity; LV=Left Ventricle; 
SBP=Systolic Blood Pressure; TFG‑β = Transforming Growth Factor 
beta; VCAM‑1=Vascular Cell Adhesion Molecule 1; * using previously 
published normative values[57]
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Statistical considerations
Adjustment for confounders
We will adjust our treatment groups for three main 
documented confounders: (a) age at treatment; 
(b) current age; and (c) bicuspid aortic valve 
(associated with impaired aortic elasticity).[49] During 
recruitment, we will attempt to frequency match the three 
treatment groups. During analysis, the treatment groups 
will be compared for each of these three confounding 
variables and adjustments will be made using multivariable 
modeling with linear and logistic regression models.
Analytic plan
Our primary outcome variable will be cfPWV assessed by 
tonometry. Differences across groups will be explored 
using one‑way analysis of variance. If differences in 
matching variables are detected among the groups, 
adjustment will be made using analysis of covariance. 
Post hoc analyses will be performed as necessary. Sample 
size estimates were obtained based on prior data that 
show that arch PWV measured by CMR is 3.3 ± 0.6 m/s 
in normal patients and 4.7 ± 1.1 m/sec after CoA 
surgery.[20,50] Sample size estimates for comparison of PVW 
between three equal‑sized treatment groups (assuming 
overall significance level = 0.05 and power = 0.8) are 
shown in Table 5. We plan on recruiting 24–30 patients 
in each group for a total sample size of 72–90.
DISCUSSION
Methodological considerations
We chose a multicenter design to overcome recruitment 
challenges secondary to restrictive enrollment 
criteria (particularly the lower treatment age limit of 
1 year, which excludes a majority of CoA patients that 
present in infancy, mostly managed by surgery) and 
need for matching treatment groups for confounders.
cfPWV is our primary outcome variable because it is 
validated as an accurate and reproducible measure of 
arterial stiffness with proven association to hard CV 
outcomes that can be reliably measured by applanation 
tonometry and CMR. We chose other parameters 
to complete a complementary and comprehensive 
assessment of vascular function in small and large 
arteries.
Importance of knowledge to be gained
This work will be the first systematic and comprehensive 
comparison of vascular function between three different 
treatment modalities in CoA patients. We postulate that 
the integrity of the arterial wall is best preserved with 
balloon dilatation, compared to stenting or surgery. We 
are aware that our population is highly selected, but 
believe that this is the only way to compare the three 
treatment types. The results of our selected population 
may be relevant when several modalities are applicable 
to one patient. Currently, the preservation of vascular 
function is not considered when choosing between 
treatment modalities. Ultimately, the results of our study 
may help clinicians choose treatment modalities based 
not only on relief of anatomic stenosis but also on their 
ability to preserve long‑term vascular health.
Study limitations
Our results will reflect vascular function in a selected 
group of optimally treated CoA patients and may not 
be generalizable to all CoA patients. We will compare 
vascular function after treatment but not before the 
treatment. Variation in antihypertensive medication 
protocols between different institutions may affect 
vascular parameters.
CONCLUSION
There is ample evidence to suggest that CoA is a systemic 
arterial disease and not merely a focal stenosis of the 
aortic isthmus. However, the current management 
paradigm continues to focus on alleviating the anatomic 
stenosis. Our study aims to refine this treatment paradigm 
by adding the preservation of vascular function to the 
goals of successful treatment. The strengths of this study 
include its multicenter design and the use of multiple 
noninvasive modalities to perform a comprehensive 
and prospective assessment of vascular function and 
CV health.
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Table 4: Classification of BP Phenotype by ABPM
Classification Office BP SBP or 
DBP*
24h Mean ABPM 
SBP or DBP†
Non‑hypertensive Pediatric: <95th %tile
Adults: <140/90 mmHg
Pediatric: <95th %tile
Adults: <135/85 mmHg
White Coat 
Hypertension
Pediatric: ≥95th %tile
Adults: >140/90 mmHg
Pediatric: <95th %tile
Adults: <135/85 mmHg
Masked 
Hypertension
Pediatric: <95th %tile
Adults: <140/90 mmHg
Pediatric: >95th %tile
Adults: >135/85 mmHg
Ambulatory 
Hypertension
Pediatric: >95th %tile
Adults: >140/90 mmHg
Pediatric: >95th %tile
Adults: >135/85 mmHg
Legend: AMBP=Ambulatory blood pressure monitoring; BP=Blood Pressure; 
ABPM=Ambulatory Blood Pressure Monitoring; Pediatric patients have age 
<18yo and adult patients age ≥18yo; %tile=percentile; BP=blood pressure; 
DBP=diastolic blood pressure; and SBP=systolic blood pressure. *For 
pediatric patients, based on the National High Blood Pressure Education 
Program Task Force normative data[54]; for adult patients, based on the 
Joint National Committee on the Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure report.[55] †For pediatric patients, based 
on normative pediatric ABPM values from the American Heart Association 
Atherosclerosis, Hypertension and Obesity in Youth Committee of the 
Council on Cardiovascular Disease in the Young;[43] for adult patients, based 
on the Subcommittee of Professional and Public Education of the American 
Heart Association Council on High Blood Pressure Research report[59]
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Appendix 2a: Applanation tonometry manual of operations
For applanation tonometry, some centers will use the NIHem system (Cardiovascular Engineering, Inc., 
Norwood, MA USA) and others the SphygmoCor device (AtCor Medical, West Ryde, NSW, Australia). The technology 
is similar and the results comparable.
The patient demographics and brachial blood pressure (BP) are entered into the system. First, the tonometer is 
placed over the right carotid artery, just lateral to the thyroid cartilage. The location is adjusted and pressure applied 
as needed to optimize waveform. After ensuring that the tracings are optimal, the tracing is recorded. The carotid 
site is marked. Then, the tonometer is placed over the right femoral artery and the same process for obtaining an 
optimal curve recording is followed. The femoral site is marked. Finally, in the centers that use the SphygmoCor 
device, a third recording of the radial artery is performed, in the same fashion. A caliper is used to measure the 
distance from the suprasternal notch to the carotid site and from the suprasternal notch to the femoral site. Both 
distances are entered in the system.
For pulse wave velocity and augmentation index calculation, both systems analyze the curves and supply the data 
with the proprietary software package, without any input from the examiner.
For pulse wave analysis (central aortic pressure and pulse pressure), the analysis procedure differed slightly between 
systems. The analysis from the NIHem system is done by the system’s software. In the centers that used SphygmoCor, 
the signal averaged carotid pulse wave is digitalized and calibrated according to a published approach:[41,51] The 
brachial diastolic and mean pressures are used and the same diastolic and mean pressures are assigned to the 
averaged carotid pulse. Moreover, the radial pressure waveform is used to retrieve the correspondent time instants 
of diastolic and mean pressures. Given the two pressure values and the correspondent time instants, it is possible to 
calibrate each averaged carotid pressure waveform. This process allows a quantitative analysis of the pulse waveform.
Appendix 2b: Cardiac magnetic resonance imaging manual of operations
Cardiac magnetic resonance (CMR) will be performed using commercially available whole‑body 1.5 T 
scanners (Achieva; Philips Healthcare, Best, the Netherlands; Signa 1.5T or GE Medical Systems, Milwaukee, WI, USA). 
Electrocardiography (ECG)‑gated steady‑state free precision (SSFP) localizers will be used in sagittal, coronal, and 
axial planes during free breathing. Ventricular function will be assessed from short‑axis stack to cover ventricles 
from base to apex, acquired using the following imaging parameters: slice thickness 5–8 mm, slice gap 0–1 mm, slice 
number 12–14, cardiac phases 30, retrospective gating with breath‑holding. In patients unable to breath‑hold 3 signal 
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averages during free‑breathing will be used. SSFP cine imaging will also be performed in two orthogonal long‑axis 
planes of the left ventricular outflow tract (during breath‑hold), short axis of the ascending aorta (AAO), and in 
the long axis of the aortic arch (free‑breathing, used as reference for pulse wave velocity measurements), proximal 
descending aorta (DAO, 2–3 cm distal to the isthmus, sufficiently distal to dephasing jets), mid‑DAO (diaphragmatic 
level), and distal DAO (just above iliac bifurcation). ECG‑gated through‑plane phase‑contrast flow measurements 
will be performed at the AAO (5 mm distal to the sinotubular junction) and in proximal‑, mid‑, and distal‑DAO 
segments (matched to location of the cine SSFP acquisitions) using the following imaging parameters: signal 
averages = 2, cardiac phases 100 (TFE factor/views per segment/ = 1 [to maximize temporal resolution]), and velocity 
encoding 200–250 cm/s (higher if needed to avoid aliasing). ECG and respiratory navigator‑gated three‑dimensional 
SSFP MRA of the aortic arch will be performed in the sagittal plane.
The patient’s right arm BP while on scanner table and length of time since last meal and content of last meal will 
be recorded. Images will be analyzed by a single observer (A.P.) in the CMR core lab using a commercial computer 
workstation (Extended Workstation; Philips Healthcare) and using commercially available analysis software 
(QMass and QFlow, Medis, The Netherlands). Ventricular function and mass will be calculated using standard techniques. 
Cross‑sectional areas of the AAO and proximal, mid, and distal DAO will be directly planimetered at peak systole and 
mid‑diastolic frames to calculate parameters of segmental aortic stiffness as previously described.[52] Pulse wave velocity 
will be measured using the transit‑time method.[20] Pulse wave velocity will be calculated for the entire aorta (AAO 
to distal DAO), as well as in the following segments: AAO to proximal DAO, proximal DAO to mid‑DAO, and mid‑DAO 
to distal DAO. Aortic arch shape will be classified and the aortic arch index calculated as previously described.[53]
Appendix 3: Endothelial pulse amplitude testing manual of operations
The testing room will be arranged to provide a quiet, restful environment with a comfortable temperature of 
22°C to 23°C. Before testing, patients will be asked to fast overnight for 12 h, except for the consumption of 
water. Unless the patients are taking a daily vitamin, they will be asked to refrain from taking vitamin pills and 
over‑the‑counter medications; in the case that an over‑the‑counter medication is used, it will be documented.
The Endo‑PAT (Itamar Medical Ltd, Caesarea, Israel) testing protocol[40] will be performed in the morning 
(starting time between 8 and 11 am) and fasting. Any restrictive clothing that could interfere with blood flow to 
the arms or fingers will be removed, including heavy coats or clothes with thick sleeves, watches or rings or other 
jewelry on the hands and fingers, and long fingernails shortened with a fingernail clipper.
Noninvasive pneumatic probes will be placed on the index fingers of both hands. The pulse wave amplitude will be 
recorded continuously from both index fingers. Reactive hyperemia will be performed by achieved by occlusion of 
the brachial artery of one arm with a BP cuff for 5 min (to 200–220 mmHg). The tracing in the nonoccluded arm will 
serve as a control for changes in overall physiologic state. The Endo‑PAT data will be analyzed with the proprietary 
software package, without any input from the examiner. The Endo‑PAT index is defined as the ratio of the average 
pulse amplitude during the 1 minute period beginning after exactly 90 s of reactive hyperemia compared with the 
average pulse amplitude during the 210‑s preocclusion baseline period.
Appendix 4a: Right arm, auscultatory blood pressures measurement manual of operations
The patient will be seated with the feet flat on the floor, with the knees at 90° and the back supported. After 5 min of 
resting quietly, with no conversation or television, the auscultatory BP will be obtained in the right arm. For cuff choice, 
the length of the bladder encircled no <80% and no more than 100%, of the bicep and the width of bladder encircled 
no <40% and no more than 50%, of the circumference of patient’s arm circumference, measured at the widest area of 
bicep, midway between the tip of the patient’s shoulder and the tip of the patient’s elbow. The patient’s right arm will be 
at placed at heart level, supported at the level of the nipple by resting arm on a table or chair arm or propped on a pillow.
The stethoscope’s bell will be placed over patient’s brachial pulse. The cuff will be inflated up to 140 mmHg and 
deflated slowly while listening for the Korotkoff sounds, systole being number when the sound is first heard 
consistently and diastole when the last pulsation is heard or when it muffles. If pulsations are immediately audible, 
the cuff will be deflated entirely and the patient allowed to sit quietly for 1 minute. Then, the cuff will be again 
inflated to 160 mmHg (or higher) and the steps above will be followed. This procedure will be repeated until the 
blood pressure (BP) is not immediately audible.
Three BPs will be obtained, allowing 1 min between deflation and reinflation of cuff for each measurement. The 
average of the 2nd and 3rd measurements will be considered the final right arm BP and interpreted according to the 
published guidelines for children [54] and adults.[55]
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Appendix 4b: Four extremity, automated blood pressures (Dinamap) measurement manual of operations
While the patient is supine, two sets of four extremity blood pressure (BP) will be measured, with the automated 
BP monitor (Dinamap).
The BP pressure gradient will be registered, between the second systolic right arm measurement and the highest of 
the two legs systolic second measurements. In the presence of an aberrant right subclavian artery that originates 
distal to the Coarctation of the aorta site, seen by cardiovascular magnetic resonance, we will use the second left 
systolic arm measurement for the residual gradient.
Appendix 4c: Ambulatory blood pressure (BP) monitor methods of operations
The patient data will be recorded. The choice of the cuff will follow the same guidelines described for manual 
auscultation of right arm BP. Cuff inflation will be programmed for 15–20‑min intervals. During nighttime, intervals 
are wider, but not fewer than one per hour and preferably more. The patient will record the sleep time, wake time, 
and any periods of vigorous exercise. The patient will be instructed to avoid direct contact of the monitor with 
water and participation in activities that could damage it.
The study will be considered adequate if there is a record of at least 1 reading per hour, i.e., no more than 1 h between 
consecutive readings for a full 24‑h study. If less than 12 h are recorded, the ambulatory blood pressure monitoring data will 
be considered inadequate. Diurnal pattern will be determined by the patient diary. Vigorous exercise periods will be excluded.
The data on 24‑h systolic BP load, 24‑h diastolic BP load, diurnal systolic dipping, diastolic dipping and 24 h, daytime 
and nighttime mean systolic BP, and mean diastolic BP will be recorded. Patients will be staged as having ambulatory 
hypertension, masked hypertension, white coat hypertension or normotensive, according to the age‑based normative 
tables based on statements for children and adolescents [43] and adults.[56] Patients currently on antihypertensive 
medication are also classified into the hypertensive group [Table 4].
Appendix 4d: Exercise test: Manual of operations
The patient information will be entered per equipment specification and the study identifier on the datasheet and the 
date of the test. For patient safety issues, medical history, medications, activity level, and symptoms will be reviewed 
and the exercise stress test protocol wil be explained. Antihypertensive medications will be continued the day of testing.
The patient will be asked to lay supine, and a right arm and right or left leg blood pressure measured using a commercial 
oscillometric and appropriate sized cuff bladders and recorded as preexercise blood pressure (BP) values and gradient. 
The patient then will step onto the treadmill and instructed to hold the handlebar throughout the test. We will use 
the standard Bruce treadmill protocol and, when available, a Met Cart. As the patient exercises, their symptoms and 
electrocardiography (ECG) will be continuously monitored. At 2‑min of each stage, a BP will be taken in the right 
arm by having the patient take their hand off the treadmill and hold onto the arm of the person performing the test. 
The test will be terminated when the patient can no longer continue the exercise, reaches a systolic BP higher than 
240 mmHg, has clinically relevant symptoms or ECG changes. Immediately after the exercise ended, BP in the right 
arm and the left leg will be recorded in a supine position. For the recovery period, the patient will sit upright in a 
chair, and right arm BP will be recorded at 1, 3, 5, and 7 min of recovery, at which time the test is ended.
The data on exercise duration, baseline and exercise right arm BP, pre‑ and post‑exercise systolic BP gradient, 
patient symptoms, ECG changes and, when available, cardiorespiratory physiological data will be documented. We 
will label exercise‑induced hypertension when the systolic BP is ≥220 mmHg.
Appendix 5: Biomarkers manual of operations
The patients will follow a low‑nitrate diet for 3 days before the blood sample collection, which avoids of a list of foods 
with a high content in nitrites that influence nitric oxide determination, including bacon, beets, broccoli, canned 
food, cauliflower, celery, Chinese cabbage, corned beef, ham, hot dogs, lettuce, old cheese, radish, salami, sausages, 
smoked fish, spinach, and turnip. After an overnight fast (for 12 h), samples will be collected by venipuncture from 
catheters maintained with saline only, since heparin interferes with accuracy of the biomarkers assessed. The first 
5–10 mL of blood will be discarded and 2.7 ml of venous blood will be collected into 3.2% sodium citrate (light‑blue) 
tubes (BD Vacutainer®), and into plastic microtubes (Safe‑Lock Eppendorf). Within 3 h of collection, samples will be 
centrifuged for 20 minutes at 3000g (4ºC). Aliquots of 250 µl of the supernatant will be collected into 14 labeled 
microtubes of 1.5 ml and immediately stored at − 80ºC until shipping to the Biomarkers Core Laboratory.
Aliquots for NOx analysis will be deproteinized using cold ethanol precipitation methodology. Ethanol will be refrigerated 
to 0ºC and added to the plasma sample in a 1:3 proportion. After letting it stand at 0ºC for 30 min, the sample will 
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be centrifuged at 14,000 rpm for 10 min. The supernatant will be then removed for analysis. The quantification of 
plasma NO levels will be carried out using a nitric oxide analyzer, the Sievers Instruments NOA 280iTM, a high sensitivity 
detector of that allows determination of NO based on a chemiluminescence reaction between NO and ozone.
Plasma asymmetric dimetilarginine (ADMA); vascular cell adhesion molecule 1 (VCAM‑1); high‑sensitivity C‑reactive 
protein (hs‑CRP) interleukin‑1‑beta (IL‑1β); MMP‑2 and MMP‑9 will be quantified using the following double‑antibody 
sandwich enzyme‑linked immunosorbent assay ELISA kits: Human asymmetrical dimethylarginine, ADMA (Sunred 
Biological Technology, Shangai, China); hs‑CRP (BoosterBio, Pleasanton, USA); VCAM‑1; IL‑1β; MMP‑9/Gelatinase A; 
MMP‑2/Gelatinase B; and transforming growth factor beta (RayBiotech, Inc. Norcross, USA).
Appendix 6: Cardiovascular health assessment manual of operations
The following questionnaires will be used.
Lifestyle questionnaire:
•	 On an average weekday, how many hours do you watch TV?
•	 On an average weekday, how many hours do you play video/computer games or use a computer for something 
that is not school/work related?
•	 In the past week, how many days were you/was your child physically active for a total of at least 30 min/day?
•	 In the past week, how many days did you/your child eat breakfast? In the past week, how many days did 
you/your child eat food from a fast food restaurant?
•	 In the past week, how many days did all or most of your family sit down and eat dinner at home?
•	 On an average weekday, how many hours of sleep do you get a night?
•	 Have you smoked one or more cigarettes in the past month? If yes, please quantify.
•	 Were you previously a smoker?
•	 Do you live in a household with a smoker?
Family history questionnaire:
For all the following questions, the possible answers will be “no,” “parents/siblings,” “grandparents/aunts/uncles,” 
and “both”
•	 Biological relatives of you/your child with overweight/obesity
•	 Biological relatives of you/your child with type 2 diabetes
•	 Biological relatives of you/your child with high blood pressure
•	 Biological relatives of you/your child with high cholesterol
•	 Biological relatives of you/your child with heart disease/stroke
•	 All answers had the following options: Parents/siblings/grandparents/aunts/uncles.
Contd...
Appendix 7. Comprehensive List of Study Variables
Variables Comments or Definitions
Medical History BSA at Initial Echocardiogram using Haycock’s Formula; m2
Minimum Transverse Arch Diameter Z‑score on Initial 
Echo
Calculated with Boston z‑scores
Isthmus z score on Initial Echo Calculated with Boston z‑scores
Initial Doppler coarctation gradient mmHg
Bicuspid/Bicommisural Aortic Valve? Yes/No
Initial arm‑leg systolic BP gradient mmHg
Type of Initial Treatment Balloon/Stent/Surgery
Currently daily medications? Yes/No. If yes, please specify. 
Local blood results Total Cholesterol mg/dL
LDL mg/dL
HDL mg/dL
Triglycerides mg/dL
Plasma Glucose mg/dL
Insulin uIU/mL
Hemoglobin A1C %
Applanation tonometry Central Systolic Blood Pressure mmHg
Central Pulse Pressure mmHg
Heart Rate bpm
Carotid Femoral PWV meters/second
Augmentation Index (%) %
Augmentation Index at HR75 %
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Variables Comments or Definitions
CMR LV End‑Diastolic Volume indexed to BSA ml/m2
LV End‑Systolic Volume indexed to BSA ml/m2
LV Ejection Fraction %
LV Mass indexed to BSA g/m2
Ascending Ao ‑ Descending Ao PWV (Ascending Ao to 
proximal, mid and distal descending Ao)
Distance (Asc Ao to Desc Ao)
Time Delay (Asc Ao to Desc Ao)
meters/second
Type of arch Romanesque; Gothic; Crenel
Aortic diameter
(Ascending, Proximal, Mid and Distal Ao)
mm/mm2
Aortic strain
(Ascending, Proximal, Mid and Distal Ao)
SistolicArea - DiastolicArea
DiastolicArea
Aortic compliance
(Ascending, Proximal, Mid and Distal Ao)
AoAreaSist - AoAreaDiast
SBP DBP−  cm2/mmHg
Aortic Distensibility
(Ascending, Proximal, Mid and Distal Ao) 
Aostrain
SBP DBP−  mmHg‑1
Aortic stiffness β index
(Ascending, Proximal, Mid and Distal Ao)
ln(SBP / DBP)
Strain
Loss of pulse amplitude
100×flow(AscAo DescAo)
flow(AscAo)
−
Aorta Young’s modulus
(Ascending, Proximal, Mid and Distal Ao) 
SBP - DBP Aodiameterdiastole
Aodiameter systole - diastole
( )
( )Aowallthickness
Arterial elastance (Ea) EndSystolicPressure
SrokeVolume  mmHg/ml
LV end‑systolic elastance (Ees) EndSystolicPressure
LVendSystolicVolume  mmHg/ml
Endo‑PAT Reactive Hyperemia Index (RHI)
Augmentation Index %
Augmentation Index at 75 bpm %
BP during the patient’s visit Residual SBP gradient (between right arm and highest of 
the legs)
Supine. Automated. Two sets of measurements; mmHg
Right arm BP Seated. Manual. Three sets of measurements; mmHg
ABPM 24 Average Systolic BP mmHg
24 Hour Average Diastolic BP mmHg
Daytime Average Systolic BP mmHg
Daytime Average Diastolic BP mmHg
Nighttime Average Systolic BP mmHg
Nighttime Average Diastolic BP mmHg
24h systolic load %
24h diastolic load %
Diurnal Systolic Variation %
Diurnal Diastolic Variation %
Exercise test Exercise Duration Minutes
Pre‑exercise right arm BP mmHg
Pre‑exercise leg BP mmHg
Pre‑Exercise SBP gradient mmHg
Post‑exercise right arm BP mmHg
Post‑exercise leg BP mmHg
Pre‑Exercise SBP gradient mmHg
Peak exercise BP mmHg
Biomarkers NOx ug/ml
ADMA ng/L
High Sensitivity CRP mg/L
VCAM‑1 ng/ml
IL‑1beta pg/ml
Contd...
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Variables Comments or Definitions
TFG‑Beta
 MMP‑2/Gelatinase A ng/ml
MMP‑9/Gelatinase B ng/ml
Legend: ADMA = Asymmetric Dimetilarginine; Ao = Aorta; BP = blood pressure; BP = Blood Pressure; BSA= Body Surface Area; CMR = Cardiac 
magnetic resonance; DBP = Diastolic Blood Pressure; HDL = High‑density lipoprotein cholesterol; Hs‑CRP = High sensitivity C‑Reactive Protein; IL‑1β 
= Interleukin 1 beta; LDL = Low‑density lipoprotein cholesterol; MMP‑2 = Matrix Metalloproteinase‑2; MMP‑9 = Matrix Metalloproteinase‑9; NOx = 
Nitric Oxide; PWV = Pulse Wave Velocity; LV = Left Ventricle; SBP = Systolic Blood Pressure; TFG‑β = Transforming Growth Factor beta; VCAM‑1 = 
Vascular Cell Adhesion Molecule 1; † using previously published normative data.[57]
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ABSTRACT
Background: Optimally treated patients with coarctation of the aorta (CoA) remain at risk for 
late vascular dysfunction. The effect of treatment modality on vascular function is unknown. 
We compared vascular function in patients with CoA treated with surgery, balloon dilation 
(BD) or stent implantation.
Methods: In successfully repaired CoA patients, we prospectively compared aortic stiffness 
by applanation tonometry and cardiac magnetic resonance (CMR); endothelial function by 
endothelial pulse amplitude testing; blood pressure (BP) phenotype by office BP, ambulatory 
BP monitoring, and BP response to exercise; left ventricular (LV) mass by CMR; and blood 
biomarkers of endothelial function, inflammation, vascular wall function, and extracellular 
matrix. 
Results: Participants included 75 patients treated with surgery (n=28), BD (n=23), or stent 
(n=24). Groups had similar age at enrollment, CoA severity, residual gradient, and metabolic 
profile but differed by age at treatment. Systemic hypertension, aortic stiffness, endothelial 
function, and LV mass were similar among groups. However, BD had more distensible ascen-
ding aortas, lower peak systolic BP during exercise, less impairment in diurnal BP variation, 
and lower inflammatory biomarkers. The results were unchanged after adjustment for po-
tential confounders, including age at treatment.
Conclusions: Treatment modality was not associated with systemic hypertension, global aor-
tic stiffness, and endothelial function. However, BD patients had a better vascular phenotype 
profile characterized by higher ascending aorta distensibility, lower night-time BP, lower peak 
exercise BP and lower levels of inflammatory markers. Further research on the association of 
our findings with long-term clinical outcomes may help improve treatment guidelines.
Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifiers: 
NCT03262753
KEYWORDS: Coarctation of the aorta (CoA), long-term outcomes, vascular function, arterial 
stiffness, pulse wave velocity, cardiac magnetic resonance imaging. 
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Current surgical and percutaneous techniques for treatment of coarctation of the aorta 
(CoA) are equally effective at eliminating the narrowing of the aortic isthmus (except in infan-
ts and young children, in whom surgery is preferred) 1. However, despite optimal anatomical 
results, late morbidity is significant with high rates of systemic hypertension.1 Secondary 
abnormalities including increased left ventricular (LV) mass,2-5 and impaired systolic3, 5 and 
diastolic function6 have also been reported. Furthermore, treated patients have reduced life 
expectancy, due to premature cardiovascular complications and stroke.7-9 Vascular dysfunc-
tion is common after CoA treatment and may contribute to these adverse outcomes.10, 11 
Patients with successfully treated CoA have been reported to have stiffer large arteries,3-5, 
11 impaired endothelial function,2, 10, 12, 13 and imbalances in biochemical and molecular pa-
thways associated with vascular function.12-17 Although vascular dysfunction is driven by im-
portant pre-treatment factors including abnormalities in the renin-angiotensin system18 and 
baroreceptor function,19 several treatment-related factors have been associated with worse 
vascular dysfunction, such as older age at treatment,3, 10, 15 longer length of follow-up, and 
residual narrowing at the site of CoA repair.2 
 It is possible that treatment modality affects vascular function by different effects on 
the stiffness of the repaired arterial segment: surgical repair creates a focal scar at the site of 
the surgical anastomosis; stenting creates a rigid, noncompliant aortic segment; and balloon 
dilation (BD) produces a controlled tear of the aortic intima and part of the media without 
affecting the adventitia.20 However, the effect of treatment modality on vascular function has 
not been systematically compared, and management is often guided by physician or insti-
tutional preference with the primary goal of alleviating the anatomic narrowing. Our study 
aims to refine this treatment paradigm by adding to the goals of therapy the preservation of 
vascular function. We hypothesized that patients with CoA treated using balloon dilation will 
demonstrate the most optimal level of vascular function because this modality is least likely 
to impact the biomechanical properties of the aortic wall. Using a prospective observational 
study design, we compared patients treated with surgery, balloon dilation, or stent implan-
tation to examine whether treatment modality is associated with parameters of vascular 
function and LV remodeling after repair. 
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METHODS
STUDY DESIGN AND SUBJECTS
This was a multicenter cross-sectional prospective observational study. Patients were recrui-
ted at 7 large pediatric cardiac centers in Europe and North America between June 2013 
and April 2017. We included patients with (a) isthmic CoA; (b) age at recruitment 8-35 years, 
and (c) CoA treatment after 1994. We excluded patients with (a) residual CoA defined as a 
systolic upper-to-lower extremity systolic BP (SBP) gradient >20 mm Hg; (b) co-morbidities 
including complex congenital heart disease (such as tricuspid atresia), vasculopathy, or gene-
tic syndrome; (c) CoA treatment using > 1 modality; (d) severe hypoplasia of the transverse 
aortic arch (z-score < -4);  (e) other cardiac defects requiring intervention (such as ventricular 
or atrial septal defect, valvar mitral or aortic stenosis); and (f) treatment under 1 year of age 
(because these patients are treated almost exclusively with surgery). We attempted to fre-
quency-match the 3 treatment groups on age at initial repair, and age at enrollment. Study 
data was collected and managed centrally using REDCap electronic data capture tools.21 The 
study protocol was approved by the Institutional Review Board or Institutional Ethics Com-
mittee at each participating center. Written consent was obtained from each participant or 
parent, as appropriate.
STUDY TESTS
All study tests occurred during a one- or two-day visit. Vascular function was assessed com-
prehensively by several modalities. Testing included assessment of (a) arterial stiffness by 
applanation tonometry and cardiac magnetic resonance imaging (CMR), (b) endothelial 
function by endothelial pulse amplitude testing (Endo-PAT), and (c) BP phenotype using 
office BP measurement, ambulatory BP monitoring (ABPM) and BP response during peak 
exercise, and blood biomarkers related to endothelial function, systemic inflammation and 
vascular remodeling. 
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APPLANATION TONOMETRY
Studies were performed using the NIHem (Cardiovascular Engineering, Inc., Norwood, MA 
USA) or the SphygmoCor device (AtCor Medical, West Ryde, NSW, Australia) to calculate ca-
rotid-femoral pulse wave velocity (PWV) using standard technique as previously described.22 
The NIHem system determines central aortic pressure as equivalent to measured carotid 
pulse waveform as calibrated by the brachial waveform to the brachial diastolic and mean BP. 
For tracings obtained using the SphygmoCor device, the signal averaged carotid pulse wave 
was digitalized and calibrated according to a previously published approach to allow a quan-
titative analysis of the pulse waveform.23 Comparability of the two approaches as described 
above has been previously established.24
CMR
Examinations were performed using commercially available whole-body 1.5 T scanners 
(Achieva; Philips Healthcare, Best, the Netherlands; Signa 1.5T or GE Medical Systems, 
Milwaukee, WI, USA). Images were analyzed by a single observer (A.P.) in the CMR core lab 
using a commercial computer workstation (Extended Workstation; Philips Healthcare) and 
commercially available analysis software (QMass and QFlow, Medis, The Netherlands). Right 
brachial artery BP was measured before the examination in the supine position by using 
commercial oscillometric BP recorders. LV function and mass were measured using ECG-ga-
ted steady state free precision image in the ventricular short axis as previously described.22 
Segmental aortic stiffness (strain, distensibility, and β stiffness index) were calculated using 
cine steady state free precision images in the short axis of the ascending aorta (AAO), pro-
ximal descending aorta (DAO, 2-3 cm distal to the isthmus, sufficiently distal to dephasing 
jets), mid DAO (diaphragmatic level) and distal DAO (just above iliac bifurcation) using pre-
viously described methodology.22 Global and segmental PWV were calculated using the tran-
sit-time method using ECG-gated through-plane phase-contrast flow measurements at the 
AAO, and proximal, mid and distal DAO segments (matched to location of the cine steady sta-
te free precision acquisitions) as previously described.22 Temporal resolution was maximized 
by reconstructing 100 cardiac phases and using a turbo factor/views-per-segment setting of 
1. ECG and respiratory navigator-gated 3-D steady state free precision magnetic resonance 
angiography of the aortic arch was performed in the sagittal plane. Aortic arch shape and the 
aortic arch index were obtained as previously described.22 
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ENDOTHELIAL FUNCTION
Flow-dependent, endothelium-mediated vasodilation was assessed using endothelial pulse 
amplitude testing (Endo-PAT; Itamar Medical, Caesarea, Israel) as previously described.22 En-
do-PAT is a novel non-invasive and reproducible technique that measures changes in pulsati-
le arterial volume with a fingertip probe. Analysis of the pulse waveform allows for automa-
ted calculation of endothelial function in one arm, while the contra-lateral serves as control. 
BP PHENOTYPE
The seated right arm office BP was measured after 5 minutes of quiet rest using the manual 
auscultation technique with arm supported and feet flat on the floor. Three recordings were 
obtained, allowing one minute between deflation and re-inflation of the cuff. The BP was 
recorded as the average of the 2nd and 3rd measurements.  BP was classified according to 
the 4th Task Force report for children25 and the 7th Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure for adults (Table I 
in the online-only Data Supplement).26 Supine, oscillometric four extremity BP was used to 
assess for residual coarctation defined as the difference between the right arm SBP and the 
highest SBP in either leg. 
 Home ABPM was performed using previously described technique.22 The examina-
tion was considered adequate if the recording lasted > 12 hours. BP averages and propor-
tion of elevated readings (load) were calculated and categorized according to the age-based 
normative guidelines previously established for children27 and adults28 and patients were 
staged as having ambulatory hypertension, masked hypertension, white coat hypertension 
or normotensive (Table II in the online-only Data Supplement). 
 Patients performed an exercise stress test using the standard Bruce treadmill pro-
tocol to assess the BP response to exercise, as previously described.22 Baseline and peak 
arm-leg SBP differences and the increase in right arm BP with peak exercise were recorded. 
Gas-exchange during exercise was assessed in a subset of patients, when feasible. 
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BLOOD BIOMARKERS
The patients followed a low-nitrate diet for three days and fasted for 12 hours prior to sample 
collection. We measured biomarkers of nitrate metabolism as regulators of endothelial func-
tion (nitrite/nitrate, NOx; and asymmetric dimethylarginine, ADMA);29, 30 systemic inflamma-
tion (high sensitivity C-reactive protein, hs-CRP; and interleukin 1 beta, IL-1β);31, 32 vascular 
wall function (vascular adhesion molecule 1, VCAM-1);31 and extracellular matrix remodeling 
(matrix metalloproteases MMP-2 and MMP-9; and transforming growth factor beta-1, TGF- 
β1).33 NOx was determined by chemiluminescence (Sievers NOAnalyzer 280i) and all remaining 
measurements were performed using commercial enzyme-linked immunosorbent assay kits: 
ADMA (Sunred Biological Technology, Shanghai, China); hs-CRP (BoosterBio, Pleasanton, USA); 
VCAM-1; IL-1β; MMP-9; MMP-2 and TGFb-1 (RayBiotech, Inc. Norcross, USA). All measure-
ments were performed as previously described,22 at the central biomarker laboratory in Lisbon.
STATISTICAL ANALYSIS
Sample size estimates were obtained based on prior reports of arch PWV measured by CMR 
in normal subjects (3.3±0.6 m/s) and in patients with CoA (4.7±1.1 m/s).4, 34 Sample size esti-
mates for comparison of CMR PWV between three equal sized treatment groups (assuming 
an overall significance level of 0.05 and power of 0.8) are shown in Table III in the online-only 
Data Supplement). Using these estimates, we planned on recruiting 24-30 patients in each 
treatment group.
Categorical patient characteristics, clinical variables, and outcomes were summari-
zed as frequencies and percentages, and compared across the three treatment groups using 
Fisher’s exact test.  Continuous variables which were approximately normally distributed 
were summarized using means and standard deviations and compared using one-way analy-
sis of variance; continuous variables which were not normally distributed were summarized 
using medians and ranges and compared using the Kruskal-Wallis test. Age at treatment and 
presence of a bicuspid aortic valve were thought to be possible confounding variables and 
were observed to differ by treatment group; therefore, linear and logistic regression models 
were used to adjust for confounding when comparing selected outcome variables across 
treatment groups.  In these models, the surgical group was used as the reference category 
against which balloon dilation and stent were compared.  Each model adjusted for age at 
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treatment as a continuous variable, and presence of a bicuspid aortic valve as a binary varia-
ble.  Analyses were performed in SAS (version 9.4, Cary, NC, USA)
RESULTS
STUDY SUBJECTS
Patient characteristics by treatment group are summarized in Table 1. At study enrollment, 
the treatment groups were similar with respect to baseline characteristics including age and 
body mass index at enrollment, residual coarctation severity, and metabolic profile. Among 
pre-treatment characteristics, the treatment groups were similar with respect to coarctation 
severity (including size of the aortic arch and isthmus, non-invasive BP and echoDoppler 
estimated gradient), sex distribution, and the prevalence of bicuspid aortic valve. However, 
patients treated with a stent were older at the time of treatment compared to those treated 
with surgery or balloon dilation.
AORTIC STIFFNESS
Results of aortic stiffness assessment by CMR and applanation tonometry are summarized 
in Table 2 and Figure 1.  At comparable distending pressures (Table 3), overall PWV was si-
milar among the treatment groups by both CMR and applanation tonometry (Figure 1). On 
segmental PWV measurements by CMR, aortic arch PWV was lowest in the balloon dilation 
group, but the difference did not reach statistical significance (Figure 1). Among CMR seg-
mental aortic stiffness parameters, balloon dilation patients had the most distensible AAO, 
while stent patients had the least distensible AAO, with surgical patients demonstrating in-
termediate values (Figure 1). Compared to stent patients, balloon dilation patients showed 
48% higher AAO distensibility and 27% lower aortic arch PWV. Segmental stiffness parame-
ters were mostly similar across treatment groups at the DAO (proximal, mid, and distal), 
except for distal DAO strain, which was lowest in the stent group. No differences were seen 
across treatment groups in measurements of central SBP or central pulse pressure by tono-
metry. Augmentation index at heart rate 75 bpm was similar among groups. 
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 To assess for potential confounding by age at treatment or bicuspid aortic valve 
(known to be associated with impaired aortic elasticity)35 on the relationship between treat-
ment modality and aortic stiffness, we used multivariable modeling for key stiffness parame-
ters. The univariate relationships shown in Table 2 remained unchanged in the multivariable 
models after adjustment for the potential confounding variables (age at treatment, and bi-
cuspid aortic valve) (Supplemental Table VI).
ENDOTHELIAL FUNCTION
Endothelial function assessed using the Endo-PAT index was similar across treatment groups 
(Table 2 and Figure 1). The univariate relationships shown in Table 2 remained unchanged 
in the multivariable models after adjustment for the potential confounding variables (age at 
treatment, and bicuspid aortic valve) (Supplemental Table VI).
BP PHENOTYPE
Results of office BP measurements and ABPM are summarized in Table 3. There were no sig-
nificant differences across treatment groups with respect to the prevalence of hypertension 
by office measurements or ABPM, and average systolic and diastolic BP by ABPM. However, 
the balloon dilation group showed lower nighttime BP and less impairment in diurnal varia-
tion, compared to the stent and surgery groups (Figure 1). On exercise stress test (Table 4), 
there were no significant differences between the treatment groups with respect to exercise 
duration, peak VO2, VE/VCO2 slope, or upper-lower extremity SBP gradient. However, the 
peak SBP during exercise was lower in the balloon dilation group (Figure 1) and this rela-
tionship persisted after adjustment for potential confounding variables (age at treatment, 
and bicuspid aortic valve) (Supplemental Table VI).
LV AND AORTIC MORPHOMETRICS
The treatment groups were similar with respect to LV size, ejection fraction, and mass (Table 
5 and Figure 1). Aortic dimensions, including those of the transverse aortic arch were similar 
between the treatment groups. Isthmic dimensions were slightly smaller in the balloon di-
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lation group compared to the surgical group but could not be measured in stented patients 
due to ferromagnetic artifact from the stent. Arch shape distribution was also similar be-
tween the treatment groups, assessed both qualitatively and quantitatively (using the arch 
shape index).36 
BLOOD BIOMARKERS
Patients in the balloon dilation group had lower levels of hs-CRP, and higher levels of MMP-9 
and TGF-β1 (Table 6 and Figure 1). These differences persisted after adjustment for potential 
confounders (Table VI in the online-only Data Supplement). Levels of other blood biomarkers 
were similar across the treatment groups.
ADJUSTMENT FOR POTENTIAL CONFOUNDERS
As seen in Table 1, despite efforts at frequency matching, there were differences between 
the treatment groups with respect to potential confounding variables including age at treat-
ment and the presence of a bicuspid aortic valve (known to be associated with impaired 
aortic elasticity).35 Analyses to assess the impact of these confounding variables are summa-
rized in the Supplemental Tables IV, V and VI. As seen in Table IV in the online-only Data 
Supplement, age at treatment was significantly associated with AAO strain, Endo-PAT index, 
right arm diastolic BP, and 24-hour diastolic BP but not with other key outcome variables. 
As seen in Table V in the online-only Data Supplement, the presence of bicuspid aortic valve 
was significantly associated with AAO strain but not with other outcome variables. Table 
VI in the online-only Data Supplement summarizes the results of multivariable modeling 
comparing key outcome variables between treatment groups while adjusting for these co-
founding variables (age at treatment and presence of bicuspid aortic valve). Adjusted and 
unadjusted models did not differ significantly for these key outcome variables, suggesting 
that the impact of these potential confounding variables on our study measurements was 
not significant. 
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DISCUSSION
In this multicenter, prospective, comprehensive comparison of optimally treated patients 
with CoA treated with surgery, balloon dilation, or stenting, we found that the treatment 
groups were similar with respect to several parameters of vascular function including the 
prevalence of systemic hypertension, global aortic stiffness, central BP, endothelial function, 
and LV mass. However, despite adjustment for potential confounding variables (including age 
at repair), the balloon dilation group showed a better vascular phenotype characterized by 
a more distensible AAO, a lower peak SBP during exercise, and less impairment in diurnal BP 
variation. 
AORTIC STIFFNESS
Global aortic stiffness assessed using cfPWV by tonometry, or using total aortic PWV by CMR, 
was higher than published normal values but was similar among treatment groups.37 Howe-
ver, in segmental assessment of PWV and other distensibility measures by CMR (strain, dis-
tensibility and β stiffness index), differences emerged between treatment groups. Proximal 
aortic (AAO and aortic arch), stiffness was lowest in balloon dilation patients and highest in 
stent patients.  Surgical patients had intermediate values of stiffness. AAO distensibility in 
balloon dilation patients was similar to values reported in normal controls, while patients 
in the stent and surgery groups had lower values.38 These findings were limited to the AAO, 
which is in line with previous studies that show that the aortic elastic properties have been 
found to be altered above, but not below, the CoA site, compared to normals.5 Increased 
proximal aortic stiffness evidenced by an elevated PWV and lower than normal distensi-
bility have been previously reported in patients with CoA.4, 10, 11  However, our study is the 
first to systematically compare aortic stiffness across treatment modalities. The mechanism 
leading to a more distensible proximal aorta in balloon dilation patients remains unclear. It 
is possible that the absence of a surgical scar or rigid stent at the isthmus contributes to a 
lower stiffness at the CoA site. We acknowledge that the balloon dilation group underwent 
treatment at a younger age, however differences in AAO stiffness persisted after adjustment 
for age at treatment.
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ENDOTHELIAL FUNCTION
Flow-dependent, endothelium-mediated vasodilation was assessed using Endo-PAT. Results 
of prior studies of endothelial function in patients with CoA have been mixed. Some studies 
showed impaired endothelium-dependent vascular reactivity,10, 39, 40 while others showed 
preserved vascular reactivity.41, 42 Our results showed that the Endo-PAT index was similar 
across treatment groups, and suggest that endothelial function is preserved after CoA treat-
ment, compared to previously reported values in healthy controls.43 Values obtained in our 
cohort are comparable to those reported using a similar technique in patients with CoA.41
BP PHENOTYPE
The prevalence of hypertension on office measurement and ABPM were similar to prior 
reports.1, 44-46 On office BP measurements, 44% patients had pre-hypertension and 9% had 
hypertension. Overall, 33% were either on an anti-hypertensive medication or had hyper-
tension. On ABPM, 36% patients were either on an anti-hypertensive medication, or had 
hypertension/masked hypertension. There were no differences between treatment groups 
with respect to the prevalence of hypertension (on office measurements and ABPM), or 
the average 24-hour systolic or diastolic BP. However, balloon dilation patients demonstra-
ted lower night-time systolic and diastolic BP, and more physiologic nighttime dipping in BP, 
compared to the surgery and stent groups. Our results are consistent with a prior report 
which found lower BP in balloon dilation patients.1 Blunted nighttime dipping in BP has been 
previously linked to the development and progression of end-organ disease in patients with 
essential hypertension, diabetes mellitus, obesity, and black race.47 The impact of this finding 
on long-term outcomes in CoA patients deserves further study.
 The balloon dilation group showed a less exaggerated BP elevation to exercise, com-
pared to the surgery and stent groups. Exercise induced hypertension has been previously 
documented in patients with treated CoA,48 and exaggerated BP response to exercise cor-
related with LV mass.49 In the general population, exercise-induced hypertension has been 
shown to be predictive of future development of resting hypertension,50 and an independent 
risk factor for cardiovascular events and mortality.51
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LV MASS
Despite differences in BP phenotype, LV mass was similar across treatment groups and 
values were normal compared to previously reported values in healthy subjects.52 Increased 
LV mass has been previously reported in patients with CoA.4 Our LV mass values were lower 
compared to this prior report but are similar to a more recent publication.46 The absence of 
significant LV hypertrophy may be related to the relatively young age of our patients, and 
good blood-pressure control in our population. 
BLOOD BIOMARKERS
NOx and ADMA are biomarkers related to endothelial function and their levels have been 
correlated with the risk of atherosclerosis due to endothelial dependent nitric oxide regula-
tion of smooth muscle-derived vascular tone.29 There were no difference in NOx or ADMA le-
vels between treatment groups, consistent with the lack of difference in endothelial function 
using Endo-PAT. Prior studies in patients with CoA found increased ADMA but unchanged 
NOx in CoA, compared to controls.12
 IL-1β and hs-CRP are biomarkers of systemic inflammation, which act on the vascular 
endothelium to upregulate a number of adhesion molecules such as VCAM, with a crucial 
role in atherogenesis.31, 32 Prior results of inflammatory biomarkers in patients with CoA are 
inconclusive.53, 54 In our study, balloon dilation patients had lower levels of hs-CRP. 
 TFG- β1, MMP-2, and MMP-9 are biomarkers related to fibrotic remodeling such as 
the aortic remodeling that occurs in response to hemodynamic changes.33 Elevated circula-
ting levels have been reported in dilated aortas in patients with inherited aortopathy,55 and 
are biomarkers for the presence and risk of rupture of aortic aneurysm.56 As previously re-
ported in patients with CoA, values of both TFG-β1and MMP-9 were elevated in our study.15, 
57 Balloon dilation patients showed the highest levels of these biomarkers. The clinical im-
plications of these findings are unclear and further research is needed to evaluate whether 
these biomarkers are related to the risk of aneurysm formation in the BD group.
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STUDY LIMITATIONS
There are several limitations to our study. Firstly, despite a multicenter design, our study is 
limited by a relatively low sample size. However, based on sample size estimates, the study 
had sufficient statistical power to detect group differences in CMR PWV. Secondly, although 
we attempted to perform frequency-matching to balance the treatment groups with respect 
to key confounding variables, our groups were not perfectly matched for these variables 
(especially age at treatment). However, surprisingly, multivariable analyses (Table VI in the 
online-only Data Supplement) showed that these potential confounding variables (including 
age at repair) did not significantly affect the comparison of key variables between treatment 
groups. Finally, we only included adequately treated CoA patients and these results are not 
generalizable to patients with significant residual CoA.
CONCLUSIONS
In this comprehensive multicenter prospective comparison of vascular function in patients 
with CoA adequately treated with surgery, balloon dilation, or stenting we found that the 
treatment groups were similar with respect to several indicators of vascular function inclu-
ding the prevalence of systemic hypertension, global aortic stiffness, endothelial function, 
and LV mass. However, the balloon dilation group showed a somewhat better vascular func-
tion phenotype with more physiologic nocturnal dipping in BP, a more distensible AAO and 
aortic arch, a lower peak SBP during exercise, and lower blood levels of pro-inflammatory 
biomarker. A possible explanation of these findings is that the introduction of a non-distensi-
ble stent or surgical scar may have deleterious effects on late vascular function. In particular, 
our results may suggest a cautious approach when considering aggressive primary stenting 
in a patient with other available treatment options, since stented patients had the worse 
vascular profile in our cohort. However, the benefits of a slightly improved vascular function 
profile after balloon dilation will need to be balanced against a higher risk of aneurysm for-
mation and reintervention.58, 59 Further research is needed to study whether these findings 
are associated with long-term clinical outcomes and if the treatment paradigm focused on 
gradient reduction should be refined by adding the goal of preservation of vascular function 
to the goals of treatment. To our knowledge, these results represent the most comprehensi-
ve prospective comparison of late vascular function between treatment modalities for CoA. 
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Further research is needed to study whether these findings are associated with long-term 
clinical outcomes.
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FIGURES
Figure 1:
FIG. 1. COMPARISON OF KEY VASCULAR FUNCTION PARAMETERS 
BETWEEN GROUPS
AAO = ascending aorta; BSA = body surface area; CMR = cardiac magnetic resonance; Endo-
PAT = endothelial pulse amplitude testing; hs-CRP = high sensitivity C-reactive protein; IL-1β 
= interleukin 1 beta; LV = left ventricle; MMP-9 = matrix metalloprotease 9; PWV = pulse 
wave velocity; SBP = systolic blood pressure; TGF- β1 = transforming growth factor beta-1
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TABLES
TABLE 1. PATIENT CHARACTERISTICS
Surgery 
(n=28)
BD
 (n=23)
Stent
(n=24) p Value
Pre-treatment data
   Age at treatment (years) 6 (1, 26) 5 (1, 17) 15 (7, 26) <0.001
   SBP gradient (mm Hg) 43.7 ± 19.3 34.6 ± 15.0 38.4 ± 21.0 0.29
   TAA diameter z-score -1.9 ± 1.0 -1.5 ± 1.4 -1.9 ± 0.8 0.38
    Isthmus diameter z-score -3.59 ± 1.21 -3.92 ± 0.89 -3.31 ± 1.37 0.32
    Initial Doppler gradient (mmHg) 48.0 ± 14.7 47.9 ± 14.8 52.5 ± 20.3 0.60
   Male sex 79% 74% 75% 0.94
   Bicuspid aortic valve 71% 45% 50% 0.13
Age at enrollment (years) 15 (8, 33) 17 (11, 26) 20 (9, 33) 0.12
BMI at enrollment 22 (15, 32) 21 (16, 33) 23 (16, 38) 0.69
SBP gradient (mm (Hg) -7.1 ± 14.0 -3.0 ± 12.3 -3.7 ± 14.5 0.52
NYHA class 0.37
   Class I 89% 100% 92%
   Class II 11% 0% 8%
Metabolic Profile
   Total cholesterol, mg/dL 159 (112, 210) 153 (123, 229) 152 (108, 227) 0.59
   LDL, mg/dL 86 (53, 145) 81 (59, 179) 85 (44, 130) 0.66
   HDL, mg/dL 53 (34, 90) 48 (31, 90) 51 (32, 88) 0.99
   Triglycerides, mg/dL 76 (29, 224) 52 (29, 149) 74 (29, 167) 0.07
   Plasma glucose, mg/dL 82 (74, 98) 81 (59, 93) 86 (63, 108) 0.15
   Insulin, uIU/mL 6 (3, 44) 6 (3, 17) 7 (2, 20) 0.86
   Hemoglobin A1c, % 5.3 (4.1, 5.7) 5.3 (4.4, 5.7) 5.3 (4.8, 5.9) 0.60
Anti-HTN Medication 14% 26% 33% 0.14
Values are mean ± standard deviation, median (minimum, maximum), or percent. BSA = 
body surface area; BMI = body mass index (weight (kg)/ height (m)2); HTN = hypertension; 
LDL = low density lipoprotein; HDL = high density lipoprotein; NYHA = New York Heart Asso-
ciation; SBP = systolic blood pressure; TAA = transverse aortic arch
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TABLE 2. AORTIC STIFFNESS AND ENDOTHELIAL FUNCTION
Surgery 
(n=28)
Balloon 
dilation 
(n=23)
Stent
(n=24) p value
CMR Parameters
PWV (m/s)
   Total 4.0 ± 0.5 4.2 ± 0.9 4.2 ± 0.7 0.72
   Aortic arch 4.7 ± 1.5 4.0 ± 1.2 5.5 ± 3.8 0.12
   Mid DAO 3.8 ± 0.9 4.0 ± 1.3 3.9 ± 1.4 0.87
   Distal DAO 4.4 ± 1.6 4.8 ± 1.7 4.5 ± 1.5 0.70
Strain
   AAO 0.38 ± 0.14 0.51 ± 0.25 0.36 ± 0.19 0.02
   Proximal DAO 0.27 ± 0.09 0.31 ± 0.13 0.30 ± 0.15 0.47
   Mid DAO 0.37 ± 0.11 0.36 ± 0.10 0.36 ± 0.16 0.97
   Distal DAO 0.37 ± 0.14 0.40 ± 0.12 0.30 ± 0.12 0.04
Distensibility (10-3mm Hg-1)
   AAO 7.8 ± 3.6 9.8 ± 5.2 6.6 ± 4.3 0.05
   Proximal DAO 5.6 ± 2.1 6.1 ± 3.3 5.6 ± 2.7 0.71
   Mid DAO 7.5 ± 2.5 6.9 ± 3.3 6.8 ± 3.4 0.67
   Distal DAO 7.8 ± 4.1 7.5 ± 3.1 5.9 ± 3.2 0.15
β stiffness index
   AAO 1.76 ± 0.73 1.59 ± 1.15 2.49 ± 1.48 0.02
   Proximal DAO 2.53 ± 1.59 2.63 ± 1.89 2.50 ± 0.96 0.96
   Mid DAO 1.75 ± 0.76 1.93 ± 0.75 2.15 ± 1.11 0.26
   Distal DAO 1.84 ± 0.91 1.72 ± 0.68 2.98 ± 3.70 0.11
Applanation Tonometry
   cfPWV (m/s) 5.2 ± 0.9 5.3 ± 1.1 5.0 ± 0.9 0.64
   AI at HR 75 bpm (%) -14 ± 13 -13 ± 21 -6 ± 18 0.24
   Central SBP (mm Hg) 114 ± 18 109 ± 14 112 ± 21 0.60
   Central PP (mm Hg) 50 ± 20 46 ± 13 45 ± 19 0.49
Endo-PAT
   Endo-PAT index 2.15 ± 0.77 2.00 ± 0.78 2.25 ± 0.68 0.51
Values are mean ± standard deviation. AAO = ascending aorta; AI = augmentation index; 
aortic arch PWV = AAO to proximal DAO pulse wave velocity; cfPWV = carotid-femoral pulse 
wave velocity; DAO = descending aorta; Endo-PAT = endothelial pulse amplitude testing; HR 
= heart rate; PP = Pulse pressure; SBP = Systolic blood pressure; total PWV = AAO to distal 
DAO pulse wave velocity
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TABLE 3. BLOOD PRESSURE PHENOTYPE
Surgery 
(n=28)
Balloon 
Dilation 
(n=23)
Stent
(n=24)
p value
Office BP 0.20
   Normal 15 (54%) 13 (57%) 7 (29%)
   Pre-HTN 10 (36%) 8 (35%) 15 (63%)
   Stage 1 HTN 3 (11%) 2 (9%) 1 (4%)
   Stage 2 HTN  0 (0%) 0 (0%) 1 (4%)
ABPM
   24-hr average SBP (mm Hg) 123 ± 13 118 ± 9 124 ± 10 0.19
   24-hr average DBP (mm Hg) 68 ± 8 66 ± 6 68 ± 8 0.77
   Day average SBP (mm Hg) 125 ± 13 122 ± 10 127 ± 10 0.34
   Day average DBP (mm Hg) 69 ± 9 69 ± 7 71 ± 9 0.82
   Night average SBP (mm Hg) 116 ± 12 106 ± 10 113 ± 10 0.005
   Night average DBP (mm Hg) 60 ± 7 56 ± 5 59 ± 4 0.05
   % SBP readings above diurnal threshold 32 ± 29 19 ± 19 30 ± 27 0.19
   % DBP readings above diurnal threshold 16 ± 20 13 ± 14 14 ± 16 0.72
   Diurnal systolic variation (%) 7 ± 7 13 ± 6 11 ± 6 0.01
   Diurnal diastolic variation (%) 13 ± 10 19 ± 6 16 ± 7 0.06
   Non-dippers (%) 17 (65%) 7 (32%) 12 (55%) 0.08
Classification by ABPM 0.76
   No HTN 16 (59%) 18 (82%) 15 (68%)
   White coat HTN 3 (11%) 1 (5%) 1 (5%)
   Masked HTN 6 (22%) 2 (9%) 5 (23%)
   HTN 2 (7%) 1 (5%) 1 (5%)
Classification including medication use
HTN/masked HTN, or anti-HTN medication 8 (30%) 9 (39%) 10 (45%) 0.49
Values are mean ± standard deviation, or number (percent). ABPM = ambulatory blood 
pressure measurement; BP = blood pressure; DBP = diastolic blood pressure; Dippers = ni-
ght-time BP dipping ≥10%, non-dippers = night-time BP dipping <10%; HTN = hypertension; 
SBP = systolic blood pressure
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TABLE 4. EXERCISE STRESS TEST
Surgery 
(n=28)
Balloon 
Dilation 
(n=23)
Stent
(n=24) p value
Exercise duration (minutes) 12 (7,21) 11 (9, 21) 13 (5,17) 0.45
Pre-exercise SBP gradient (mm Hg) -3 ± 21 1 ± 9 6 ± 18 0.17
Peak-exercise SBP gradient (mm Hg) 32 ± 30 33 ± 22 26 ± 27 0.64
Peak right arm SBP (mm Hg) 177 ± 35 157 ± 27 177 ± 33 0.05
Peak right arm DBP (mm Hg) 71 ± 13 75 ± 9 73 ± 11 0.50
VO2 Max (ml/Kg/min) 41 ± 11 32 ± 27 41 ± 11 0.30
VE/CO2 slope 26 ± 4 26 ± 5 26 ± 6 0.98
Values are mean ± standard deviation, or median (minimum, maximum). DBP = diastolic 
blood pressure; SBP systolic blood pressure; VO2 Max = peak exercise oxygen consumption; 
VE/CO2 = relationship between ventilation and CO2 output
TABLE 5. CMR LV AND AORTIC MEASUREMENTS
Surgery 
(n=28)
Balloon 
Dilation 
(n=23)
Stent 
(n=24) p value
LV Measurements
   EDV (ml/m2) 71 ± 13 76 ± 17 73 ± 18 0.64
   Ejection fraction (%) 63 ± 6 61 ± 5 62 ± 5 0.52
   Mass (g/m2) 56 ± 13 58 ± 9 57 ± 13 0.83
Aortic Diameters (mm/BSA0.5)
   Ascending aorta 19.1 ± 3.0 20.6 ± 3.2 20.7 ± 3.4 0.18
   Proximal transverse arch 12.6 ± 1.2 12.8 ± 1.8 12.7 ± 2.9 0.96
   Distal transverse arch 11.5 ± 1.7 11.2 ± 1.6 11.9 ± 2.1 0.45
   Isthmus 12.6 ± 3.7 10.4 ± 2.8 N/A* 0.03
   Descending aorta 12.4 ± 1.1 12.6 ± 1.8 12.5 ± 1.6 0.95
Arch Shape 0.33
   Romanesque 11 (39%) 10 (43%) 10 (42%)
   Crenel 2 (7%) 5 (22%) 2 (8%)
   Gothic 14 (50%) 6 (26%) 12 (50%)
Arch Shape Index 0.64 ± 0.14 0.65 ± 0.11 0.68 ± 0.13 0.64
Values are mean ± standard deviation, or number (percent). * N/A = not available, due to 
presence of stent artifact. Arch Shape Index = aortic arch height divided by width; BSA = 
body surface area; EDV = end-diastolic volume
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TABLE 6.  BLOOD BIOMARKERS
Surgery       
(n=28)
Balloon 
Dilation 
(n=23)
Stent         
(n=24)
p value
NOx (ug/mL) 18 (12, 31) 20 (12, 37) 20 (10, 34) 0.18
ADMA (ng/L) 6 (1, 45) 7 (1, 51) 3 (0, 31) 0.20
hs-CRP (mg/L) 1.28 (0.74, 
1.49)
1.26 (0.66, 
1.41)
1.30 (0.95, 
1.46)
0.02
VCAM-1 (ng/mL) 133 (66, 
203)
134 (61, 
206)
128 (66, 
168)
0.42
IL-1β (pg/mL) 0.91 (0.04, 
1.26)
1.06 (0.68, 
1.98)
0.95 (0.06, 
1.49)
0.1
TGF- β1(ng/mL) 0.35 (0.12, 
1.24)
0.64 (0.23, 
3.21)
0.31 (0.05, 
2.07)
0.006
MMP-2/gelatinase A (ng/mL) 1.14 (0.10, 
3.37)
1.53 (0.00, 
4.93)
0.62 (0.00, 
3.62)
0.26
MMP-9/gelatinase B (ng/mL) 474 (91, 
3157)
738 (158, 
4453)
421(487, 
1739)
0.01
Values are median (minimum, maximum). ADMA = asymmetric dimethylarginine; hs-CRP = 
high sensitivity C-reactive protein; IL-1β  = interleukin 1 beta; MMP = matrix metalloprotease; 
NOx = nitrite/nitrate; TGF- β1 = transforming growth factor beta-1; VCAM-1 = vascular 
adhesion molecule 1
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